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Chapter 1 
Introduction 

1 Introduction 
Only few descriptions of neurologic diseases precede James Parkinson's "Shaking 
Palsy'. In this monograph, published in 1817, he clearly and accurately described a 
constellation of signs that now bears his name' The definition he proposed largely 
contained what now is used to designate parkinsonism clinically (Figure 1.1). 
SHAKING PALSY. (Paralysis Agitans,) 
Involuntary tremulous motion, with lessened 
muscular power, in parts not in action and 
even when supported; with a propensity 
to bend the trunk forward, and to pass 
from a walking to a running pace: the 
senses and intellects being uninjured. 
Figure 1.1 The definition of "Shaking Palsy" as was published in James Parkinson's 
monograph in 1817. 
At present, Parkinson's disease (PO), after Alzheimer's disease, is generally 
considered to be the most frequent progressive neurodegenerative disease in the 
elderly. Due to the growing proportion of elderly in many populations, more and more 
persons will be affected by this disabling disease which constitutes a large burden to 
man and society. Since the publication of James Parkinson's essay, almost two 
centuries have elapsed and, in spite of numerous efforts to unravel the nature of the 
disease, the etiology of PO is still unknown. Yet, the neuropathologic and biochemical 
changes that cause the signs of the disease seem to be settled, based on knowledge 
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that was mainly accumulated in only the past three decades. Neuropathologically, PO 
is defined by selective degeneration of pigmented neurons of the pars compacta of 
the substantia nigra and other brainstem ganglia, with cytoplasmic inclusions, called 
Lewy bodies, in the surviving neurons as the hallmark. '·5 These lesions lead to a 
deficiency of striatal dopamine. It is now considered that parkinsonian signs only 
become clinically overt after dopaminergic cell loss of approximately 50%,'·6 and that 
at that moment the endogeneous dopamine content is depleted by 80%.'·4-6 
Hitherto, many hypotheses on the etiology of PO and reports on the frequency of the 
disease have emerged, and as many have been critized. In Chapter 2 of this thesis, 
a brief overview of the most important items with regard to epidemiologic research 
on PO will be given, focusing on developments from the past decade. 
In the following chapters of the thesis, various epidemiologic aspects of PO will be 
addressed. All studies that are described in this thesis are community-based studies 
in which each participant was examined in person. In Chapter 3, we discussed 
diagnostic issues in population studies on PO. Several aspects of screening for 
parkinsonism in a general elderly population are described in Chapter 3.1. In Chapter 
3.2, another methodologic aspect of epidemiologic studies on PO is dealt with, 
namely the impact of different diagnostic criteria for PO on prevalence estimates of 
the disease, and the applicability of these criteria in an epidemiologic setting. In 
Chapter 4 data are shown on frequency of PO. Results from stUdies on prevalence 
of parkinsonism and PO in The Netherlands, comparisons of prevalence estimates 
derived from five similar European studies, and on incidence rates in the Rotterdam 
Study are presented in Chapters 4.1, 4.2, and 4.3, respectively. In Chapter 5 results 
are given from four etiologic stUdies on PO that pertain to various determinants that 
have been linked with PO. The cross-sectional relation between dietary antioxidant 
intake and PO is described in Chapter 5.1. Chapter 5.2 deals with the association of 
apolipoprotein E genotype with PO and dementia in PO. Chapter 5.3 is about the 
allegedly protective effect of smoking against PO, an issue which is still controversial. 
Chapter 5.4 shows the risk of PO conditional on a positive family history of PO or 
dementia. Finally, in Chapter 6, methodologic issues and findings of the presented 
studies are discussed, as well as the implications of these findings for the 
understanding of PO, and for future research. 
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Chapter 2 
Epidemiology of Parkinson's disease: a review 

2 Epidemiology of Parkinson's disease: a review 
In 1817, the British physician James Parkinson' was the first who recognized and 
described several neurologic symptoms as one entity which now bears his name. 
Parkinson's disease (PO) is one of the most frequent chronic neurodegenerative 
diseases in the elderly. Due to the growing proportion of elderly in many populations, 
more and more persons will be affected by the disease. Excessive dopaminergic cell 
death in the substantia nigra in the brain leads to the disease,'·' but the cause of this 
cell loss is still poorly understood. Relatively little epidemiologic reseach has been 
conducted on PD. We will now review developments in epidemiologic research of PO, 
most from the past decade, and discuss diagnosis, disease frequency, risk factors, 
comorbidity, and prognosis. 
Diagnosis 
Diagnostic criteria 
For the diagnosis of PO, the postmortem neuropathologic examination of the brain 
is generally considered to be the gold standard. Neuropathologically, PO is defined 
by selective degeneration of pigmented neurons of the pars compacta of the 
substantia nigra and other brainstem ganglia,'·'·' with specific inclusions in the 
surviving neurons, referred to as Lewy bodies, as the pathognomonic hallmark6 } Still, 
the neuropathologic diagnosis is not that distinct: additional Alzheimer's disease 
lesions frequently occur in pathologically confirmed PD;'·1O·" in 21%13 up to 55%14.15 
of patients with Alzheimer's disease or other neurodegenerative diseases concomitant 
PO lesions are reportedly found; in pathologically confirmed non-demented PO 
patients correlations between distinct clinical patterns and neuropathologic patterns 
have been observed;' and in a substantial proportion of non-parkinsonian subjects 
older than 60 years Lewy bodies are found 6 .16 For the clinical diagnosis of PO, the 
generally accepted prerequisite is assessment of the presence of parkinsonism, 
based on a combination of four typical clinical features, referred to as cardinal signs, 
i.e. resting tremor, bradykinesia, rigidity, and impaired postural reflexes. Various 
combinations of these cardinal signs have been proposed for ascertainment of the 
presence of parkinsonism 6 •17•20 The diagnosis of PO, sometimes referred to as 
idiopathic parkinsonism or idiopathic PO, requires that other causes of parkinsonism 
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be excluded, For the diagnosis of PO, sometimes additional requirements related to 
duration of symptoms, asymmetry of signs, or responsiveness to levodopa treatment 
are used, In a recent report, it was argued that for use in epidemiologic settings the 
diagnosis of PO requires the presence of at least two of resting tremor, bradykinesia, 
and rigidity in absence of other possible causes of parkinsonism and without 
additional requirements," The correlation between the clinical picture and postmortem 
findings is relatively poor: 24% of the cases who during life had been diagnosed as 
PO had a neuropathologic diagnosis other than PO,' Application of very strict clinical 
criteria may improve the cliniconeuropathologic correlation,"" but will lead to 
exclusion of more than 30% of pathologically genuine PO patients," 
Differential diagnosis 
Besides PO, which accounts for 70%22,23 to 85%" of all parkinsonian patients, many 
other disorders (such as dementia, Lewy Body disease, multiple system atrophy, 
progressive supranuclear palsy, drug-induced parkinsonism, and vascular 
parkinsonism) may cause parkinsonism, Most of these disorders are distinguished 
from PO by typical features or a specific time relation between putative cause and 
disease, In practice, however, the clinical distinction between PO and other 
parkinsonian syndromes is often difficull to make",·,13,18,,,,,,,,, PO is clinically 
heterogeneous in age of onset,,,,30 predominance of motor signs,12,18,29,31,32 
responsiveness to levodopa treatment,12,33 and clinical course,18,33,34 and may, 
consequently, mimic a secondary cause of parkinsonism, In general, some 
misdiagnosis of PO is inevitable but can be reduced by applying strict exclusion 
criteria such as presence of pyramidal signs, cognitive deficils that occurred clearly 
before the onset of the parkinsonian syndrome, poor levodopa responsiveness, 
neuroleptic-induced parkinsonism, cerebellar ataxia, marked autonomic dysfunction, 
or abnormalities of eye movements,""" 
Frequency 
Methodologic considerations 
Differences in case-finding procedures, diagnostic criteria, and response rates may 
hamper comparison of prevalence and incidence figures across studies, Broadly, two 
case-finding methods have been used to study prevalence of PD. One is based on 
existing medical records, Patients who fail to seek medical attention for their 
parkinsonism, and those whose records were lost or could not be retrieved, will not 
be included in the prevalence estimates, The other case-finding method relies on in-
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person screening of all subjects within a defined population."'''''' Often, a two-stage 
design is used which encompasses in the first stage a brief screening of all subjects 
in a population and subsequently, in the second stage, a more extensive evaluation 
of those who screened positive,,,,35,37 This method should reduce the number of 
undiagnosed patients by identifying persons with parkinsonism before they have come 
to medical attention. It was shown that the percentage of newly diagnosed patients 
due to the screening can grow to considerable proportions in the range from 24%",39 
to 35% and 42%, ",35 and increases with age." Apart from case-finding methods, 
different diagnostic criteria may also have their impact on frequency estimates.20,39 
Prevalence 
All studies on the prevalence of PO that were published before 1985 were based on 
existing medical records, as were most prevalence studies published during the last 
decade."'" The prevalence estimates based on these studies varied widely." In 
many register-based studies, it was found that the prevalence of PO increased with 
age till a certain age with a decline thereafter.43,46." Since 1985, when the results of 
the first community-based prevalence survey on PO were published,35 evidence has 
been growing that a decline in prevalence in the highest ages is artefactual. All 
community-based prevalence surveys with an in-person screening showed an 
increase in the prevalence of PO or parkinsonism with age, even in the highest age 
categories.",,,,35,,,.,,,39.50.,, Overall, the prevalence estimates ranged from 0.6% for 
those aged 65 to 69 years to 3.5% for those aged 85 to 89 years, with an overall 
prevalence of 1.6% for subjects aged 65 years or older." The prevalence estimates 
derived from these studies are remarkably similar (Figure 2.1), suggesting no clear 
variation across countries if similar methodologies and diagnostic criteria are used. 
The discrepancy between the results of a Chinese study, 51 that showed low age-
specific prevalence figures, and the other community surveys could be due to 
differences in survival or classification of PO patients, or in etiologic factors. The 
eight-fold higher prevalence estimates that were reported for East Boston, 
Massachusetts," referred to all parkinsonism, as no distinction between PO and other 
parkinsonism could be made, and were probably inflated due to broad diagnostic 
criteria. 
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Figure 2.1 Age-specific prevalence, for both sexes combined, of Parkinson's disease 
from several community-based surveys with an in-person screening to detect 
Parkinson's disease. 
Incidence 
Incidence rates could provide better estimates of occurrence of PD, avoiding 
differences in survival of PD patients across countries, but studies on incidence of PD 
are scarce. Only few studies provide age-specific,,·53." or age- and sex-
specific"·45.47.55.56 incidence rates of PD. In none of these, except two,"·56 a screening 
instrument to detect PD was administered to each individual. The incidence rates per 
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100,000 person years varied; for the age-group 75 to 84 years from 133 in New 
York," and 132 in Honolulu, Hawaii,54 to 254 in Rochester," and 510 in Rotterdam, 
The Netherlands56 with in the latter three studies a drop beyond the age of 85 years 
(Figure 2.2). The figures from the two studies with an in-person screening varied 
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Figure 2.2 Age-specific incidence rates of Parkinson's disease from several 
communily-based surveys. 
considerably.54.56 The reason for this is speculative, but, as in the Hawaiian study 20 
years had elapsed between the previous, register-based, screening and the most 
recent in-person screening, many parkinsonian subjects who did not come to medical 
attention will not have been included in the incidence estimates. Also, in the 
Rotterdam Study the number of incident cases per age-group was small leading to 
more unstable estimates. More incidence estimates provided by community surveys 
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with an in-person screening at both baseline and follow-up have to be awaited to 
establish the true incidence of PO and to confirm the decline of incidence at higher 
ages. 
Risk factors 
Methodologic issues 
Numerous studies on risk factors for PO have been published. Almost exclusively, 
these studies were based on register-based prevalent cases which have some well 
known methodologic drawbacks, such as information bias and selection bias. 
Selection bias may have occurred if mortality in patients is selectively influenced by 
the determinants studied or when diagnosis of PO is dependent on, or promoted by, 
putative risk factors (e.g., head trauma, postive family history of PO, depression 
before the diagnosis of PO). Also, the selection of controls may have been biased: 
the use of spouses as controls will lead to overmatching if for example dietary habits 
are investigated, and hospital controls may not properly reflect the distribution of risk 
factors in the population from which the cases were derived. Information bias (e.g., 
recall bias) may have been introduced where healthy controls or spouses served as 
controls. In this section, we will mainly focus either on the few prospective studies in 
which the exposure was measured before the onset of the disease or on large cross-
sectional studies. The associations between most putative determinants and PO still 
have to be confirmed in cohort studies, ideally in a community-based setting. 
Gender 
Higher prevalences of PO for men"4' or for women"·57 have been reported in 
register-based studies, while in most community surveys with an in-person screening 
no significant differences in the prevalence of PO between men and women were 
found."·23.35.".38.50 Even if we look at register-based incidence studies on PO with age-
and sex-specific estimates, no differences between sexes seem to exist,24.45.53.55 
except in twO."·48 These findings may indicate a similar risk of PO in men and women 
if putative differences in survival or in probability of diagnosis of PO patients have 
been avoided. 
Smoking 
Smoking is one of the determinants of PO that has been studied most frequently. 
Since Oorn first reported an inverse association between smoking and PO,58 this 
finding has been confirmed in most other studies,""" but not in all."·" Most studies 
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that found an inverse association were based on prevalent cases and the inverse 
association was disputed with various arguments like biased results due to 
confounding, selective mortality, cause-effect bias, symptom suppression, or 
diagnostic competition,59 To date, few prospective studies eXist,58M,.3,68,71 all 
suggesting an on average two- to three-fold reduction of the risk of PD among 
smokers, However, all but two, .',.3 focused on mortality follDw-up of smokers and nDn-
smokers, PD diagnosis was retrieved through death certificates in which smoking 
related diseases may overshadow PD as the listed cause Df death, especially in 
smDkers, thus erroneDusly implying less frequent occurrence Df PD among smokers, 
Even in countries with excellent death certificate registration, in only 70% of 
diagnDsed PD patients the PD diagnosis is listed on death certificates'" The two 
prospective community-based studies based on an in-persDn screening for PD 
showed a similarly reduced risk of PD among smokers .. ,,·3 
It is still speculative which biologic mechanism may explain the protective effect. 59," 
In the sUbstantia nigra of smokers, monDamino oxidase 8 (MAO 8) levels are 
reduced," As a result, less dopamine will be oxidated, yielding a neuroprotective 
effect thrDugh reduced free radical production, Less dopamine oxidation will result in 
increased synaptic dopamine availability, thereby reducing the symptom severity Dr 
delaying the onset of clinical PD,59 MAO 8 mediated oxidatiDn Df protoxins tD 
neurotoxins may be reduced as well.",7. The cDmpounds of cigarette smDke that 
inhibit MAO 8 are not knDwn, ",77,78 Also, smDking may induce other enzymatic 
processes that are invDlved in the metabDlism of xenobiotics, thereby augmenting 
protectiDn against oxidative stress or tDxins, 7. Other possible mechanisms include that 
nicDtine may directly stimulate dopamine release",ao or nicotine receptors,"'" or that 
smoking-associated carbDn monoxide could protect against hydrogen peroxide related 
perDxidation of the membrane," A different pDint Df view contains that persons 
predestinated to get PD may exhibit a (premorbid) persDnality that predelicts persDns 
to restrain from smoking",·,,,,85 which leads to a seemingly higher risk Df PD among 
non-smokers, However, personality differences in PD patients have only been 
assessed retrospectively and recall bias may have Dccurred, 
In general, one could argue for the existence of a true inverse associatiDn of smoking 
with PD, because of consistent, biologically plausible, findings in epidemiolDgic 
studies that have been confirmed in prDspective community-based stUdies, 
Antioxidants 
Increased free radical production and an inadequate antiDxidant defence system may 
playa rDle in the etiolDgy of PD,""" Indications for such oxidative stress were found 
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in several neuropathological studies:'-95 some suggesting increased lipid peroxidation 
in the dopaminergic cells."·97 It has been speculated that high intake of antioxidants, 
eilher through diet or supplements, may decrease the risk of PO or slow down its 
progression. The few studies on dietary antioxidant intake and the association with 
PO yielded equivocal results."·'04 Two recent large case-control studies based on 
prevalent cases found no protective effect of dietary antioxidants on PO."·'o, but 
potential biases could not be excluded'"' A recent case-control study, nested in a 
prospective study, suggested a significant inverse association between PO and 
consumption of vitamin E containing foods (legumes) more than 25 years before 
(odds ratio of 0.28 per at least one serving per day).'03 Theoretically, B-carotene'05 
and vitamin C could have an antioxidative effect in the brain as well, but in studies 
on PO such an effect has not been found.',·,o,.,o,.,o'.106-'o, Considering the currently 
existing evidence, vitamin E may be a dietary antioxidant that protects against the 
development of Parkinson's disease but this needs to be confirmed in more 
prospective community-based studies. 
Toxins 
Renewed interest in neurotoxins that may cause PO was raised when it was observed 
that through intravenous injection, or possibly also through inhalation, '0'.110 the 
chemicaI1-methyl-4-phenyl-1 ,2,3,6-tetrahydropyridine (MPTP) causes a parkinsonian 
syndrome strikingly resembling PO, both clinically and pathologically. 111 Much 
research was focused on the relation between PO and direct or indirect exposure to 
potentially toxic compounds such as MPTP (and its metabolite MPP') containing 
pesticides, especially herbicides.'12 As shown in Table 1, a positive relation with PO 
has been found for pesticide use, or for rural living, farming, and well water drinking 
(all reflecting possible exposure to compounds of pesticides). Some other studies 
indicated an association between exposure in industrial environments (e.g., heavy 
metals) and PO (Table 2.1)."0 A positive link with pesticide use was also reported by 
Butterfield et al.'13 and Hubble et al.,'14 but in the latter study PO was not linked to 
rural living. farming, and well water drinking'14 To date, it is not clear whether 
environmental neurotoxins are potentiated by genetic defects in detoxification systems 
in the brain, 115.116 but there are some indications that polymorph isms of such 
susceptibility genes are involved in the etiology of PO." 7-120 As all case-control studies 
were retrospective and register-based, the results have to be interpreted with caution. 
Information bias may have occurred, especially when the notion exists that inhalation 
of toxic compounds could cause some brain damage. Moreover, almost exclusively 
the associations have been established indirectly without direct measurement of the 
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true exposure. In the future, job exposure matrices may be a more objective tool to 
evaluate the relation between PD and the precise exposure, interaction between toxin 
exposure and susceptibility genes could be investigated, or cohorts of farmers or 
industrial workers could be followed to assess whether or not they are exposed to an 
increased risk of PD. 
Head trauma 
The notion that a severe head injury, as observed by James Parkinson,' can cause 
parkinsonism, '21.122 that persons, like boxers, who have experienced multiple head 
trauma in the past may develop parkinsonian signs, and that head trauma may 
(temporarily) worsen the disease severity in PD patients,123 led to the hypothesis that 
PD and head trauma may be etiologically related. This could be through directly 
trauma-induced damage of the striatal pathway, or it could be that the stress that 
accompanies the head trauma induces (transient) parkinsonian signs,123.125 possibly 
through depression of striatal dopamine levels.'23.'25 In most recent studies on head 
trauma and the occurrence of PD, the relation remained controversial,o.61.67.11,.126.,31 
A significant positive association was observed in only three case-control studies 
(Table 2.2),126.127.'30 but recall bias could not be excluded. A follow-up study from 
Rochester, Minnesota, among persons with a severe head trauma revealed no 
increased risk of either PD or Alzheimer's disease, '32 nor did the Rotterdam Study.'33 
(Table 2.2). These observations in follow-up studies make a etiologic relation between 
PD and head trauma unlikely. 
Genetics 
Until the seventies it was generally considered that hereditary factors played an 
important role in the etiology of Parkinson's disease. Negative findings in some twin 
and case-control studies, and the increasing popularity of the toxic hypothesis during 
the eighties, temporarily discredited the genetic hypothesis. However, the nineties 
have come with a revival of the belief in genetic components being involved in the 
development of the disease. 
Familial aggregation, twin studies, and multiplex families 
Earlier studies of familial aggregation of PD were methodologically flawed or 
imperfect,13' in that they were based on highly selected hospital-series often without 
confirmation of positive family histories or including atypical or monosymptomatic 
family members, or based on parkinson-plus syndromes. 135 More recent, and 
methodologically better, studies do show family aggregation, with a relative risk of 
Table 2.1 The associations' between potentially toxic environmental factors and Parkinson's disease from selected 
case-control studies 
Number of Rural living 
Investigator (reference) patients 
He et al. 232 35 2.2 (1.0-5.0)' 
Tanner et aJ.233 100 0.6 (0.2-1.0) 
Koller et al. 234 150 1.9 (1.2-3.0)' 
Golbe et al.'oo 106 2.0 (1.1-3.7)' 
Wong et at 235 38 4.3 (1.4-13.7)' 
Stem et al.127 149 1.7 (0.9-3.1) 
Semchuk et aI.126.236,237'11 130 0.8 (0.5-1.2) 
Seidler et a1.61 - 380 1.0 (0.7-1.4) 
* Odds ratios (OR) with 95% confidence intervals (95% el) in parentheses. 
t In or'lginal paper, 95% CI was not presented. We reconstructed the 95% CI. 
~ Wheat growing. 
Farming Well water 
drinking 
1.7 (0.8-3.8) 
0.4 (0.2-0.8)' 0.7 (0.4-1.3) 
1.3 (0.9-2.1) 1.7 (1.0-2.7) 
1.3 (0.7-2.6) 1.1 (0.6-2.3) 
2.7 (0.7-9.5) 2.8 (0.9-8.2) 
0.8 (0.5-1.6) 
1.9 (1.1-3.3) 1.1 (0.6-2.0) 
0.8 (0.6-1.1) 0.8 (0.6-1.2) 
§ In original paper, 95% CI was not presented. We reconstructed the 95% CI by using the McNemar test for matched pairs. 
II Herbicide use, the OR for insecticide use was 0.5 (0.2-1.1). 
1T Exposure in first 45 years of life. 
# No association (in article, OR was not provided) . 
Pesticides use 
3.6 (1.0-12.9) 
1.1 (0.7-1.7) 
7.0 (2.0-25.0) 
1.0 
0.9 (0.6-1.5)1 
2.3 (1.3-4.0) 
1.6 (1.1-2.4) 
.... In original paper, exposures were categorized. The overall ORs for exposure versus no exposure were kindly provided by the investigators. 
tt Exposure to anorganic compounds. assessed through job exposure matrix. Data were kindly provided by the investigators. 
Industrial 
toxins 
2.4 (1.3-4.3) 
-' 
1.0 (0.7-1.4)" 
'" 
'" 
Q 
i 
'" 
Table 2.2 The associations' between risk factors and Parkinson's disease from follow-up and selected case-control studies 
Type of study Head trauma Head trauma Family history of 
Investigator (reference) (any) (with loss of PD 
consciousness) 
Stern et aJ. 127 Case-control 2.9 (1.5-5.8) 
Williams et al. 132 Retrospective follow-up 0.9 (0.4-1.9) 
Factor et al. 13O Case-control 2.3 (1.0-4.9)' 3.1 (1.1-8.7)' 
Semchuk et al.126 Case-control 4.0 (1.9-8.3) 5.1 (2.2-11.9) 
Breteler et al.61 Case-control 0.8 (0.5-1.2) 1.3 (0.7-2.3) 2.9 (1.4-6.1) 
De Michele et at 60 Case-control 2.3 (1.0-5.6) 14.6 (7.2-29.6) 
Seidler et al.so Case-contro[ 1.3 (0.8-2.0)' 12.6 (4.4-36.1) 
de Rijk et a1. 133 Prospective follow-up 0.7 (0.3-1.7) 0.6 (0.1-2.5) 2.5 (0.9-7.3) 1 
~ Odds ratios (OR) with 95% confidence intervals (95% el) in parentheses. 
t In original paper, 95% CI was not presented, We reconstructed the 95% CI. 
:t: In original paper, exposure was categorized. The overall OR for exposure versus no exposure was kindly provided by the investigators. 
§ In original paper, data were not presented. Data were kindly provided by the investigators. 
~ Unpublished data. 
Family history of 
dementia 
1.0 (0.6-1.5) 
8.2 (1.7-39.0)' 
1.4 (0.7-3.0)1 
{;1 
'" ~ 
0-
~ 
" 
f 
0-
~ 
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& 
~ 
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around 3 for subjects with first-degree relatives with Parkinson,.,,136,'37 but some 
showed a more elevated risk (Table 2,2),60,61 Several twin studies inititally reported 
very low concordance rates in twins and no differences in concordance rates between 
monozygotic and dizygotic twins, which was interpreted as excluding an important 
genetic component. 138-140 Reappraisal of these studies, however, showed that they 
were methodologically limited and far from conclusive, and their results compatible 
with autosomal dominant inheritance with reduced penetrance, heterogeneity, or a 
multifactorial etiology,'41 A considerable number of studies have been published 
describing families in which several members were affected with PO, 134,142-145 of which 
some with a highly typical clinical picture and pathological confirmation, at least in 
some cases,145 The segregation ratios in most of these families suggest autosomal 
dominant inheritance with reduced penetrance, Recently, in one of these families 
linkage was shown with chromosome 4 (4q21-23), 146 Several groups reported that on 
positron emission tomography of discordant twin pairs many of the clinically 
unaffected sibs showed a decreased 18Fluoro-dopa uptake in the striatum,147-149 and 
the same was found by Brooks and colleagues for some asymptomatic members of 
multicase families, This may suggest that genetic factors do playa role but also that, 
given the difference in clinical expression, environmental factors influence the 
expression of the disease, 
Anticipation 
Increasing number of trinucleotide repeats have been recognized to playa role in the 
etiology of a large number of neurodegenerative diseases in the latest years, Several 
researchers reported a younger average age at onset in the proband generation as 
compared to the parental generation in families with PO'50-'52 However, dectection 
bias could not be excluded in any of these studies and no other evidence for 
trinucleotide repeats involvement in PO exists to date, 153 
Mitochondrial inheritance 
Among PO patients disfunction of the mitochondrial energy chain have been 
described,,,,93,95 Part of the enzyme complexes involved in the mitochondrial electron 
transport are encoded for by the mitochondrial ONA.'54 There is, however, no 
evidence for an increased maternal transmission of the disease,155 Since nuclear DNA 
is also involved in the functioning of the mitochondrial respiration chain genetic 
disturbances in one of these genes remains possible, 156 
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Candidate genes 
Several genes that on biochemical or pathofysiological grounds might be involved in 
PO have been evaluated in association studies. Most of these studies showed no 
allelic associations with PO and candidate gene polymorph isms, 157·160 but associations 
with gene polymorphisms of monoamino oxidase B and A (MAO B, MAO A), 161.162 and 
cytochrome P450 (CYP206)'16.11'.I63.'64 have been reported. As PO, and especially PO 
dementia, shares many neuropathologic and other features with Alzheimer's 
disease,'·10·11.,65.,69 it has been hypothesized that the apolipoprotein E4 genotype, 
which is an important genetic determinant for late-onset Alzheimer's disease, 170·172 
may be associated with PO dementia or PO in general. 173·"0 Yet, in most studies no 
association was found.174-176,180 
Gene-environment interaction 
The most likely hypotheses regarding the etiology of Parkinson's disease at the 
moment are that the disease results from a genetically determined susceptibility for 
exogeneous toxins, from a genetically determined defect that leads to overproduction 
of endogeneous neurotoxins or a decreased clearing of toxic substances that 
normally appear in the brain, or an inherited mitochondrial dysfunction.19•m .l81 It 
seems plausible that there is at least some interaction between genetic and 
environmental factors and that the disease is heterogeneous. With regard to CYP206 
polymorph isms it has been suggested that there might be interaction with smoking, 
and this could also be the case with MAO B.73 However, studies exploring this 
hypothesis have not yet been performed. 
Prognosis 
Progression of the disease 
In PO, extrapyramidal signs only become clinically overt after dopaminergic cell loss 
of approximately 50%,'·5.182.183 and endogeneous dopamine is depleted by 80% at that 
moment'·5.1" The first question that arises is when the excessive degeneration of 
dopaminergic cells actually starts. Several models and time frames have been 
proposed. "5·189 For long, the prevailing idea has been that the duration of the 
preclinical phase in PO is probably more than 20 years. 3.'.I16.'" New evidence, 
however, in part based on positron emission tomography-scanning studies correlating 
in vivo the proportion of functional dopaminergic neurons with the disease duration, 
advocates a much shorter presymptomatic period of approximately 5 years. ' ''·I90 The 
rate of deterioration of nigral cells is probably most prominent and curvilinear in the 
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preclinical or very early phase of Parkinson's disease,3,5,'84,I",'90 approaching a linear 
pattern later on,I87,I88 The rapid decline may be associated with a higher age of 
onset,29,34 (not observed by others)",'91 with more severe symptoms at onset, 
especially bradykinesia and gait disturbances, 29,191 and with cognitive dysfunction, f91, 192 
Goetz et al. did not find external factors (e,g" chemicals, herbicides, antiparkinsonian 
drugs) associated with a rapid progression,34 In some of these studies, no age 
adjustment was made which may have resulted in confounding of the prognostic 
meaning of for example cognitive decline and age, Moreover, as most studies were 
carried out in specialized movement disorder (outpatient) clinics and selected patient 
series, it is not clear whether the results can be generalized to a general PO patients 
population, 
Depression 
A large percentage of PO patients will encounter a depression during their disease, 
the most reliable estimates being around 45%,193-198 which is much higher than in the 
general population. The nature of this mental disorder in PO is not clear. Depression 
has been regarded as reactive to PO, but this hypothesis has been opposed by 
others. 196 An endogenous origin of the depression was proposed as the depression 
is independent of the severity of PO 193, 1'8-201 and appeared often to have its onset 
before, or just after, the symptoms of PO began 67.1'3.1" Reduced serotonin in the 
brain of PO patients has been implicated in the etiology of depression.2°o,202 Low 
serotonin levels in PO patients could partly be attributed to concurrent 
neurodegeneration of serotonin pathways as a result of PO alterations in the 
brain.7"".", Although there may be biological support for serotonergic dysfunction in 
PO, epidemiologic evidence for frequent episodes of depression before the onset of 
PO is limited as it was only found in one community-based" and two hospital-based 
case-control studies, 193,199 and could not be confirmed in the only prospective 
community-based study.133 
Cognitive function 
Dementia appears in a high frequency in PO patients during the course of their 
disease. Estimates of dementia in PO vary around 35%46,203,204 In non-demented PO 
patients, mild cognitive changes such as visuospatial deficits, impaired executive 
functions, and verbal fluency may occur as well,205,206 and the latter might predict 
incident dementia.206 In most studies it was shown that PO patients have a two- to 
three-fold increased risk of dementia when compared with non-parkinsonian 
persons,129,203,207.208 with one community-based study yielding a five-fold increased 
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risk,209 The dementia said to be typical for PD has been referred to as "subcortical 
dementia", but both term and appropiateness are debated;205,21o,21! the pathologic 
substrate has not unequivocally been established nor has a distinct neuropsychologic 
pattern, 
The etiology of dementia in PD remains unsettled, PD dementia may be caused by 
neuropathologic lesions located in the middle part of the sUbstantia nigra",212 or 
cortex,213,2" but concurrent Alzheimer's disease pathology may, in some instances, 
attribute to the dementia in PD as weIL"IO,11,215 In all these neuropathologic studies, 
the number of cases were small, and not always consecutive series were used which 
may lead to selection bias, Little research has been conducted on risk factors for 
dementia in PD, The development of dementia may be promoted by various factors, 
such as predominance20' or severity21' of parkinsonian signs, older age at onset of 
motor manifestation,203,204,207,216 depression,203,216 or rapid progression of the PD,203,207 
Comorbidity 
Concurrent diseases in PD, other than depression and dementia, have less well been 
established and only few recent studies exist. Mostly, information on concomitant 
diseases was retrieved through death certifiates or medical records which limitations 
we have discussed earlier in this review, In PD, low frequencies of cancer,204,21',220 
cerebrovascular diseases,20"2",,,, and ischemic heart diseases20,,22! have been 
reported, in contrast to a higher frequency of lung diseases,,,,20,,219,,,, But these 
findings are conflicting; for PD patients also increased risks of death with heart 
diseases",219 and cancer" were observed, although for cancer this was not 
significant. When comparisons were made between a relatively unselected PD 
population and population controls, Ben-Shlomo and Marmot observed among PD 
patients a higher adjusted risk of dying from ischemic heart disease, cerebrovascular 
disease, and respiratory disease (hazard ratios were 2,3, 3,6, and 3,7, 
respectively)."o The use of different study populations and methodologies could 
account for the ambiguity, Prospective follow-up studies in which disease status is 
directly measured, preferably in a community-based setting, are needed to provide 
more evidence, 
Mortality 
It could be expected that the burden of concurrent diseases, like dementia and 
depression, will reduce the life expectancy of PD patients, Indeed, without exception 
a standardized mortality ratio higher than 1 was observed,,,,,,,,,,,223,22' ranging from 
1,624 to 3.4,22' It was hypothesized that since the beginning of the seventies when 
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levodopa treatment became available, survival in PD patients may have been 
prolonged. Rajput et al. found a marginally favorable effect of levodopa treatment on 
survival but noticed that PD patients who did not receive treatment were in a poorer 
general health." In a more recent study also from Rochester, Minnesota,226 that 
showed improved survival attributed to levodopa therapy, a similar selection bias may 
have occurred and it is doubtful whether this bias can adequately be controlled for. 
Kurtzke and Murphy found some evidence of a 5 years increase in survival in PD 
patients since the introduction of levodopa.227 A shift in PD mortality rates has 
occurred towards the older ages since,'" or even before,"'·22' the introduction of 
levodopa therapy, suggesting an increase in survival of PD patients. It still remains 
unclear whether this is due to levodopa treatment or better general management of 
PD patients. On the other hand, many studies, all based on death certificates, 
reported an increase in age-adjusted PD mortality rate in the last decades.227,228,230,231 
These observations, however, could be readily explained by improved accuracy of 
death certificates or changes in certification,22' changes in diagnostic criteria, 
improved diagnosis, and increased awareness of PD as a prominent 
neurodegenerative disease in the higher ages. Reduced survival has been associated 
with higher age of onset, more severe motor signs at diagnosis, and cognitive 
impairment, 192,224,226,229 
Conclusions and considerations for future research 
PD is among the most frequent neurodegenerative disorders in the elderly and its 
etiology is still largely unknown. In this review, we have discussed diagnostic criteria, 
frequency, determinants, and prognosis of PD. 
In an epidemiologic setting, a diagnosis of PD based on the presence of at least two 
out of three cardinal signs (i.e., bradykinesia, resting tremor, and rigidity) seemed to 
be most applicable but several other criteria have been proposed. The prevalence 
increases with age: from 0.6% for persons between the age of 65 to 69 years to 3.5% 
for those between the age of 85 to 89 years. The incidence has been less well 
established. It has been shown through population screening that register-based 
prevalence figures are probably underestimated. 
Many determinants of PD have been investigated, almost always in a case-control 
design and based on prevalent cases. Women probably run the same risk as men to 
develop PD. There is strong evidence that smokers have an approximately two- to 
three-times reduced risk of PD. This has consistently been reported, also in 
prospective studies, and several plausible explanations based on biologic 
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mechanisms exist. As oxidative stress may be etiologically involved in PD, intake of 
antioxidants may reduce the risk of PD. Of all antioxidants that have been 
investigated, only vitamin E intake may exert a protective effect. The results of 
studies on the associations between PD and toxins, environmental risk factors, and 
head trauma are less unequivocal. Many case-control studies showed a positive 
association between PD and exposure to potentially neurotoxic products such as 
pesticides but these findings may have been flawed by various biases. Nor for 
environmental factors neither for head trauma clear patterns were discerned. 
The duration of the preclinical period in PD is disputed but could be as short as five 
years. The progression of the disease is more rapid if the age of onset of motor 
symptoms is above 70 years of age, if the motor symptoms at time of diagnosis are 
more severe, or if cognitive impairment is present early in the disease. Concomitant 
diseases in PD patients are prevalent, especially dementia, depression, and 
respiratory diseases, but cerebrovascular and ischemic heart diseases may be 
frequently found as well. PD patients have an on average two-fold higher mortality 
rate when compared with control subjects. Pneumonia is of one of the causes of 
death that has been reported most conSistently but vascular diseases have been 
implicated as well. Among PD patients, cancer may occur in a remarkably low 
frequency. However, most studies on comorbidity and mortality were based on death 
certificates, of which the reliability has been proven to be poor, and this could explain 
the discrepancy in findings from various studies. 
To overcome biased study results, more prospective cohort studies on determinants 
of PD patients are needed, preferably in a community setting in which each individual 
is regularly screened for PD. Some of these studies are under way. This design will 
also allow to study prevalence and incidence, and to compare comorbidity, mortality, 
and causes of death between persons with and without PD. Also, cohorts with a 
higher than usual exposure to specific substances that have been involved in the 
etiology of PD, e.g., farmers, could be followed up prospectively or retrospectively. 
In vitro experiments may give clues to which deficits in the cell metabolism, for 
example due to differences in enzyme activity, contribute to the cause of PD. 
Evidence exists that polymorphisms of candidate genes encoding for enzymes 
involved in the production or elimination of free radicals, in specific subunits of the 
mitochondrial respiratory chain, or in xenobiotics, and genes involved in dopamine 
synthesis or metabolism are linked to PD, but this is not conclusive. It seems likely 
that it is not only genetic factors, but the interplay between genetically determined 
susceptibility and specific environmental factors that lead to PD. Therefore, if the 
interaction between these candidate genes and environmental factors will be studied, 
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the results might be more promising. With regard to smoking and neurotoxins in 
relation to PO, the extent to which the effect of exposure is modified or potentiated 
by putative susceptibility genes could be investigated in populations, but this requires 
large numbers of patients. 
Eventually, insight into the etiology of PO could give clues to neuroprotective 
treatment and may result in effective measures to prevent this devastating disease 
in the elderly. 
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3.1 Screening for Parkinson's disease 
3.2 Diagnostic criteria for Parkinson's disease 

3.1 Screening for Parkinson's disease 
Parkinson's disease (PO) is a common neurodegenerative disorder among the elderly 
and its prevalence has been investigated in many studies'·' In studies in which a 
population is actively screened for parkinsonism, usually a stepped diagnostic 
approach is applied, with first a screening for all individuals (by either questions or 
examination, or both) followed by a complete neurological assessment for those who 
screened positive.5.' However, neither the prevalence of complaints suggestive for 
parkinsonian signs, nor the usefulness and test characteristics of a questionnaire as 
a screening instrument to detect probable parkinsonian signs and PO in a general, 
non-hospital· based, population are known. Therefore, we investigated the prevalence 
of subjective complaints and related physical signs suggestive for parkinsonism, the 
capability of a screening questionnaire to detect such physical signs, and the 
sensitivity of a screening questionnaire to detect PO in a general elderly population. 
Methods 
Study population 
The study was part of the Rotterdam Study, a community-based prospective cohort 
study on the frequency and determinants of chronic diseases in the elderly.' The 
conduct of the study has been approved by the Medical Ethics Committee of Erasmus 
University Rotterdam. The study started in June 1990 and the baseline survey was 
completed in June 1993. All inhabitants aged 55 years or over of Ommoord, a suburb 
of Rotterdam, The Netherlands, were invited to participate. Both independently living 
persons and institutionalized persons were included. Of the 10,275 eligible subjects, 
7,983 (78%) agreed to participate and signed informed consent statements. All 
participants were interviewed at home and were invited for subsequent examinations 
at a research center. In the present study we included those 6,568 subjects (82.3%) 
of whom information on subjective complaints was available, who underwent the 
complete neurologic screening examination at the research center, and, to guarantee 
adequate numbers for age-specific analyses, were between 55 and 95 years of age. 
Oata collection 
In the home interview, trained research assistants asked the participants whether they 
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had any tremor, and whether they had experienced slowness and/or stiffness of 
movement. These questions had been reported to be most useful and feasible when 
screening for parkinsonism.7,9 During the screening examination at the research 
center, the presence of related parkinsonian signs (i.e., resting tremor, rigidity, and 
bradykinesia) and essential tremor in a subject was assessed by trained study 
physicians who used a structured protocol and were unaware of the complaints 
reported by the subject." The results from this examination were regarded the gold 
standard. The persons who were suspected of a possible PO were further evaluated 
for a final diagnosis of PO by a neurologist." 
Data analysis 
We calculated age- and sex-specific prevalence estimates by 10 year age categories 
of self-reported tremor and slowness/stiffness of movement as well as of parkinsonian 
signs, postural tremor, and action tremor as assessed by the study physiCians. 
Regarding the use of a questionnaire as a screening tool or diagnostic test, we 
compared the relation between presence of subjective symptoms and corresponding 
physical signs by calculating sensitivity (the probability of a positive test result if the 
disease or sign is actually present) and specificity (the probability of a negative test 
result given the absence of the disease). In addition, we calculated the positive 
predictive values of the subjective complaints for the presence of parkinsonian signs 
(the probability that a person who screened positive actually has the disease or sign), 
and the likelihood ratio of a positive screen ing result (the ratio of the probability of a 
positive test result if the disease is present and the corresponding probability if the 
disease is absent). Positive predictive values inform the clinician about how good the 
test is at predicting the disease and depend on the prevalence of the disease,",12 the 
likelihood ratio indicates whether a test result is informative or not (a ratio greater 
than 1 for a specific variable indicates a raised probability of the presence of the true 
sign or disease whereas a ratio of 1 implies a failure to discriminate between 
presence or absence of the disease). 
The various combinations of symptoms and signs that we used for these calculations 
were the following: (1) we compared tremor as a complaint with the presence of any 
tremor, including resting tremor, postural tremor, and action tremor; (2) we compared 
complaints of slowness and/or stiffness of movement with the combination of either 
bradykinesia and rigidity, and the combination of either bradykinesia, rigidity, or 
reduced fingertapping speed; (3) and we compared the presence of any of the 
complaints with the presence of any of the signs as assessed by the study 
physicians. 
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We also assessed the sensitivity of the screening questions to detect PO patients in 
a population, for all PO patients combined, and stratified according to patients who 
were diagnosed through the study or were already known to be affected by the 
disease. 
Finally, we investigated the extent to which the test characteristics were dependent 
on age. 
Results 
Prevalence 
Table 3.1.1 shows the age distribution of the study population, the percentages of 
subjective complaints as reported by the subjects, and the prevalence of related signs 
as assessed by the study physicians. Thirty-nine percent of the study population were 
men. The proportion of persons who reported to have a tremor and the proportion of 
persons who had experienced slowness/stiffness increased with age and was overall 
higher, for slowness/stiffness even more than three times higher, than estimated by 
the study physicians. The age-specific prevalence estimates for both men and women 
were virtually similar. 
Screening and diagnostic test 
The comparisons between self-reported symptoms and objectively assessed signs, 
calculated as sensitivity, specificity, likelihood ratios, and positive predictive values 
of these subjective complaints for the presence of signs are shown in Table 3.1.2. 
Since we found no differences in prevalences for men and women, we report the data 
for both sexes combined. Both sensitivity and positive predictive values proved to be 
rather low. If questions on tremor and slowness or stiffness would be used to detect 
subjects with either possible tremor, rigidity, or bradykinesia, approximately half of the 
subjects would be missed. 
If the questionnaire was used to detect PO patients with true PO, the sensitivity was 
higher (88.9%), but the screening questionnaire still failed to detect more than 10% 
of the cases. This percentage of missed PO patients increases with age, from 0% in 
the age-group 55 to 64 years, to 25% in the age-group 85 to 94 years. In the latter 
group, the prevalence of PO is high, and, consequently, a substantial number of PO 
patients (3 out of 12) would not have been detected by the screening questionnaire. 
This is illustrated in Figure 3.1.1. After stratification according to patients already 
known to be affected by the disease and those who were detected through the 
screening in the study, the sensitivity was 90.0% and 81.8% (Table 3.1.3). 
Table 3.1.1 Age distribution of the study population and the age-specific prevalence (%) of subjective complaints and 
corresponding signs as assessed by the study physicians 
Subjective complaints Signs as assessed by physicians Numbers of 
subjects 
Age (years) Tremor Slowness/stiffness Any tremor Bradykinesia/rigidity Bradykinesia! 
rigidity/reduced 
fingertapping speed 
55-64 8.6% (218), 18.4% (467) 4.6% (117) 2.6% (66) 3.0% (77) 2533 
65-74 12.5% (295) 21.9% (519) 10.4% (245) 6.4% (151) 7.2% (171) 2367 
75-84 20.5% (271) 32.4% (428) 16.5% (218) 12.2% (162) 15.1% (200) 1323 
85-94 24.9% (86) 49.3% (170) 23.8% (82) 23.8% (82) 29.3% (101) 345 
Total 13.2% (870) 24.1% (1584) 10.1% (662) 7.0% (461) 8.4% (549) 6568 
.. Number of subjects are given in parentheseS. 
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Table 3.1.2 Age-specific sensitivity (sens), specificity (spec), positive predictive values (PPV), and likelihood ratios of 
a positive screening test result (LR) of subjective complaints in screening for corresponding signs (as assessed by 
study physician) 
Tremor Slowness/stiffness Tremor or slownesS/stiffness 
Sens Spec PPV LR Sens Spec PPV LR Sens Spec PPV LR 
Age (years) (%) (%) (%) (%) (%) (%) (%) (%) (%) 
55-64 27.4 92.3 14.7 3.6 39.4 82.1 5.6 2.2 42.4 77.6 12.1 1.9 
65-74 36.3 90.3 30.2 3.7 39.1 79.2 11.4 1.9 48.7 73.9 24.1 1.9 
75-84 45.4 84.4 36,5 2,9 43,2 69.2 16.4 1.4 60.8 63,8 34.5 U 
85-94 48.8 82,5 46.5 2.7 62.2 54.8 30.0 1.4 72.9 50.0 46.5 1,5 
Total 39.3 89,7 29.9 3,8 44.7 77.4 13.0 2,0 54,8 72.7 25,6 2.0 
If reduced fingertapping speed had been included in the gold standard, then for all age categories the sensitivity would have been 58.3%, specificity 71.1 %, and the 
positive predictive value 15.6%. 
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Figure 3.1.1 Sensitivity of either tremor or slowness/stiffness of movement as a 
screening tool for Parkinson's disease (PO) by age (left y-axis). Also, the true age-
specific prevalence of PO is shown, and the prevalence of PO as would have been 
estimated if a screening for PO solely relied on questions on these subjective 
complaints (right y-axis). 
Table 3.1.3 Sensitivity' of any of the subjective complaints (either tremor or 
slowness/stiffness, or both) suggestive for Parkinson's disease (PO) as a screening 
tool for all PO patients, for those who were known to be affected by the disease, and 
for those who were detected through the screening in the study (early PO) 
Age (yrs) 
55-64 
65-74 
75-84 
85-94 
Total 
• Sensitivity in percentage. 
All PD patients 
100.0 
91.3 
89.7 
75.0 
88.9 
Known PD 
100.0 
90.5 
93.8 
72.7 
90.0 
Early PD 
100.0 
100.0 
71.4 
100.0 
81.8 
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Prevalence 
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In this study we provided age-specific prevalence figures of subjective complaints that 
may indicate the presence of parkinsonism. To date, these figures were hardly 
available. Only in the study by Morgante et al. information was shown that might be 
indicative for the age- and sex-specific prevalence of such complaints in an elderly 
population.6 The investigators reported the prevalence of persons that screened 
posilive for possible parkinsonism, using a combination of symptom queslionnaire and 
some physical tests. Their estimates were similar to the prevalence of a comparable 
combination of subjective complaints as eslimated in our study. These findings 
suggest that a surprisingly large proportion of elderly experience slowness or stiffness 
of movement, or tremor, or a combination of these. 
Screening and diagnostic test 
In community surveys on frequency of disease complete case-ascertainment is 
pursued, and a sensilive screening instrument is necessary. However, in a two-phase 
approach, as often used in community surveys on the frequency of PD, a highly 
sensilive screening instrument may load neurologists with a large number of persons 
who have to be evaluated in the second phase but falsely screened positive. A large 
proportion of false posilives will lead to loss of time, more costs etcetera and will 
thereby reduce the benefits of such stepped-screening approach. On the other hand, 
a very specific (and probably time and cost effective) screening instrument may lead 
to underestimation of the frequency of the disease. 
In our study, the screening characteristics of the queslionnaire proved to be poor to 
detect corresponding signs. Allhough the detection rate of PD was considerably 
better, this decreased with age, in particular in the highest age-group, where the 
prevalence of PD is high; the sensitivy of questions to detect PD was only 75%. 
In the ideal study of validiting a screening instrument, all subjects should also 
undergo "the gold standard" test, independently of the screening instrument that is 
evaluated, as was done in our study. The gold standard should ideally be 100% 
accurate. For clinical signs of parkinsonism, especially in an epidemiological setting, 
this will be difficull to achieve. Especially in elderly, comorbidity may mimic signs 
suggestive for parkinsonism, especially slowness or stiffness of movement, and thus 
reducing the discriminative ability of these complaints. Also, in an early stage of the 
disease, some of the parkinsonian signs may be very subtle or, especially tremor, 
may be infrequently present and will not always be noticed during the screening 
examination. This may have caused us to misclassify some subjects who actually had 
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signs as having no signs. As a result, we may have underestimated the sensitivity of 
the questionnaire. Moreover, incorporation of more questions related to complaints 
typical for parkinsonism into the screening questionnaire may improve the sensitivity. 
The high prevalences of subjective complaints compared to the relatively low true 
prevalence of probable parkinsonian signs (and, eventually, even lower prevalence 
of parkinsonism),,10 will result in low positive predictive values for parkinsonian signs 
as shown in our study. The positive predictive values were higher in the higher age 
groups. This was expected since positive predictive values increase with increasing 
prevalence."·14 
Modification of test characteristics 
The very few published studies that reported on sensitivity and specificity of screening 
questionnaires for parkinsonism showed higher values for sensitivity and 
specificity.5,7,9 These studies were based on small samples of well diagnosed hospital-
based PO patients and healthy controls. As the spectrum of disease in the people 
included in these validation studies probably differed from the spectrum of disease 
in the general population in which the test was to be used, the reported sensitivities 
and specificities will have overestimated the actual performance of the screening 
instrument. Sensitivity and specificity are partly functions of individual patient 
characteristics,,,,,,,15,16 As clearly demonstrated in our study, age was such a 
characteristic that strongly modified sensitivity and specificity, Moreover, if a general 
population is screened for parkinsonism, both PO patients in a very early phase of the 
disease, with cardinal signs less prominenlly present, and PO patients with a clear 
clinical picture will emerge, Intuitively, it can be conceived that in both PO populations 
a screening questionnaire will perform differenlly as we showed with our data, being 
less sensitive and specific in patients in an early phase of the disease, However, in 
the latter population, the age-specific estimates of the sensitivity fluctuated due to the 
small number of newly detected PO patients, 
We conclude that complaints suggestive for parkinsonism, such as tremor, slowness 
of movement, and stiffness, are frequent in a general elderly population. Their 
presence increases the likelihood that parkinsonian signs are present, but are of 
relatively litlle use when applied as the sole screening instrument to detect 
parkinsonian signs in a general elderly population. The validity of a screening 
instrument should be assessed only in the same population in which the screening 
instrument will be used, and preferably in subgroups. 
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3.2 Diagnostic criteria for Parkinson's disease 
None of the numerous diagnostic criteria for Parkinson's disease (PO) have been 
compared in diverse population settings. Our preliminary experience in a South 
American city is that the application of different criteria may significantly impact on 
prevalence data.' Differing diagnostic criteria may obscure the comparison of 
prevalence studies from different regions, and etiologic insights drawn from such 
comparisons may be flawed. In this article, we assess, for three recent community 
studies, the extent to which various diagnostic criteria for PO may affect prevalence 
estimates. We also address, in general, the usefulness and limitations of these 
diagnostic criteria for community studies. 
Methods 
We used data from three separate community studies of PD. These studies were 
conducted in Junln, a small city in Buenos Aires Province, Argentina; 1.2 in Ommoord, 
a suburb of Rotterdam, the Netherlands;' and in Riposto (Catania Province), Santa 
Teresa di Riva (Messina Province), and Terrasini (Palermo Province), three semi-rural 
municipalities in Sicily, Italy'" For simplicity, we refer to these investigations as "the 
Junln Study," "the Rotterdam Study," and "the Sicily Study." Each investigation relied 
on a two-phase approach to detect PD. In phase 1, specially trained personnel 
screened all participants for parkinsonism, and those suspected of having the 
syndrome were invited for a neurological examination. In phase 2, project 
neurologists conducted the examinations, and, when parkinsonism was present, they 
distinguished PO from other causes of this syndrome. Table 3.2.1 provides additional 
details for the populations studied and the case-finding methods used. 
Diagnostic criteria 
In the current research, we applied eight sets of diagnostic criteria to assess the 
impact of different clinical definitions of PD. The sets included variations of cardinal 
signs (i.e., resting tremor, bradykinesia, rigidity, and impaired postural reflexes), and 
of additional clinical features (i.e., duration of symptoms, asymmetry of cardinal signs, 
and response to drug treatment). For each set, the diagnosis of PO in a subject with 
parkinsonism was made only if no other cause of parkinsonism was apparent. 
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The eight sets of diagnostic criteria are specified in Table 3.2.2. Set 1 was used in 
the Rotterdam Study and the Sicily Study.'" Because this set is the least restrictive, 
it was used as the reference for comparison with other sets. Set 2 was used in the 
Junin Study.' Set 3 was derived from the United Kingdom Parkinson's Disease 
Society Brain Bank criteria.' Set 4 was applied in a prevalence study from Bombay, 
India,' and also resembles the diagnostic criteria of Caine et al.'o Set 5 ignores 
impairment of postural reflexes, and was derived from diagnostic criteria of Rajput et 
al." Sets 6-8 require cardinal signs (same as set 1) and specify additional clinical 
features: duration of symptoms, asymmetry of cardinal signs, or response to anti-
Table 3.2.1 Sample or popUlation sizes and case-finding methods for three studies of 
Parkinson's disease: Junin (Argentina), Rotterdam (the Netherlands), and Sicily (ltaly)* 
Sample or population 
size, restricted to 
persons 50-89 years of 
age, except for 
Rotterdam where the 
age range is 55-89 
years 
Phase 1: 
screening 
Questions 
(personnel) 
Examination 
(personnel) 
Junfn 
5,728 inhabitants; 
systematic sample 
of blocks and 
dwellings 
throughout the city 
Questions only, to 
one responsible 
adult who answers 
for all adult 
household 
members 
Tremor, 
bradykinesia, 
rigidity, previous 
diagnosis of PO 
(interviewers) 
Not applicable 
Rotterdam 
6,833 inhabitants; 
complete 
enumeration of 
the suburb 
Ommoord 
Questions and 
brief physical 
examination, in 
each individual 
Previous 
diagnosis of PO, 
antiparkinsonian 
drug use 
(interviewers) 
Resting tremor, 
bradykinesia, 
rigidity, impaired 
postural reflexes 
(physicians) 
Sicily 
6,746 inhabitants; 
complete 
enumeration of 
three semi-rural 
municipalities 
Questions and brief 
physical test, in each 
individual 
Tremor, 
bradykinesia, rigidity, 
previous diagnosis of 
PD 
(physicians) 
Tandem gait, elbow 
tone 
(physicians) 
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Table 3.2.1 (continuation) 
Junin Rotterdam Sicily 
Phase 2: 
neurological Assessment of Motor part of Assessment of 
examination of resting tremor, UPDRS,15 additional resting tremor, 
persons screened bradykinesia, rigidity, neurological items bradykinesia, 
positive impaired postural (neurologists or rigidity, impaired 
(personnel) reflexes, additional specially trained postural reflexes, 
neurological Items residents in additional 
(neurologists) neurology) neurological Items 
(neurologists) 
Documentation of Dichotomous Five-point scale of Dichotomous 
cardinal signs UPDRS 
Documentation of From history, From history, From history, 
duration verification in medical verification in medical verification In 
records records medical records 
Documentation of Not systematically Score difference of Dichotomous 
asymmetry of assessed ;;:.;2 on UPDRS for all 
cardinal signs 8 bilateral iternst 
Documentation of From history, From history r From history, 
treatment verification in medical Verification in medical verification in 
responsiveness records records medical records 
* Abbreviations: PO, Parkinson's disease; UPDRS, Unified Parkinson's DIsease Rating Scale. 
t Resting tremor of hand or foot; rigklity of upper or lower extremity; finger lappIng; grip; rapid alternating hand movements; 
leg agility. 
parkinsonian medication. The requirement of at least one year duration of motor 
symptoms (set 6) was proposed by Koller," and the requirement of asymmetry (set 
7) was advanced by Caine et al. 1O Responsiveness to antiparkinsonian medication 
(set 8), where applicable, is widely accepted as an inclusion criterion.""'" 
In the Junln Study and the Sicily Study",4 a dichotomous scale was used to assess 
the presence or absence of cardinal signs, whereas in the Rotterdam Study' the five-
point Unified Parkinson's Disease Rating Scale (UPDRS) was applied." To increase 
methodologic comparability across the studies, we converted the data from the 
Rotterdam Study to a dichotomous scale by scoring any presence of resting tremor, 
bradykinesia, or rigidity (score 1-4 on the UPDRS) as "present." 
Table 3.2.2 Prevalence (cases per 100,000 population) of Parkinson's disease, by diagnostic criteria, age, and study 
'" 
'" Junin" Rotterdamt Sicilif 
Diagnostic criteria Age (yrs) Cases Prevalence Cases Prevalence Cases Prevalence 
Cardinal signs only: 
Set 1 (reference) 
At least two cardinal signs of the following 50-59 3 153 2 172 3 116 
four: resting tremor, bradykinesia, rigidity, 60-<39 17 773 10 367 13 621 
and impaired postural reflexes. 70-79 21 1,727 27 1,320 31 1,978 
80-89 11 3,125 28 3,111 15 3,055 
Total 52 67 62 
Set 2 
At least two cardinal signs of the following 50-59 3 153 2 172 3 116 
four: resting tremor, bradykinesia, rigidity, 60-69 14 637 10 367 13 621 
and impaired postural reflexes. One sign 70-79 21 1,727 27 1,320 31 1,978 
must be either resting tremor or 80-89 11 3,125 28 3,111 15 3,055 
bradykinesia. Total 49 67 62 
Set 3 
At least two cardinal signs of the following 50-59 51 2 172 3 116 
four: resting tremor, bradykinesia, rigidity, 60-69 8 364 10 367 12 574 
and impaired postural reflexes. One sign 70-79 19 1,563 27 1,320 28 1,787 
must be bradykinesia. 80-89 10 2,841 28 3,111 13 2,648 
Total 38 67 56 
Set 4 
At least three cardinal signs of the following 50-59 51 2 172 3 116 
four: resting tremor, bradykinesia, rigidity, 60-69 9 500 9 330 11 526 9 
and impaired postural reflexes. 70-79 17 1,398 18 880 26 1,659 
-§ 
80-89 8 2,273 21 2,333 12 2,444 0-~ 
Total 35 50 52 
"' '" 
Set 5 
" or At least two cardinal signs of the following 50-59 3 153 2 172 3 116 <0 ~ 
three: resting tremor, bradykinesia, and 60-69 637 10 0 14 367 13 621 • a: 
rigidity. 70-79 21 1,727 26 1,271 31 1,978 n 
" 80-89 11 3,125 26 2,889 15 3,055 0 
Total 49 64 62 
~. 
0-
Cardinal signs with additional clinical ~ ;;0 
features: §: 
• 0 
Set 6 ~ 
.' At least two cardinal signs of the following 50-59 3 153 3 116 ~ 
0 
four: resting tremor, bradykinesia, rigidity, 60-69 12 546 13 621 0 • 0 
and impaired postural reflexes. 70-79 20 1,645 28 1,787 
There must be at least one year duration of 80-89 8 2,273 15 3,055 
symptoms. Total 43 59 
Set 7 
At least two cardinal signs of the following 50-59 86 39 
four: resting tremor, bradykinesia, rigidity, 60-69 5 183 4 191 
and impaired postural reflexes. 70-79 17 831 10 638 
One Of more of the first three signs must 80-89 14 1,556 7 1,426 
display asymmetry. Total 37 22 
SetS 
At least two cardinal signs of the following 50-59 2 102 2 172 2 77 
four: resting tremor, bradykinesia, rigidity, 60-69 8 364 7 257 9 430 
and impaired postural reflexes. 70-79 13 1,069 17 831 21 1,340 
If treated, there must be a therapeutic 80-89 7 1,989 25 2,778 8 1,629 
response to anti-parkinsonian medication. Total 30 51 40 
... Denominators were: 50-59 = 1,962; 60-69 = 2,198; 70-79 = 1,216; 80-89 = 352. 
t Denominators were: 50-59 = 1,161; 60-69 = 2,726; 7Q..79 = 2,046; 80-89 = 900. 
a> 
+: Denominators were: 50-59 = 2,596; 60-69 = 2,092; 70-79 = 1,567; 80-89 = 491. '"' 
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Data analysis 
We examined the data in terms of the different sets of diagnostic criteria, both within 
and across the three studies. For each study separately, we present the number of 
subjects with PO, by age, according to the various sets of diagnostic criteria. We also 
present age-specific prevalences. Our analyses pertained to subjects younger than 
90 years of age because the Junln Study and the Sicily Study included only a few 
individuals who were 90 years of age or older. We decided not to present data 
separately by sex because recent prevalence data have an inconsistent sex pattern. 
Results 
Table 3.2.2 shows the impact of various sets of diagnostic criteria on numbers of 
cases of PD. Set 1 was the reference for comparison, and it yielded the highest 
numbers of cases. Sets 1-5 pertain only to cardinal signs. Among these sets, set 4 
led to the greatest loss of cases: Junln, 33%; Rotterdam, 25%; Sicily, 16%. That set 
required three or four cardinal signs. The least loss of cases (Junin, 6%; Rotterdam, 
0%; Sicily, 0%) came with set 2 which required two, three, or four cardinal signs with 
one being either resting tremor or bradykinesia. For set 5, which ignored impaired 
postural reflexes, the loss of cases was also minor: Junin, 6%; Rotterdam, 5%; Sicily, 
0%. 
Sets 6-8 required at least two of the four cardinal signs, together with additional 
clinical features. For set 6, which required at least one year duration of symptoms, 
the loss of cases was greater in the Junin Study than in the Sicily Study, 17% versus 
5% (again using set 1 as reference). The Rotterdam Study was excluded from this 
comparison because data on duration of symptoms were lacking for several subjects 
with PD. For set 7, which required any of resting tremor, bradykinesia, or rigidity to 
display asymmetry between left and right limbs, the loss of cases was severe: 45%, 
Rotterdam; 65%, Sicily. Data on asymmetry were not systematically obtained in the 
Junln Study. For set 8, which required a therapeutic response for those subjects 
treated with anti-parkinsonian medication, the loss of cases was also substantial: 
42%, Junin; 24%, Rotterdam; 36%, Sicily. 
Table 3.2.2 shows also the impact of the above-mentioned sets of diagnostic criteria 
on the age-specific prevalence of PD. The patterns seen here are consonant with the 
results presented above. For example, the most restrictive requirement is that one or 
more of resting tremor, bradykinesia, or rigidity display asymmetry (set 7). This 
finding holds true across the spectrum of age, for both the Rotterdam and Sicily 
studies. 
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Discussion 
In prevalence studies of PO in geographically defined communities, there is a need 
for diagnostic criteria that are credible yet practical to apply, even outside of clinics. 
Postmortem neuropathologic examination of the brain is generally considered to be 
the gold standard for the diagnosis of PO' but during life, the diagnosis can only be 
based on the clinical picture. Although many recent prevalence studies of PO have 
followed similar case-finding approaches (involving door-to-door screening and 
physical examination),'·3.4.9.16." there has been little agreement on what diagnostic 
criteria to use and it has remained unclear to which extent different diagnostic criteria 
may affect prevalence estimates of PD. 
Our study clearly demonstrates the differential impact of alternative sets of diagnostic 
criteria on the prevalence of PD. Some combinations of at least two cardinal signs 
(i.e., sets 1-2 versus set 5, Table 3.2.2) did not appreciably change the prevalence. 
By contrast, the use of at least two cardinal signs together with additional clinical 
requirements (viz., set 1 versus sets 7-8, Table 3.2.2) led to more pronounced drops 
in prevalence. We will consider some issues related to the diagnosis of PO, and 
finally endorse a set of diagnostic criteria for use in community studies. 
Resting tremor or bradykinesia, or both 
The requirement that one cardinal sign must be either resting tremor or bradykinesia 
had almost no effect on prevalence (set 1 versus set 2, Table 3.2.2). We see no 
reason to recommend this requirement for community studies of PD. 
Bradykinesia 
The requirement that one cardinal sign must be bradykinesia had mixed effects on 
prevalence (set 1 versus set 3, Table 3.2.2). We do not know whether this 
requirement has value for community studies of PO; the possibility remains that it 
may cause the prevalence to be somewhat understated. 
Three of four cardinal signs 
The requirement of at least three cardinal signs from resting tremor, bradykinesia, 
rigidity, and impaired postural reflexes reduced the prevalence noticeably (set 1 
versus set 4, Table 3.2.2). We cannot recommend this requirement for community 
studies of PO because it would exclude less severe forms of the condition. 
Impaired postural reflexes 
Disregarding impaired postural reflexes as a cardinal sign appears to alter prevalence 
only slightly (sets 1-2 versus set 5, Table 3.2.2). This finding calls into question the 
need to consider impaired postural reflexes in the diagnostic criteria of PO, especially 
since 1) impaired postural reflexes in the elderly is not specific for PO, and 2) the sign 
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usually occurs late in the course of the disease.19 
Duration of symptoms 
The requirement of at least one year duration of symptoms had noticeably more 
impact on prevalence for the Junin Study than for the Sicily Study (set 1 versus set 6, 
Table 3.2.2). Thus, at least in some populations, a duration requirement would likely 
exclude several subjects with recent onset of PD. For this reason, we do not endorse 
incorporating a duration requirement into diagnostic criteria for community studies of 
PD. 
Asymmetry of cardinal signs 
The requirement that at least one of resting tremor, bradykinesia, or rigidity displays 
asymmetry had a dramatic impact on prevalence (set 1 versus set 7, Table 3.2.2). 
A rigorous assessment of asymmetry may require expertise in PD that is not always 
available in the field setting of a community study. Treatment of PD may obscure the 
asymmetry, and, in the more advanced stages of the condition, asymmetry of 
symptoms may be inapparent. Moreover, asymmetry of cardinal signs of parkinsonism 
is not unique to PD; it is reported in some cases of progressive supranuclear palsy 
and multiple system atrophy."'" These considerations suggest the impracticality of 
requiring asymmetry of cardinal signs in the diagnostic criteria for community studies 
of PD. 
Response to anti-parkinsonian medication 
The requirement of treatment response (set 1 versus set 8, Table 3.2.2) had a lesser, 
but still sizable, impact on prevalence than did the requirement of asymmetry of 
cardinal signs (set 1 versus set 7). Treatment response is of questionable value in 
the field setting of a community study. First, treatment response presupposes that a 
treatment was administered. Some community studies have identified many persons 
with PD who had never been diagnosed previously and, therefore, had never been 
treated.f.'.fS Such persons would be judged differently than established, treated PD 
patients. A bias may be introduced if there are important differences, clinical or 
sociodemographic, between treated and untreated persons with PD. Second, 
treatment response relates to the choice of medication (Ievodopa versus other drugs), 
the timing of starting treatment (earlier versus later in the course of the disease), and 
the adequacy of the dosing. Third, there is no completely satisfactory approach to 
measuring treatment response. Objective scales such as the UPDRS are not routinely 
used in medical practice. Subjective assessment is hampered in patients with long 
disease duration who no longer recall the initial effect of a treatment that over time 
has provided diminishing benefit. Medical records documenting the initial treatment 
response may not always be available. Because of these limitations, we would not 
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include treatment response as a requirement in the diagnosis of PD when conducting 
community studies. 
Final recommendation 
For community studies of PD, we favor diagnostic criteria that are more easily applied 
in the field context and that tend to be more inclusive than exclusive. We recommend 
the following: at least two of resting tremor, bradykinesia, or rigidity, in the absence 
of other apparent causes of parkinsonism. 
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4.1 Prevalence of Parkinson's disease in the 
Rotterdam Study 
Parkinson's disease (PO) is among the most frequent chronic neurodegenerative 
diseases in the elderly. However, prevalence estimates of PO vary widely, ranging 
from 10 to 405 per 100,000 population.' This variation may be due to differences in 
case-finding procedures, in diagnostic criteria, and in the age distribution of 
populations. We present the results of a population-based PO prevalence survey 
among 6,969 subjects living in Rotterdam, the Netherlands, in which we examined 
each individual neurologically. 
Methods 
Study population 
This study forms part of the Rotterdam Study, a population-based cohort study on 
prevalence, incidence and determinants of diseases in the elderly.' The four main 
areas of interest of the Rotterdam Study are neurologic diseases, ophthalmologic 
diseases, locomotor diseases, and cardiovascular diseases. The cross-sectional 
survey started in 1990 and was completed in June 1993. All inhabitants of Ommoord, 
a suburb of Rotterdam, the Netherlands, who were 55 years of age or older, either 
living independently or institutionalized, were invited to participate in the study by mail 
and were contacted by telephone 2 weeks later. Names and addresses were drawn 
from the municipal register, which is reliable, complete and updated weekly. Of the 
10,275 eligible subjects, 7,983 (78%) agreed to participate and signed informed 
consent statement. All participants were interviewed at home and most were 
subsequently examined at a research center. The number who visited the research 
center decreased slightly, to 7,129 (69%), due to refusal, disease, or death. In this 
prevalence study we included the 6,969 (68%) subjects who had a neurologic 
screening examination or who were using antiparkinsonian medication or reported 
that they had PD. 
Case-finding and diagnostic procedures 
To assess the prevalence of PO we used a two-phase design. In the first phase, all 
participants were asked about previous diagnosis of PO, and any drug use was coded 
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according to the Anatomical Therapeutic Chemical (ATC) classification index.' In 
addition, every participant was neurologically examined by one of the study 
physicians. All subjects who either used antiparkinsonian drugs (ATC-code N04), 
reported that they had PO, or had at least one possible cardinal sign of parkinsonism 
(Le., resting tremor, rigidity, bradykinesia, or impaired postural reflexes) at the 
neurologic screening examination were invited for further evaluation in a second 
phase. 
In the second phase, those who screened posilive were examined by a neurologist 
or a neurologist-in-training. A structured clinical work-up, comprising the motor 
examination of the Unified Parkinson's Disease Rating Scale (UPDRS),' a neurologic 
examination, and standardized history taking, was used to establish the diagnosis 
parkinsonism and to classify this parkinsonism. We used diagnostic criteria agreed 
upon in EUROPARKINSON (European Community Concerted Action on the 
Epidemiology of Parkinson's disease).' Parkinsonism was diagnosed as 'definite' if 
at least two of the cardinal signs were present in a subject not taking anti parkinsonian 
drugs, or if in a subject treated wilh antiparkinsonian medication one or more signs, 
documented by medical history, had improved by treatment. Parkinsonism was 
classified as 'possible' if only one sign was present in an untreated subject or if a 
specifically treated patient did not report benefit from treatment and had only one 
cardinal sign. Possible parkinsonism is not included in the prevalence figures. All 
newly diagnosed patients with definite parkinsonism were reevaluated by a second 
neurologist. 
PO was defined in a person with definite parkinsonism by exclusion of all other 
possible causes of parkinsonism. Parkinsonism associated with other causes included 
(1) drug-induced (Le., following use of neuroleptics or other anti-dopaminergic drugs 
in the 6 months before onset of symptoms and with no history of parkinsonism); (2) 
parkinsonism related to cerebrovascular disease (Le., with a clear time relationship 
between cerebrovascular event and onset of atypical parkinsonism, preferably 
supported by neuroimaging, usually without tremor); (3) parkinsonism associated with 
dementia; (4) parkinsonism in multiple system atrophy or progressive supranuclear 
palsy; and (5) other parkinsonism. Included in this last category were subjects with 
more than one possible cause or wilh no clear time relationship between the possible 
cause and the parkinsonism, as well as those subjects in whom all other possible 
causes of parkinsonism could be excluded but who had not shown any progression 
over more than 15 years in the course of the disease and who did not respond to 
anti parkinsonian drugs. 
Some screened positive subjects could not be evaluated in the second phase for a 
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variety of reasons, such as refusal, disease, or death. For these subjects we obtained 
additional information from medical records of neurologists and general practitioners. 
They had to meet the same inclusion and exclusion criteria for parkinsonism and PO 
as those who could be examined. 
In demented patients the neurologic screening examination was often difficult to 
conduct or to interpret. Therefore, irrespective of the results of the screening, we 
reviewed the medical records of demented institutionalized participants to check for 
a previous diagnosis of PO or secondary parkinsonism. 
Data analysis 
We calculated age- and sex-specific prevalence figures of parkinsonism and PO for 
the study population that underwent a complete first-phase screening. The prevalence 
figures are presented in 10-years age groups and are presented separately for men 
and women. To determine whether overall age-adjusted prevalences for men and 
women differed significantly, we performed a logistic regression analysis in which 
gender and age were entered as determinants in the model. 
Results 
Of the 6,969 participants, 653 (9.4%) screened positive and were invited for 
evaluation in the second phase. Table 4.1.1 shows the age and sex distributions of 
the study population and the percentages of subjects who screened positive. 
Table 4.1.1 Age and sex distribution of the study population and percentages 
of subjects screening screen positive 
Men Women Totat 
Age Totat Screen- Total Screen- Total Screen-
(years) positive positive positive 
55-64 1098 4.4 (48) 1471 3.1 (45) 2569 3.6 (93) 
65-74 1090 9.1 (99) 1389 7.3 (102) 2479 8.1 (201) 
75·84 521 18.2 (95) 940 14.8 (139) 1461 16.0 (234) 
85-94 101 25.7 (26) 336 27.7 (93) 437 27.2 (119) 
95+ 3 (0) 20 30.0 (6) 23 26.1 (6) 
Total 2813 9.5 (268) 4156 9.3 (385) 6969 9.4 (653) 
.. Numbers of subjects who screened positive are given in parentheses. 
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In the second phase, 499 subjects who screened positive (76%) were clinically 
examined. Of the subjects evaluated, we found 89 subjects to have parkinsonism, 
and in 69 of these this parkinsonism was attributed to PD. In 128 of the 154 subjects 
who screened positive who could not be further examined, we obtained a sufficient 
amount of other medical information on which to base the diagnosis. This revealed 
another 40 subjects with parkinsonism, of whom 28 met the diagnostic criteria for PD. 
Therefore, we identified a total of 129 subjects with parkinsonism of whom 97 
subjects were suffering from PD. The other diagnoses included parkinsonism 
associated with dementia (9/129); drug-induced parkinsonism (3/129); parkinsonism 
related to vascular disease (1/129); multiple system atrophy (2/129), or progressive 
supranuclear palsy (1/129); and other parkinsonism (16/129). Table 4.1.2 presents 
the age- and sex-specific prevalence figure~ of parkinsonism and PO in the total 
study population. 
Table 4.1.2 Prevalence' (%) of any parkinsonism (PS) and Parkinson's disease (PO) 
in the Rotterdam Study 
Men Women Tolal 
Age PS PD PS PD PS PD 
(yrs) 
55-64 0.4 (4) 0.4 (4) 0.3 (5) 0.2 (3) 0.4 (9) 0.3 (7) 
65-74 1.4 (15) 1.2 (13) 1.1 (15) 0.8 (11) 1.2 (30) 1.0 (24) 
75-84 3.8 (20) 2.7 (14) 4.5 (42) 3.4 (32) 4.2 (62) 3.1 (46) 
85-94 5.0 (5) 3.0 (3) 6.3 (21) 4.8 (16) 5.9 (26) 4.3 (19) 
95' (0) (0) 10.0 (2) 5.0 (1) (2) (1) 
Tolal 1.6 (44) 1.2 (34) 2.0 (85) 1.5 (63) 1.9 (129) 1.4 (97) 
* Numbers of patients are given in parentheses. 
The prevalence increased with age, even in the highest age categories. The 
prevalence of PO did not differ significantly between men and women. 
Twelve subjects with PO (12%) were newly diagnosed through the study protocol; 11 
of them were 70 years of age or older. Of the 75 subjects who reported that they had 
PO, 12 (16%) turned out to be not affected by the disease. Seven of those participants 
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had never been diagnosed with PD, and five subjects with a previous diagnosis of PD 
were excluded since they did not fulfill the inclusion criteria for PD used in this study; 
one of these patients had a nonprogressive hemiparkinsonism; two patients did not 
have parkinsonism according to the UPDRS, and the two other patients had more than 
one possible cause for their parkinsonism. In addition, we classified one subject with 
a previous diagnosis of multiple system atrophy and two subjects with a previous 
diagnosis of progressive supranuclear palsy as having PD since no other neurologic 
symptoms were present to justify the previous diagnoses. Of all patients with PD, 73 
(75%) used antiparkinsonian medication. 
Discussion 
We found a consistent and rapid increase in the prevalence of both parkinsonism and 
PD with age, with no leveling off in the highest age categories and no significant 
gender difference. 
The overall response in our study was good but nonresponse may have led to a certain 
underestimation of the prevalence. Indeed, in the Rotterdam Study, the prevalence of 
PD was higher among those who screened positive who could not be examined in the 
second phase than among those who could. Furthermore, we classified parkinsonian 
participants with atypical parkinsonism or with no clear time relationship between the 
possible cause and the parkinsonism as having 'other parkinsonism'. This may also 
have resulted in some underestimation of the prevalence of PD in our study. 
Prevalences of PD, reported in various studies, show wide variation.' Many of these 
studies were based on existing medical records.'·" Differences in case-finding 
procedures, in diagnostic criteria, and in accessibility and level of medical services may 
hamper comparison. Some of these studies dated from before levodopa treatment was 
available, and the advent of this treatment may have influenced survival of 
parkinsonian patients,13.14 and thus the prevalence. Moreover, patients who failed to 
seek medical attention for their parkinsonism were not systematically included in these 
studies. PD is a neurodegenerative disease with an insidious onset, and parkinsonian 
symptoms are likely to remain unrecognized or to be misclassified or accepted as part 
of a normal aging process. This also leads to underestimation of the prevalence and 
might explain the lower prevalence estimatess." than that reported in our study, as well 
as the decrease in prevalence of PD in the higher age categories reported in some 
studies.9.11 
Not until 1985 were there published results of population-based prevalence studies on 
PD. All population-based studies showed an increase in the prevalence with age, even 
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in the highest age category. 15-21 Although the methodology used in these studies should 
limit the underestimation of prevalence mentioned before, the age-specific prevalence 
estimates for the age category 70 to 80 years varied from 0.6% in China 15 to 1.3% in 
France," 1.8% in our study, and 2.0% in Sicily." The prevalence estimates of 
parkinsonism and PD in our study are among the highest reported thus far and are in 
concordance with the results of the Sicilian and French studies, which, together with 
the Chinese study, were the only ones to administer a direct screening instrument to 
each individual, including a brief neurologic examination by a physician. The 
discrepancy between the results of the Chinese study and those of the studies 
conducted in Rotterdam, Sicily, and France could be due to differences in survival of 
PO patients, in classification, and in etiologic factors. 
Although some prevalence studies indicated higher prevalences for men'···15.20 or for 
women:'!O we, like some other investigators,"·"·f7·2f found no significant gender 
differences in the prevalence. 
The screening instrument used in this study enabled us to detect 12 subjects with PO 
(12%) who had not been diagnosed before. Remarkably, overall prevalence figures in 
our study were similar to those in the Sicilian and French studies, in spite of a lower 
percentage of newly diagnosed subjects in the Rotterdam Study (12% versus 35% and 
27%), which may be due to differences in referral habits and in accessibility of medical 
services. 
In conclusion, we found an increase in the prevalence of parkinsonism and PO with 
age, even in the highest age categories. A substantial proportion of patients with PO 
were previously undetected, especially among the oldest. 
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4.2 Prevalence of Parkinson's disease in Europe 
Parkinson's disease is one of the most common chronic neurodegenerative diseases 
in the elderly. Prevalence estimates of Parkinson's disease vary widely across studies 
and countries 1 but the interpretation of this geographical variation is hampered by 
differences in methodology and diagnostic criteria. Consequently, it remains unclear 
whether a true variation exists. As part of a European Community Concerted Action 
on the Epidemiology of Parkinson's disease (EUROPARKINSON),' we conducted a 
collaborative comparison of five European prevalence surveys of all types of 
parkinsonism, including Parkinson's disease. 
Methods 
EUROPARKINSON is a collaborative effort to study the prevalence, incidence, and 
determinants of Parkinson's disease in Europe including five studies, one each from 
France,' Italy,' and the Netherlands,' and two from Spain. All five studies are 
community surveys of both independently living and institutionalised elderly subjects 
55 years of age or older, with a sample size of at least 1, 000 subjects. The 
characteristics of the five study populations are summarised in Table 4.2.1. 
Case finding procedures 
All studies used a two-phase design to assess the prevalence of parkinsonism and 
Parkinson's disease. In phase 1, participants were screened in person using a 
symptom questionnaire and a brief physical examination. Those who screened 
positive were extensively evaluated by neurologists in phase 2. The only exception 
was the study in France in which the physical examination was not used to screen 
independently living subjects, while all institutionalised participants were examined by 
a neurologist without any screening. Details of the screening procedures used in each 
study are presented in Table 4.2.2. 
Diagnostic criteria 
With two exceptions, the five studies adhered to common diagnostic criteria for 
parkinsonism and Parkinson's disease. Parkinsonism was diagnosed when at least 
two of four cardinal signs (Le., resting tremor, rigidity, bradykinesia, and impaired 
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Table 4.2.1 Characteristics of the study populations 
Population Investigators Geographic Urban Size Res- Age Type of Years 
location or of panse (yr) sample 
of 
rural study rate 
popu- study 
latian 
France Oartigues Gironde Urban 3,149 71% 65+ Stratified 1988-
(GirofJde) et al.3 region and random 1989 
rural sample 
ttaly Amaducci 8 provinces Urban 4,510 80% 65+ Stratified 1992-
(8 centers) et al.
4 across Italy and random 1994 
rural sample 
The Breteler City of Urban 6,969' 68% 55+ Complete 1990-
Netherlands et al.6 Rotterdam, enumerat 1993 
(RoUetdam) Ommoord Ion 
district 
Spain Lopez-Pousa Group of Rural 1,450 64% 70+ Complete 1990-
(Girona) et al. villages in enumerat 1991 
Girona ion 
province 
Spain Manubens- City of Urban 1,127 82% 70+ Stratified 1991 
(Pamp/ona) Bertran et al. Pamplona random 
sample 
* In the present comparison, persons aged 55 years to 64 years (n = 2569) who particpated in the Rotterdam 
Study, were excluded. 
postural reflexes) were present in a subject not receiving antiparkinsonian medication, 
or if one or more cardinal signs, documented by medical history, had improved by 
antiparkinsonian treatment. However, in the study from France, untreated subjects 
with an isolated typical resting tremor were also included. In the study from Girona, 
Spain, only untreated subjects with at least three cardinal signs or treated subjects 
with at least two cardinal signs were included. Parkinson's disease was defined 
among those affected by parkinsonism by exclusion of all other possible causes. 
Parkinsonism associated with other causes included: (1) parkinsonism in dementia 
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Table 4.2.2 Case-finding procedures 
Population 
France 
(Glronde), 
Italy 
(8 centers)' 
The 
Netherlands 
(Rotterdami' 
Spain 
(Glrona)' 
Spain 
(Pamplonajf 
Phase 1 
Screening procedure' 
Questions: 
Tremor plus rigidity or 
bradykinesia, anti-
parkinsonian drugs 
Questions: 
Tremor, previous diagnosis, 
anti-parkinsonian drugs 
Neurological examination: 
Walking on heels, elbow tone 
Questions: 
Previous diagnosis, anli-
parkinsonian drugs 
Neurological examination: 
Resting tremor, rigidity or 
cogwheeling, bradykinesia, 
impaired postural reflexes 
Questions: 
Tremor, previous diagnosis, 
anti-parkinsonian drugs 
Neurological examination: 
Tremor, rigidity, bradykinesia 
Questions: 
Previous diagnosis, anti-
parkinsonian drugs 
Neurological examination: 
Tremor, gait disturbances, 
clinical impression 
Personnel 
Psycho-
loglsts 
Trained 
interviewers 
Physicians 
Trained 
interviewers 
Physicians 
Physicians 
Physicians 
Physicians 
Physicians 
Phase 2 
Diagnostic 
protocol 
81 
Personnel 
Structured clinical Neurologists 
work-up (UPDRS.' 
neurological 
examination) 
Structured clinical Neurologists 
work-up (UP DRS.' 
neurological 
examination) 
Structured clinical 
work-up (UPDRS.' 
neurological 
examination) 
Structured clinical 
work-up (UPDRS,t 
neurological 
examination) 
Structured clinical 
work-up (UPDRS.' 
neurological 
examination) 
Neurologists 
Neurologists 
Neurologists 
,. Screening was positive if alleast one of the screening items was positive. In the institutionalized subjects from the French study, 
the phase·2 procedures were directly applied without any screening. 
t UPDRS '" Unified Parkinson's Disease Rating Scale.21 
:I: Screening was positive if at least one question was answered positively or two signs were present at the screening examination. 
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(Le., onset of dementia clearly before the occurrence of parkinsonism); (2) 
parkinsonism with associated features (e.g., multiple system atrophy, or progressive 
supranuclear palsy); (3) drug-induced parkinsonism (Le., parkinsonism following the 
use of neuroleptics or other anti-dopaminergic drugs in the six months preceding 
onset of symptoms and with no history of parkinsonism); (4) vascular parkinsonism 
(Le., clear time-relationship between a cerebrovascular event and onset of atypical 
parkinsonism, preferably supported by neuroimaging, usually without tremor); and (5) 
unspecified parkinsonism. Included in this last category were patients with no clear 
time-relationship between the possible cause (e.g., dementia, antidopaminergicdrugs) 
and parkinsonism, or with more than one possible cause. Patients otherwise fulfilling 
the criteria for Parkinson's disease who showed no progression of the disease over 
15 years or were not responsive to antiparkinsonian drugs were considered 
"unspecified". To increase reliability across studies, the medical records of most 
parkinsonian subjects were reviewed by an adjudication panel composed of 
neurologists from each of the participating centers. 
Data analysis 
We calculated age- and sex-specific prevalence figures of parkinsonism and 
Parkinson's disease for each survey separately, and for all studies combined. The 
overall prevalence was directly age-standardised using the 1991 European population 
as the standard. The prevalence estimates are presented by 5-year age groups. To 
obtain stable prevalence estimates, age groups with less than 10 subjects in the 
denominator were discarded. Since the study from France oversampled 
institutionalised subjects, prevalence estimates in this study were weighted for the 
sampling fraction. The prevalence estimates for the age range from 65 to 90 years 
(70 to 90 years for the two studies from Spain) were also displayed in graphical form, 
plotted in the middle of the corresponding age group. For the three smallest studies 
(the French and the two Spanish studies), we presented the data graphically by 10-
year age groups to obtain a monotonous curve, not influenced by unstable estimates 
due to small numbers. The likelihood ratio test was performed to test for 
heterogeneity across centers. To investigate whether age- and sex-adjusted 
prevalence figures of Parkinson's disease differed across studies, we calculated 
prevalence ratios and the corresponding 95% confidence intervals (95%CI) using 
Poisson regression analyses with the Rotterdam study (the largest) as reference for 
comparison. We also used Poisson regression analysis to determine whether the 
overall age-adjusted prevalence was significantly different in men and women. 
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Results 
The overall study population comprised 17,205 elderly individuals, of whom 14,636 
were 65 years of age and older (Table 4.2.1). The response rates ranged from 68% 
in the survey from the Netherlands to 84% for the survey from Girona, Spain (Table 
4.2.1). Prevalence figures and the prevalence ratios of parkinsonism and Parkinson's 
disease for the individual studies and overall are shown in Tables 4.2.3 and 4.2.4, 
and in Figures 4.2.1 and 4.2.2. The overall age-standardised prevalence (%) in 
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Figure 4.2.1 Age-specific prevalence, for both sexes combined, of parkinsonism in 
five European swveys. The prevalence estimates are plotted in the middle of the 
corresponding age groups: for the studies from /faly and the Netherlands by 5 year 
age groups, for the studies from France and Spain by 10 year age groups. Overall 
age-specific prevalence for women and men is shown in the right figure. 
subjects 55 years of age or older was 2.3 for parkinsonism and 1.6 for Parkinson's 
disease. Prevalence figures of parkinsonism increased from 0.9 for those aged 65 to 
69 years to 5.1 for those 85 to 89 years. The prevalence figures for Parkinson's 
disease increased from 0.6 for those aged 65 to 69 years to 3.5 for those 85 to 89 
0> 
.. 
Table 4.2.3 Age- and sex-specific prevalence (%) of parkinsonism' and overall age- and sex-adjusted prevalence ratios 
Age group (year)' 
Prevalence ratio 
Population 65-69 70-74 75-79 80-64 85-89 90-94 95-99 (95% GI) 
France Women 0.6 1.2 2.8 3.2 3.8 5.3 28.6 
(Gironde!' (4/667) (8/656) (14/507) (16/496) (13/340) (61113) (8/28) 
0.7 (0.5-0.9) 
Men 0.8 0.6 2.1 3.2 3.9 4.5 
(5/641) (3/473) (6/285) (6/190) (5/129) (1/22) 
Italy Women 1.4 2.4 4.1 5.7 
(8 centers) (8/568) (13/538) (221541) (31/542) 
Men 1.2 1.8 5.3 7.0 1.3 (1.0-1.7) 
(7/585) (11/602) (30/571) (39/555) 
The Netherlands Women 0.9 1.3 3.7 5.6 6.9 4.4 10.0 
(Rotterdam) (61705) (9/664) (20/544) (221396) (17/245) (4191) (2120) 
Men 0.8 2.1 2.9 5.6 5.1 4.5 Reference 
(5/613) (10/477) (10/341) (10/180) (4179) (1/22) 
Spain Women _t 1.5 5.0 4.1 4.4 5.0 
(Girona) (5/328) (13/256) (71170) (4/90) (1/20) 
Men 0.4 4.0 2.6 6.7 1.0 (0.7-1.3) 
(1/262) (6/150) (3/114) (3/45) 
~ 
0-
~ 
.. 
'" 
Spain Women 1.3 3.8 2.0 3.6 6.8 
(Pamplona) (1/75) (61159) (31150) (51137) (3144) 
Men 4.2 2.6 6.6 7.0 8.9 0.9 (0.6-1.3) 
(3/71) (41152) (10/152) (10/142) (4145) 
Total Women 0.9 1.6 3.7 4.5 4.8 5.2 20.8 
(18/1940) (36/2281) (75/2007) (79/1754) (39/812) (14/268) (10/48) 
Men 0.9 1.5 3.7 5.7 5.6 6.7 
(17/1839) (28/1885) (56/1499) (68/1191) (22/395) (6/89) 
.. Numbers in parentheses indicate the actual numerator and denominator. 
t Dashes indicate age groups that were not included in the surveyor for which prevalence estimates were not computed because of small numbers. 
:t: Prevalence estimates of the French study were weighted according to the sampling procedure: the denominators reported in the table were artificially computed dividing the observed number 
of cases by the weighted prevalence. 
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Table 4.2.4 Age- and sex-specific prevalence (%) of Parkinson's disease' and overall age- and sex-adjusted prevalence ratios 
Age group (year)' 
Prevalence ratio 
Population 65-69 70-74 75-79 80-84 85-89 90-94 95-99 (95% el) 
France Women 0.2 0.2 1.8 1.0 2.2 1.9 7.1 
(Gironde!' (1/500) (21974) (9/487) (5/493) (7/324) (2/113) (2128) 
Men 0.7 0.5 1.3 2.9 1.6 4.5 0.4 (0.3-0.6) 
(4/556) (21399) (4/308) (5/173) (21125) (1/22) 
Italy Women 0.9 2.2 3.0 4.1 
(8 centers) (5/568) (121538) (16/541) (221542) 
Men 0.5 1.0 3.7 5.0 1.2 (0.9-1.6) 
(3/585) (6/602) (21/571) (28/555) 
The Netherlands Women 0.6 1.0 2.4 4.8 5.3 3.3 5.0 
(Rotterdam) (41705) (7/684) (13/544) (19/396) (13/245) (3191 ) (1/20) 
Men 0.8 1.7 2.3 3.9 3.8 Reference 
(5/613) (8/477) (8/341) (7/180) (3179) (0/22) 
Spain Women 
-' 1.5 4.7 3.5 4.4 5.0 
(Girona) (5/328) (121256) (6/170) (4/90) (1/20) 
Men 0.4 4.0 2.6 6.7 0.7 (0.5-1.1) 
(1/262) (6/150) (3/114) (3/45) 
'" '" 
~ 
~ 
'" " 
Spain Women 3.1 1.3 2.2 2.2 (0175) (Pamp/ona) (5/159) (2/150) (3/137) (1/44) 
1.4 Men 1.3 4.6 4.9 2.2 1.1 (0.8-1.6) 
(1/71 ) (2/152) (7/152) (7/142) (1/45) 
Total Women 0.6 1.0 2.8 3.1 3.4 2.6 6.3 
(10/1773) (26/2599) (55/1987) (54/1751) (271796) (7/268) (3/48) 
Men 0.7 1.0 2.7 4.3 3.8 2.2 
(1211754) (18/1811) (4111522) (5011174) (151391 ) (2/89) 
... Numbers in parentheses indicate the actual numerator and denominator. 
t Dashes indicate age groups that were not included in the surveyor for which prevalence estimates were not computed because of small numbers. 
:t: Prevalence estimates of the French study were weighted according to the sampling procedure; the denominators reported in the table were artificially computed dividing the observed number 
of cases by the weighted prevalence. 
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years. The prevalence of both parkinsonism and Parkinson's disease increased with 
age, following a similar pattern in all studies, wilh no decrease in extreme ages. After 
adjustment for age and sex, there were no statistically significant differences across 
surveys, except for the French study in which prevalences were consistently lower. 
The likelihood ratio test showed heterogeneity across centers when the survey form 
France was included (p<0.001). When the survey from France was excluded, there 
were no statistically significant differences across centers (p = 0.21). The overall age-
and sex-specific prevalences of parkinsonism and Parkinson's disease are graphically 
presented in Figures 4.2.1 and 4.2.2. The prevalences for men and women were not 
significantly different; for parkinsonism the women-men ratio was 0.96 (95%CI: 0.80-
1.16), and for Parkinson's disease 0.94 (95%CI: 0.75-1.18). 
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Figure 4.2.2 Age-specific prevalence, for both sexes combined, of Parkinson's 
disease in five European surveys. The prevalence estimates are plolted in the middle 
of the corresponding age groups: for the studies from Italy and the Netherlands by 
5 year age groups, for the studies from France and Spain by 10 year age groups. 
Overall age-specific prevalence for women and men is presented in the right figure. 
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The frequency distribution by type of parkinsonism for all studies combined was as 
follows: Parkinson's disease 68%, parkinsonism in dementia 9%, drug-induced 
parkinsonism 5%, parkinsonism with associated features 1 %, vascular parkinsonism 
3%, and unspecified parkinsonism 14%. The proportion of subjects with Parkinson's 
disease who were newly diagnosed through the surveys varied from 11 % in France 
and 13% in the Netherlands, to 26% in Girona, Spain, 31% in Italy, and 52% in 
Pamplona, Spain. In all surveys, the percentage of newly diagnosed patients with 
Parkinson's disease increased with age. For all studies combined, this percentage 
increased from 18% for those aged 65 to 70 years to 36% for those 80 to 85 years. 
Discussion 
Methodological considerations 
The striking variation in prevalence estimates of Parkinson's disease reported from 
various studies and different populations, ranging from 10 to 405 cases per 100,000 
population,' may be caused, partly or completely, by variation in the methods used. 
The three most important methodological elements are the case finding strategy,· the 
diagnostic criteria for parkinsonism and Parkinson's disease, and the degree of 
coverage of the target population (response rate). 
As for case finding strategies, studies that rely on existing medical records exclude 
from the prevalence estimate those patients who failed to seek medical attention for 
their symptoms, those who were incorrectly diagnosed, and those whose records 
were not retrieved. The alternative case finding approach involves the direct or 
indirect contact of all subjects in the study population to assess their disease status. 
This approach should eliminate the underestimation of prevalence and should be 
more suitable for international comparisons since it reduces the variation due to 
differences in access to and quality of medical care in various populations. 
Our study is the first comparison of results from several prevalence surveys of 
Parkinson's disease which used similar case finding strategy and diagnostic criteria. 
Allhough the five EUROPARKINSON surveys were not designed as a multicenter 
study, the investigators met and exchanged their methods and data collection 
instruments early in the planning of the surveys. Therefore, we have reached an 
unprecedented level of methodological homogeneity. To increase comparability 
across centers, the medical documentation of a majority of parkinsonian patients 
underwent a centralised review by an adjudication panel. 
Despite this effort to homogenize our methodology, the five surveys still present some 
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variation. The screening procedures were somewhat different in number of items 
tested and personnel involved. In the French study, no physical examination was 
performed as part of the screening, while in the four remaining studies it was. Also 
the use of diagnostic criteria for parkinsonism varied somewhat with a broadening of 
the criteria in the French study and a restriction of the criteria in the Girona study. 
There were variations in the differential diagnosis of parkinsonism by specific 
aetiology. Parkinson's disease represented 70% to 96% of all parkinsonisms in Italy, 
the Netherlands, and Girona, Spain, whereas Parkinson's disease was only 59% of 
all parkinson isms in Pamplona, Spain, and 48% in France. A large percentage of 
parkinsonian subjects in the French study had concurrent dementia with no clear 
time-relationship between onset of dementia and onset of extrapyramidal signs. 
These subjects were classified as "unspecified parkinsonism". In addition, a high 
percentage of subjects in France were receiving antidopaminergic agents, and were 
classified as "drug-induced parkinsonism". It was again difficult in these subjects to 
isolate the role of antidopaminergic drugs from the independent occurrence of 
Parkinson's disease. 
In a two-phase survey, failure to study a large segment of the target population (non-
response) due to refusal or other obstacles may cause an underestimation or an 
overestimation of prevalence.' Unfortunately, the five surveys had different response 
rates, and the impact of this variation on our findings is unknown. 
Age 
The prevalence of parkinsonism and Parkinson's disease increased with age in all 
five surveys for both men and women, with no decrease at higher ages. This 
suggests that the prevalence, and probably also the incidence, of Parkinson's disease 
continues to increase beyond age 85 or 90 years. Various other surveys based on 
a design of direct'" or indirect'·10 contact of all subjects in the population also showed 
a continuing increase in the prevalence of Parkinson's disease with age. By contrast, 
other prevalence studies based on existing medical records showed a peak in 
prevalence and a decline among the oldest old."-14 We speculate that these 
contrasting patterns are due to the underascertainment of Parkinson's disease among 
older subjects which occurs when patients are detected through medical records only. 
Our five surveys showed indeed that the percentage of subjects with Parkinson's 
disease who had not been previously diagnosed increases with advancing age in the 
general population. 
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Sex 
Most prevalence studies that indicated higher prevalences of Parkinson's disease in 
men,,12,15-17 or in women,",14 were based on medical records, whereas most surveys 
with an in-person screening for parkinsonism, like our study, found no significant 
gender differences."" to," These findings suggest that the riskof Parkinson's disease 
is equal in men and women, but the referral to medical services varies by gender 
across populations. 
Geographical comparison 
It has been postulated that geographic differences in the prevalence of Parkinson's 
disease may yield etiological clues."-21 After adjusting for the effect of age and sex 
using Poisson regression models, our data did not suggest significant differences in 
prevalence across European countries, with the exception of the French survey. 
Morgante et al. showed that a substantial proportion of parkinsonian subjects go 
undetected when only a questionnaire screening, as in the French survey, is used.' 
We think that the differences in methodology and in diagnostic criteria discussed 
above may partly account for the lower prevalence estimates of Parkinson's disease 
in the French survey. Therefore, our overall impression is that there is no evidence 
for the prevalence of Parkinson's disease being different across European countries. 
Although the overall prevalences were similar in our five surveys, there was a wide 
variation in the percentage of newly diagnosed patients with Parkinson's disease who 
were detected through the screening. This may be due to differences in referral 
pattern and in access to medical services across the four countries. These findings 
emphasize the importance using a direct screening when assessing Parkinson's 
disease prevalence. 
Comparing our findings with those from other recent surveys based on a similar case 
finding approach, we found striking similarities with the Sicilian study.' This 
comparison strengthens our overall impression of limited geographic variation in 
prevalence when methods are homogeneous. 
Some authors reported that persons living in a rural environment have a higher risk 
of developing Parkinson's disease than persons living in towns, and suggested an 
environmental cause for Parkinson's disease"'" In our study, the more rural 
population (Girona) or mixed populations (France, Italy) did not have a higher 
prevalence of Parkinson's disease than the more urban populations (Pamplona, 
Rotterdam). 
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Conclusions 
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To allow comparisons across countries, an effort was made in EUROPARKINSON to 
increase homogeneity of case finding strategy and diagnostic criteria in five European 
surveys on the prevalence of Parkinson's disease. Accounting for the French study 
which deviated somewhat from the common methods, our findings suggest that the 
prevalence of Parkinson's disease is similar across European countries. The 
prevalence of both parkinsonism and Parkinson's disease increases steeply with age, 
and is similar in men and women. 
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4.3 Incidence of Parkinson's disease in the 
Rotterdam Study 
The prevalence of parkinsonism and Parkinson's disease (PO) is high and strongly 
increases with age, even in the oldest old.'" Incidence rates yield an estimate of the 
absolute risk of PO, but studies on incidence of PO are scarse. Only few studies have 
provided age-specific,'" or age- and sex-specific"" incidence estimates of PO, but 
all but one' were register-based. One of the limitations of register-based studies is 
that these will fail to include patients who have not come to medical attention for their 
parkinsonian signs, thereby underestimating the risk of the disease.""" A recent 
comparative study of European community-based prevalence surveys on PO showed 
that underestimation of the prevalence by medical records may vary from 11 % to 52% 
and increases with age.' Register-based incidence rates may be even more severely 
underestimated. We present the results of a study in Rotterdam, the Netherlands, on 
the incidence of parkinsonism and PO in a general elderly population, in which 
participants underwent a neurologic screening examination at baseline and follow-up. 
Methods 
Study population 
This study was part of the Rotterdam Study, a community-based cohort study on the 
frequency, etiology, and prognosis of chronic disabling diseases in the elderly." The 
study focusses on four groups of diseases: neurologic, cardiovascular, locomotor, and 
ophthalmologic disorders. All residents of Ommoord, a suburb of Rotterdam, the 
Netherlands, who were 55 years of age or older, either living independently or 
institutionalized, were invited to the study. The study has been approved by the 
Medical Ethics Committee of Erasmus University. The baseline survey started in 1990 
and was completed in June 1993. Of the 10,275 eligible subjects, 7,983 (78%) agreed 
to participate and signed informed consent statements. Follow-up examinations took 
place from September 1993 until the end of 1994. At baseline, all participants were 
interviewed at home and thereafter 7,129 were examined at a research center. The 
number who underwent the complete screening examination for parkinsonism was 
somewhat lower (6,969) due to refusal, disease, death, or logistic reasons. At 
baseline, 129 subjects were identified with parkinsonism,14 and for two subjects the 
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disease status was uncertain. This resulted in a cohort of 6,838 persons who had a 
neurologic screening examination at baseline and were at risk to develop a 
parkinsonian syndrome during follow-up. For the cohort at risk for PO we further 
excluded 272 subjects who were demented at baseline as a diagnosis of dementia 
before the onset of parkinsonism precludes a diagnosis of PD,14 leaving 6,566 
subjects at risk for PO (Table 4.3.1). 
Table 4.3.1 Age and sex distribution of the study population at risk for any incident 
parkinsonism' (including Parkinson's disease), and for incident Parkinson's diseaset 
separately 
Persons at risk for any Persons at risk for Parkinson's 
parkinsonism diseaset 
Age-group Men Women Totat Men Women Total 
(years) 
55-64 849 1,135 1,984 847 1,131 1,978 
65-74 1,144 1,413 2,557 1,134 1,406 2,540 
75-84 614 1,026 1,640 579 966 1,545 
85-94 153 456 609 126 345 471 
95+ 9 39 48 5 27 32 
Total 2,769 4,069 6,838 2,691 3,875 6,566 
* Persons with parldnsonism at basenne (n :.129) have been excluded. 
t Persons with either parkinsonism or dementia at baseline (n = 401) have been excluded. 
Case-finding and diagnostic procedures 
Both at baseline and at follow-up, we used a two-phase design to identify subjects 
with PD." In the first phase, each participant was briefly neurologically examined by 
one of the study physicians. All subjects who had at least one possible cardinal sign 
of parkinsonism (i.e., resting tremor, rigidity, bradykinesia, or impaired postural 
reflexes) at the neurologic screening examination or those persons with incident 
parkinsonism who were reported by their general practitioner or neurologist during 
follow-up, were invited for further evaluation in a second phase by a neurologist or 
a neurologist-in-training. In the second phase, a structured clinical work-up comprising 
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the motor examination of the Unified Parkinson's Disease Rating Scale (UPDRS),15 
a neurologic examination, and standardized history taking, was used to establish the 
diagnosis parkinsonism and to classify this parkinsonism. Most incident PO patients 
were reevaluated by a second neurologist. For the subjects who could not be 
reexamined for parkinsonism at follow-up (due to death, migration, disease, logistic 
reasons, or refusal) we obtained information through a surveillance system that 
continuously monitors the total cohort for interval cases of parkinsonism. Through this 
surveillance system that consists of computer linkages with the general practitioners' 
and pharmacies's automated medical record systems, we were notified of incident 
patients wilh parkinsonism, including PO, and had access to their medical records. 
Parkinsonism was diagnosed if at least two of the cardinal signs were present in a 
subject, irrespective of anti parkinsonian medication, or if in a subject treated with 
antiparkinsonian medication (Ievodopa) one or more signs, documented by medical 
history, had improved by the treatment. PO was defined in a person with 
parkinsonism if other possible causes of parkinsonism were absent. The diagnostic 
criteria for the several subtypes of parkinsonism have been reported previously." In 
short: parkinsonism due to other causes included (1) parkinsonism associated with 
baseline dementia as assessed by a three-phase approach; 16 (2) drug-induced 
parkinsonism (Le., following use of neuroleptics or other anti-dopaminergic drugs in 
the 6 months before onset of symptoms and with no history of parkinsonism); (3) 
parkinsonism related to cerebrovascular disease (Le., with a clear time relationship 
between cerebrovascular event and onset of atypical parkinsonism, preferably 
supported by neuroimaging, usually without tremor); (4) parkinsonism in multiple 
system atrophy or progressive supranuclear palsy; and (5) other parkinsonism. 
Included in this last category were subjects with more than one possible cause or with 
no clear time relationship between the possible cause and the parkinsonism, as well 
as those subjects in whom all other possible causes of parkinsonism could be 
excluded but who did not respond to antiparkinsonian drugs. As the age of onset of 
parkinsonism and PO, we took the midpoint between the age at baseline and the age 
at diagnosis. 
Data allalysis 
We calculated age- and sex-specific incidence rates per 10 year age-groups by 
dividing the number of incident patients by the number of person-years (the sum of 
each participant's contribution offollow-up time per age-group), and Poisson standard 
errors and 95% confidence intervals (95% CI) of the incidence estimates. The follow-
up period ended at follow-up screening, age of onset of parkinsonism or PO, or death. 
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For those participants who were not rescreened, were not reported with incident 
parkinsonism through the surveillance system, and did not die, follow-up time was 
counted till the end of December 1994. We determined whether overall age-adjusted 
incidence rates for men and women differed significantly through Cox regression 
analysis, with age at baseline and sex as covariates (expressed as relative risk; RR). 
Results 
Table 4.3.1 shows the age- and sex-distributions of the 6,838 subjects who were at 
risk to develop any parkinsonism, and of the 6,566 persons at risk for PD. For those 
at risk for parkinsonism, 5,313 (77.7%) were completely reexamined in person at 
follow-up screening. Of those who could not be reexamined, 449 had died, 558 
refused screening examinations, 62 could not be reached, and in 456 the screening 
examination was incomplete or not conducted due to logistic reasons. Of the subjects 
at risk for PO, 5,236 (79.7%) underwent the complete in-person screening at follow-
up, 339 had died, 497 refused screening examinations, 55 could not be reached, and 
in 439 the screening examination was not complete. All who did not undergo the 
screening at follow-up could be followed by the surveillance system. 
After a mean follow-up period of 2.14 years (SO ± 0.86), 62 subjects with incident 
parkinsonism were identified of whom 35 (56%) had incident PD. In Table 4.3.2, the 
follow-up time, and the incidence rates are shown for the parkinsonism cohort. For 
the subjects at risk for PO, similar information is presented in Table 4.3.3. Incidence 
rates of both parkinsonism and PO increased with age, except for the higest age-
group in women where the incidence rate of PO seemed to decrease. The incidence 
estimates in the highest age-groups, however, were based on small numbers and, as 
a consequence, the 95% CI were relatively wide. The differences between men and 
women were statistically non-significant; for women compared with men the age-
adjusted RR of parkinsonism was 1.18 (95% CI 0.68-2.04), and of PO 1.16 (95% CI 
0.66-2.04). Although between the age of 75 to 94 years the age-specific incidence 
rates of PO for men seemed higher, this was again statistically statistically not 
significant. Besides PO (35/62), the other diagnoses were parkinsonism associated 
with dementia (8162); drug-induced parkinsonism (1/62); multiple system atrophy 
(2/62); progressive supranuclear palsy (1/62); and other parkinsonism (15/62). 
Table 4.3.2 Age- and sex-specific follow-up time in person years (pyrs) of the cohort at risk for parkinsonism', number 
of incident cases with parkinsonism (PS), and incidence rates (cases per 1,000 pyrs, with 95% confidence interval) of 
any parkinsonism in the Rotterdam Study, 1990-1994 
Men Women Total 
Age-group Pyrs PS Rate 95% CI Pyrs PS Rate 95% Cl pyrs PS Rate 95% CI 
(years) 
55-64 1.796 0.6 0.1-3.9 2.569 0.4 0.1-2.8 4,366 2 0.5 0.1-1.8 
65-74 2,317 4 1.7 0.7-4.6 3,112 17 5.5 3.4-8.8 5,430 21 3.9 2.5-5.9 
75-84 1,244 11 8.8 4.9-16.0 2,326 12 5.2 2.9-9.1 3,572 23 6.4 4.3-9.7 
85-94 279 3 10.7 3.5-33.2 934 12 12.8 7.3-22.6 1,214 15 12.4 7.4-20.5 
95+ 15 0 55 18.3 2.6-129.0 70 14.3 2.0-101.2 
Total 5,651 19 3.4 2.1-5.3 8,997 43 4.8 3.5-<>.4 14,65 62 4.2 3.3-5.4 
2 
., Persons with parkinsonism at baseline (n =129) have been excluded. 
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Table 4.3.3 Age- and sex-specific follow-up time in person years (pyrs) of the cohort at risk for Parkinson's disease', number 
of incident cases with Parkinson's disease (PD), and incidence rates (cases per 1,000 pyrs, with 95% confidence inteNa/) 
of PD in the Rotterdam Study, 1990-1994 
Men Women Total 
Age-group Pyrs PO Rate 95% CI Pyrs PO Rate 95% CI Pyrs PO Rate 95% CI 
(years) 
55-64 1,792 0 2,560 0.4 0.1-2.8 4,352 0.2 0.0-1.6 
65-74 2,290 2 0.9 0.2-3.5 3,085 11 3.6 2.0-6.4 5,376 13 2.4 1.4-4.2 
75-84 1,172 8 6.8 3.4-13.6 2,163 9 4.2 2.2-8.0 3,335 17 5.1 3.2-8.2 
85-94 234 2 8.6 2.1-34.2 719 2 2.8 0.7-11.1 952 4 4.2 1.6-11.2 
95+ 8 0 39 0 47 0 
Total 5.496 12 2.2 1.2-3.8 8,566 23 2.7 1,8-4.0 14,062 35 2.5 1.8-3.5 
... Persons with either parkinsonism or dementia at baseline (n = 401) have been excluded. 
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Discussion 
We found a strong and consistent increase in the incidence of both parkinsonism and 
PO with age, at leasts till the age of 84 years, and no significant gender differences. 
Our study had several strengths. Both at baseline and follow-up, participants were 
screened in person by the use of a similar examination and similar diagnostic work-
up. Only a small proportion who screened positive in the screening phase did not 
undergo the second, diagnostic, phase. For those, and for the persons who were 
screened at baseline but could not be examined at follow-up, we were able to achieve 
a complete follow-up and to obtain information through a population surveillance 
system. In the latter group, however, we may have missed some subjects with very 
mild signs and those who had not sought medical attention yet. Our follow-up period 
was relatively short. This reduced the proportion of subjects who could not be 
rescreened in person due to death, disease, or migration, and ensured a more 
complete case-ascertainment. It also allowed us to take the midpoint between the age 
at baseline and the age at diagnosis as the age of onset of parkinsonism and PO, an 
approach we had chosen because in a parkinsonian syndrome it may be hard to 
indicate objectively when the first symptom has started. However, due to the short 
follow-up period, the numbers of both person-years of follow-up time and incident 
cases were comparatively low, resulting in less stable incidence estimates as 
reflected by the wide 95% CI (Table 4.3.3). 
The expected pattern of age-specific incidence rates will follow depends on the 
underlying process or event that causes PO. Several patterns pertaining to the rate 
of excessive degeneration of dopaminergic cells in PO have been proposed."·18 
Fearnley and Lees in their neuropathologic study of non-parkinsonian subjects 
reported a linear decrease in the number of dopaminergic neurons with advancing 
age in the substantia nigra." Also, in healthy persons the number of Lewy bodies, 
that may indicate presymptomatic PO, increases with age." In line with these 
observations, PO may be caused by an accelerated normal aging process and an 
increase in the incidence of PO with age would be expected, even in the highests 
age-groups. If, on the contrary, the degenerative process in PO is induced by, for 
example, accumulated toxic exposures in genetically susceptible individuals, then at 
a certain age people may have outlived their risk of PO and a decrease in incidence 
rates in the highest age-groups will be a possibility as well. Our data on the incidence 
pattern in the oldest old are inconclusive; for both sexes the incidence rates of 
parkinsonism continued to rise until the highest age, but the rate of PO in women 
decreased after the age of 85 years. 
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In all published population-based studies on incidence of PO, age-specific incidence 
estimates were lower compared with ours, as is shown in Figure 4.3.1. All but one' 
were based on existing medical 
records or case-finding strategies that 
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Figure 4.3.1 Age-specific incidence rates 
of Parkinson's disease from the 
Rotterdam Study compared with three 
large population-based swveys; one from 
Rochester, Minnesota,9 one from New 
York," and one from Honolulu, Hawaii. 7 
not systematically included incident 
PO patients who had not recognized 
their parkinsonian symptoms yet or 
had not come to medical attention for 
their parkinsonism.'·11 The number of 
PO patients that go undetected in a 
population can grow to considerable 
proportions; 1.3 e.g., in a study in 
Copiah County, Mississippi, 40% of 
the PO patients were newly detected 
through the in-person screening,12 
and thus register-based incidence 
rates will be underestimated. The only 
published community-based study, 
thusfar, on the incidence of PO in 
which each participant was screened 
at follow-up showed also lower 
incidence estimates than our study.' 
This study, however, is not completely 
comparable with ours because no 
baseline in-person screening was 
conducted and it was restricted to 
Hawaiian men of Japanese and 
Okinawan ancestry. Also, as in the 
Hawaiian study 20 years had elapsed 
between the previous, register-based, screening and the screening for PO, many 
parkinsonian subjects who did not come to medical attention, or were lost in the 
interval, will not have been included in the incidence estimates. 
In many, if not most, studies the prevalence of PO has been reported to be higher in 
men than women" In contrast to these, in most incidence studies with age- and sex-
specific estimates no sex differences were founds.'.11 These findings are in line with 
our findings and may indicate a similar age-specific risk of PO in men and women. 
If the survival of persons with different causes of parkinsonism were similar, one 
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would expect that among incident parkinsonian patients the proportion of PD patients 
would be the same as among the parkinsonians subject that had been identified in 
the prevalence survey. In the present incidence study, however, 56% of the incident 
parkinsonian syndrome was caused by PD whereas in the prevalence survey of the 
Rotterdam Study this proportion was 75%.14 This reflects the less favorable survival 
of patients with a secondary parkinsonism, compared with PD patients. Indeed, 
strongly reduced survival has been implicated in parkinsonism associated with 
dementia,"·23 multiple system atrophy,"'" and progressive supranuclear palsy.'" 27 
We conclude that the incidence of parkinsonism and PD is higher than expected, that 
the incidence continues to rise with age at least till the age of 85 years, and that men 
and women run the same age-specific risk in developing PD. Longer follow-up and 
more prospective cohort studies are awaited to confirm these findings and to provide 
more precise estimates, especially in the oldest old. 
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Chapter 5 
Determinants of Parkinson's disease 
5.1 Apolipoprotein genotype and Parkinson's disease 
5.2 Dietary antioxidants and Parkinson's disease 
5.3 Smoking and the risk of Parkinson's disease 
5.4 Family history and the risk of Parkinson's disease 

5.1 Apolipoprotein genotype and Parkinson's 
disease 
The etiology of Parkinson's disease (PO) and dementia in PO is still largely unknown. 
Links between PO and Alzheimer's disease (AD) have been suggested,1.2 and 
clinicopathological studies have implicated AD pathology, especially ~-amyloid 
plaques, as a possible contributing factor to dementia in PD.'·' The apolipoprotein E 
4 allele (APOE*4) has been associated with both AD' and Lewy Body disease (LBO)," 
and may mediate ~-amyloid plaques formation in the brain.'" Reports on the APOE*4 
in PO with and without dementia, however, are contradictory; few suggesting an 
association between APOE*4 and PO dementia, and most no association' Gearing 
and colleagues showed an association between the APOE*4 and PO-related changes 
in AD.' We investigated the association of APOE genotypes with PO and dementia 
in PO in a large sample of the Rotterdam Study. 
Methods 
This study formed part of the Rotterdam Study, a community-based cohort study 
among 7,983 independently living and institutionalized inhabitants, 55 years of age 
or older, from a suburb of Rotterdam, the Netherlands.1O Informed consent was 
obtained from the participants and the study was approved by the Medical Ethics 
Committee of Erasmus University Rotterdam. 
Diagnosis of Parkinson's disease and dementia 
We identified subjects with PO through a two-phase design with an in-person 
screening of all participants, followed by a diagnostic work-up of those who were 
suspected of parkinsonism." The diagnostic criteria for PO have been described 
previously" Participants were also screened for dementia." For the diagnosis "PO 
dementia", onset of PO had to have clearly preceded the onset of the cognitive 
changes and the OSM-III-R criteria for dementia had to be fulfilled. 
Study population 
Blood samples of 80 of the 97 prevalent PO patients in the Rotterdam Study were 
available for APOE genotyping. Of those 80 PO patients, 19 were demented. In three 
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(16%) of these, the pattern of cognitive deficits was compatible with possible 
concurrent AD. APOE genotype was also assessed in 1,008 randomly selected 
subjects who were not necessarily healthy but had neither signs of parkinsonism nor 
dementia. 
ApoE genotyping 
APOE genotyping was performed on coded blood samples without knowledge of the 
clinical diagnosis." 
Data analysis. 
We used logistic regression analysis to calculate odds ratios (OR) with 95% 
confidence intervals (95%CI) to assess whether the APOE'4 and APOE'2 alleles 
were associated with PD. The most frequent APOE genotype (APOE3E3) was used 
as the reference. In addition, we assessed the associations of APOE'4 and APOE'2 
with dementia within the PO patient group. In subanalyses, we excluded subjects with 
APOE2E4 since this genotype may obscure differences between APOE'4 and 
APOE'2 carriers; and the three demented PO patients wilh possible concurrent AD. 
In all analyses, we adjusted for age and sex. 
Results 
The characteristics of the study population and the distribution of the APOE 
genotypes are summarized in Table 1. PO patients, especially the demented, were 
on average older and the proportion of women among them was higher than in the 
rest of the population. The distribution of genotypes in the control population was in 
Hardy-Weinberg equilibrium. We found no association of APOE'4 and APOE'2 with 
total PO; for carriers of APOE'4 the OR of PO was 0.9 (0.5-1.5), and 1.2 (0.7-2.3) for 
APOE'2 carriers. Within the PO patients group, both carriers of APOE'4 and APOE'2 
were more often demented as compared with PO patients with the APOE3E3; the OR 
of dementia for APOE'4 carriers was 4.8 (1.3-17.9), which was statistically significant, 
and for APOE'2 carriers 3.3 (0.8-14.5). Exclusion of subjects with APOE2E4 did not 
substantially alter the results (within the PO patient group, the OR of dementia 
became 5.3 (1.3-21.1) for APOE'4 carriers, and 3.0 (0.7-14.0) for APOE'2 carriers). 
Also in the PO group, the association between APOE'4 and dementia appeared to 
be robust if the demented PO patients with possible concurrent AD were excluded 
(OR 3.7 (1.0-14.6)). 
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Table 5.1.1 The characteristics of the study population and the distribution of the 
APOE genotypes and alleles (PO is Parkinson's disease, POD· is PO without 
dementia, POD+ is PO dementia) 
All PO POO· POO+ Controls 
(n=80) (n=61) (n=19) (n=1,00B) 
Age (±SD) 78 (8) 77 (8) 82 (8) 69 (8) 
Proportion men (%) 33.8 37.7 21.1 39.9 
APOE genotype frequency 
APOE3E3 (%) 57.5 (46), 65.5 (40) 31.6 (6) 56.2 (566) 
APOE2E2 (%) 1.3 (1) 0.0 (0) 5.3 (1) 1.0 (10) 
APOE2E3 (%) 17.5 (14) 16.4 (10) 21.1 (4) 14.B (149) 
APOE2E4 (%) 3.8 (3) 3.3 (2) 5.3 (1) 1.9 (19) 
APOE3E4 (%) 17.5 (14) 13.1 (B) 31.6 (6) 24.2 (244) 
APOE4E4 (%) 2.5 (2) 1.6 (1) 5.3 (1) 2.0 (20) 
APOE allele frequency 
APOE'2 (%) 11.9 (19)t 9.8 (12) 18.4 (7) 9.3 (188) 
APOE'3 (%) 75.0 (120) 80.4 (98) 57.9 (22) 75.7 (1525) 
APOE'4 (%) 13.1 (21) 9.8 (12) 23.7 (9) 15.0 (303) 
'" Numbers of subjects are given in parentheses. 
t Numbers of alle!es are given in parentheses. 
Discussion 
We found that among PO patients APOE'4 was significantly associated with an 
almost five-fold increased risk of dementia, and that the risk for APOE'2 carriers was 
increased as well, though this failed to reach significance. These associations are 
unlikely to result from misclassification of AO or LBO patients as PO dementia 
patients because we carefully restricted the diagnosis of PO to those in whom the 
onset of parkinsonian signs had clearly preceded the cognitive changes in absence 
of other clinical features. However, as AO and PO may have shared determinants, 
concurrent AO in a proportion of the PO patients might have occurred in a higher 
frequency than would be expected in a non-PO population. It could be conjectured 
that this could, in part, account for the associations we found. However, the majority 
of the demented PO patients in our study sample displayed clinical features atypical 
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for AD and exclusion of those with possible concurrent AD did not affect the 
associations. 
In most previous studies on the APOE genotype and PD, neither the comparison 
within the PD patient group has been made, nor age-adjustment was used. In 
contrast to other studies, our control population was both derived from the same 
source population as the PD patients and based on a general, not necessarily 
healthy, elderly population, including institutionalized persons. This methodology may 
explain why we were able to find an effect of APOE*4 on dementia in PD, whereas 
others did not' 
Our findings might indicate that APOE*2 is associated with PD dementia as well. 
However, this association was statistically non-significant, possibly because APOE*2 
is a rare allele and, as a consequence, we had too little power in our study to 
evaluate this. APOE*2 has been related to a larger B-amyloid plaque burden in LBD,' 
and may increase the risk of early-onset AD." In reports on APOE genotype and PD 
or PD dementia, hardly any attention was paid to the APOE*2 allele frequency. In 
most of these reports, however, but not all,14 the APOE*2 allele frequency was higher 
in PD patients,'·lS-17 or in PD dementia"'" than in controls, but larger studies may be 
needed to confirm a putative association. 
We conclude that among elderly PD patients, carriers of the APOE*4 allele appear 
to have a strongly increased risk of dementia. 
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5.2 Dietary antioxidants and Parkinson's disease 
The cause of dopaminergic cell loss in patients with Parkinson's disease (PO) is still 
unknown but increased free radical production and an inadequate antioxidant defence 
system may playa role.'-3 Therefore, it has been postulated that high intake of 
antioxidants may reduce the risk of PO or may decrease the progression of the 
disease.'-' We investigated the association between dietary antioxidant intake and PD 
in non-demented independently living participants from the community-based 
Rotterdam Study in which each person was individually screened for PD. 
Methods 
This study formed part of the Rotterdam Study, a community-based cohort study on 
prevalence, incidence and determinants of diseases in the elderly as extensively 
described elsewhere.7 The study started in 1990 and the cross-sectional survey was 
completed in June 1993. All inhabitants of Ommoord, a suburb of Rotterdam, the 
Netherlands, who were 55 years of age or older, either living independently or 
institutionalized, were invited to participate. Of 10,275 eligible subjects, 7,983 
accepted (78%) and signed informed consent statements. All participants were 
interviewed at home and most were subsequently examined at a research center. The 
study was approved by the Medical Ethics Committee of Erasmus University. 
Information on dietary intake 
Information on daily dietary intake in the last year was obtained from a modified 
version of a previously validated 170 item semi-quantitative food frequency 
questionnaire.' In order to elicite reliable dietary information, dietary data were 
obtained from those subjects who were aged 55 to 95 years, showed no cognitive 
impairment at baseline (Mini Mental State Examination score > 25 and a Geriatric 
Mental State Schedule score equal to 0),' and were non-institutionalized (n = 5,646). 
The food questionnaire was administered during the home interview as part of the 
standard study protocol. Each questionnaire was reviewed by a dietician during the 
subject's visit to the research center before the diagnosis of PO was established. 
Respondents also indicated the number of years without a change in the dietary habit 
and were asked whether they consumed vitamin supplements and if so which brand 
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names and what quantity. Average daily dietary nutrient intake was calculated by 
multiplying the frequency and amount consumed for each food item by its nutrient 
content listed in an automated version of the Dutch Food Composition Table.1O 
Diagnosis of Parkinson's disease 
We used a two-phase design to identify subjects with PD in the total study 
population." The screening consisted of questions regarding a previous diagnosis of 
PD, registration of any drug use, and a brief neurological examination by one of the 
study physicians. Those who screened positive were evaluated in a second phase by 
a neurologist or a neurologist in training. A structured clinical work-up, that comprised 
the motor examination of the Unified Parkinson's Disease Rating Scale (UPDRS),12 
a neurological examination and standardized history taking, was used to establish the 
diagnosis parkinsonism and to classify this parkinsonism. PD was diagnosed if at 
least two of four cardinal signs (Le., resting tremor, rigidity, bradykinesia, or impaired 
postural reflexes) were present in a subject not taking antiparkinsonian drugs or when 
in a subject treated with antiparkinsonian medication one or more signs, documented 
by medical history, had improved by treatment In addition, all other causes of 
parkinsonism had to be absent 
Study population 
The study population consisted of all non-demented independently living participants 
of the Rotterdam Study. For the current analyses, persons whose reported dietary 
intake contained inconsistencies (n = 211), persons who had one or more 
parkinsonian signs but did not have PD (n = 44), persons who were demented but 
were erroneously administered the food frequency questionnaire (n = 19), and 
persons who had missing information on confounding variables (n = 30) were 
excluded. Among the 5,342 subjects who could be included in the analyses, 31 had 
PD. Eight of these PD patients were detected through the screening for PD and had 
not been diagnosed previously. The Hoehn & Yahr stage 13 of the 31 PD patients 
ranged from 1 to 3 (median 1.9), and the median disease duration was 2.8 years. 
Data analysis 
We investigated the association between PO and the following dietary antioxidants: 
vitamin E, ~-carotene, vitamin C, and flavonoids. Because patients with PD may 
specifically seek a beneficial effect from the use of vitamin supplements we also 
performed the analyses with exclusion of the supplement users. We used analysis of 
variance to compare average daily caloric and antioxidant intake, adjusted for 
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differences in age and sex, between subjects with and without PD. We used mulliple 
logistic regression analysis to calculate the odds ratios (OR) with corresponding 95% 
confidence intervals (95%CI) to assess the relation between daily dietary antioxidant 
intake and PD. We analyzed dietary antioxidant intake as a continous.variable as well 
as categorized by tertiles with the lowest level of intake as the reference. In all 
analyses, we adjusted for the potential confounding factors age, sex, current smoking, 
and energy intake." For the water-soluble vitamin C and flavonoids the adjustment 
was made for caloric intake, and for the fat-soluble vitamin E and B-carotene the 
adjustment was made for the percentage energy from fat intake. Food-patterns may 
change as a result of advanced PD. Therefore, to assess whether the associations 
were affected by patients with more advanced disease, we performed an analysis 
restricted to PO patients with a Hoehn & Yahr stage 1 to 2. 
Results 
Characteristics of the PO patients and the control subjects and their mean age- and 
sex-adjusted daily energy and dietary antioxidants intake are shown in Table 5.2.1. 
Table 5.2.1 Characteristics of the study population, and the age- and sex-adjusted 
mean daily dietary energy and antioxidant intake' (± SO) in the Parkinson's disease 
(PO) patients and the control population 
Age (years) 
Proportion women (%) 
Vitamin supplement users (%) 
Caloric intake (KcaUday) 
Percentage energy from fat 
Vitamin E (mg/day)' 
B·carotene (mg/day)' 
Vitamin C (mg/day)' 
Flavonoids (mg/day)' 
k Addilional~ adjusted for energy intake. 
t ± SD. 
t: P '" 0.013 
PO patients 
(n '" 31) 
71.0 (6.6)' 
48 
16 
1834 (436) 
37.3 (7.1) 
11.7 (5.6)' 
1.37 (0.59) 
118 (42) 
27.5 (9.5) 
Control 
subjects 
(n = 5311) 
67.7 (7.8) 
59 
12 
1976 (504) 
36.3 (6.2) 
13.9 (6.2) 
1.53 (0.76) 
120 (54) 
28.5 (12.2) 
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Table 5.2.2 The association between daily dietary antioxidant intake and Parkinson's 
disease (PD), calculated as crude and adjusted' odds ratios (OR) with corresponding 
95% confidence intelVals (95% CI), with and without PO patients with a Hoehn & 
Yahr stage (H& Y) over 2 
All PO patients All PO patients PO patients with H& Y 
(n=31) (n=31) stage ,,;2 (n=23) 
Crude OR' Adjusted OR" Adjusted OR" 
Vitamin E 0.6 (0.3·1.2) 0.5 (0.2-0.9) 0.6 (0.3-1.4) 
(per 10 mg/day) 
a-carotene 0.6 (0.3-1.1) 0.6 (0.3-1.2) 0.8 (0.4-1.6) 
(per 1 mg/day) 
Vitamin C 0.8 (0.4-1.6) 0.9 (0.4-1.8) 0.8 (0.3-1.9) 
(per 100 mg/day) 
Flavonoids 0.9 (0.7-1.2) 0.9 (0.7-1.2) 1.1 (0.7-1.5) 
(per 10 mg/day) 
• Adjusted for age, gender, current smoking, and energy intake. 
None of the differences in mean intake were statistically significant, except for vitamin 
E which intake was lower in the PD patients group. The number of years without a 
change in dietary habits did not differ significantly between the PD patients and the 
control population (4.4 versus 4.7 years). Table 5.2.2 shows the relations between 
daily dietary vitamin intake and PD. Subjects with higher vitamin E intakes had PD 
significantly less often than those with lower vitamin E intakes (adjusted OR of 0.5 
(95%CI; 0.2-0.9) per 10 mg daily vitamin E intake). B-carotene intake was also 
inversely related to PD but this association was not significant. Dietary vitamin C and 
dietary flavonoids intake were not associated with PD. When we confined the 
analyses to PD patients with a Hoehn & Yahr stage 1 to 2 (n = 23), the association 
for vitamin E was similar, but no longer significant, probably due to the smaller 
numbers (Table 5.2.2). Exclusion of vitamin supplement users yielded exactly the 
same estimates. 
When analyzed in tertiles, the association between dietary intake of vitamin E and PD 
appeared to be dose-dependent: compared with the lowest terti Ie, the OR of PD for 
the middle tertile was 0.8 (95%CI; 0.4-1.8), and for the upper tertile 0.3 (95%CI; 0.1-
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0.9); p-trend is 0.03. For fl.-carotene, Vitamin C, and flavonoids intake, no clear 
patterns were discerned (Figure 5.2.1). 
10 
Vltaml" E 8·carotene VJtamln C Flavonolds 
-
1 
I -1 
p.trtnd .0.027 p.trtnd -0.11 p.trtnd .. o.7e p.trtnd .0.40 
~ 0,0 
2 3 2 3 2 3 2 3 
Level of anlloxldanllnlake (Iertlles) 
Figure 5.2.1 The association of level of daily dietary vitamin intake, categorized by 
terti/es, with Parkinson's disease expressed as adjusted odds ratios (dots) with the 
corresponding 95% confidence intervals (bars). Level 1, low antioxidant intake, is 
reference level. 
Discussion 
In this study we found a significant inverse relation between dietary vitamin E intake 
and PO among non-demented independently living persons. The magnitude of this 
relation seemed to be dose-dependent. We first have to consider whether the 
limitations that were inherent in our study may invalidate our results. 
This is a cross-sectional study and a possible explanation for the observed 
relationship could be that the lower dietary intake of vitamin E in PO patients is a 
consequence rather than a cause of the disease. However, our data do not suggest 
that different dietary habits in PO patients resulted from the disease. When we 
excluded PO patients with more advanced disease, or those who used vitamin 
supplements, the associations did not change. Moreover, the study sample included 
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31 relatively mild PD patients of whom eight were detected through the screening and 
had not been diagnosed previously. Finally, the PD patients did not report changing 
their dietary habits more often than the controls. These observations, and evidence 
that the food frequency questionnaire properly reflects dietary habits over the past 
five years," suggests that we have measured dietary habits in PD patients prior to 
the onset of their disease which started on average less than three years ago. 
It is unlikely that the dietary data collection was biased as there is no specific 
hypothesis that relates a specific food item to PD. Also, dietary vitamin intake was 
indirectly calculated using a food composition table. Importantly, the food frequency 
questionnaire was administered as part of the larger base-line data collection in the 
Rotterdam Study and the dieticians were not informed of any of the diseases in the 
participants. Furthermore, one quarter of the PD patients included in this current 
study were not aware of their disease. 
Findings in several neuropathological studies have implicated oxidative stress in the 
pathogenesis of PD,16'" some suggesting increased lipid peroxidation in the 
dopaminergic cells."·24 A high intake level of fat-soluble antioxidants like vitamin E 
and ~-carotene might reduce lipid peroxidation in the substantia nigra. Only few 
studies on dietary antioxidant intake and the association with PD exist.'·6."." Two 
retrospective case-control studies suggested an inverse association between PD and 
intake of food items high in vitamin E."'" In these studies, however, dietary intake 
was not quantitated and the PD patients had to rate their food consumption compared 
with that of their spouses. Two case-control studies found no protective effect of 
dietary antioxidants on PD"" In the first one a large fraction of the PD patients were 
demented (36%) whereas the controls were non-demented' while the latter was 
hospital-based and found that the associations between PD and food items were 
influenced by disease duration, suggesting potential biases." In a recent nested 
case-control study among Hawaiian men of Japanese and Okinawan ancestry, an 
inverse association was found between PD and consumption of vitamin E containing 
foods (legumes) more than 25 years before" The large DATATOP study, that 
investigated whether in PD patients treatment with the antioxidant tocopherol (a 
component of vitamin E) slowed down the progression of the disease, could not 
detect such a protective effect." As extrapyramidal signs only become clinically overt 
after dopaminergic cell loss of approximately 50%,30.31 and the rate of deterioration 
of nigral cells is probably most prominent in the preclinical or very early phase of 
PD,"'" a putative beneficial effect of treatment with tocopherol in PD patients may 
be harder to detect than a protective effect of cumulative dietary intake of vitamin E 
over an extended period in the past. The richest sources of vitamin E are vegetable 
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oils, nuts, wheat germs, and cod liver oil. 
Theoretically, B-carotene may also inhibit lipid peroxidation in the brain" and vitamin 
C and flavonoids could have their anti oxidative effect in the brain as well. In the few 
published studies, however, in which the associations between PD and B-carotene 
and vitamin C were investigated no effect could be found'·27.".37." Flavonoids are 
antioxidants naturally occurring in vegetables, fruit, tea, and Wine," and have recently 
gained much attention regarding a protective effect in coronary heart disaese."·41 To 
date, the association between PD and flavonoids has never been investigated. 
Although in vitro flavonoids inhibit lipid peroxidation, ".42 we found no protective effect 
by flavonoids intake at all. 
In conclusion, we found a dose-dependent inverse association between dietary intake 
of vitamin E and PD. This is compatible with a protective effect of high dietary 
antioxidant intake against the development of PD. These findings need to be 
confirmed in prospective studies, in which dietary habits have been measured before 
the onset of PD. 
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5.3 Smoking and the risk of Parkinson's disease 
Since the late fifties, when an apparent protective effect of smoking on Parkinson's 
disease (PO) was first reported in studies on mortality follow-up of smokers,' many 
investigators have focused on the relation between cigarette smoking and PO.' 
Although in most studies an inverse association of smoking with PO was found,'·' a 
reduced risk of PO among smokers remains controversiaL"'" Most studies that 
reported an inverse association were based on prevalent cases and it was suggested 
that the apparent inverse association could be artefactual due to confounding, 
selective mortality, cause-effect bias, symptom suppression, or diagnostic 
competition.' The few prospective studies that paid attention to the association 
between smoking and PO also reported a two- to three-fold reduction of the risk of 
PO among smokers.""'·' However, all but one,' investigated follow-up of smokers and 
non-smokers through death certificates in which smoking-related diseases may 
overshadow PO as the recorded, underlying, cause of death, especially in smokers. 
This possible underreporting of PO might erroneously suggest a less frequent 
occurrence of PO among smokers, 
Considering these limitations in previous studies and new biologically plausible 
evidence for a neuroprotective mechanism mediated by smoking that could protect 
against PO, 10 we prospectively investigated the risk of PO in non-smokers compared 
with smokers in a general elderly population. In our community-based cohort study, 
subjects were examined neurologically at baseline and at follow-up, 
Methods 
Study population 
This study was part of the Rotterdam Study, a community-based cohort study on 
prevalence, incidence and determinants of chronic disabling diseases in elderly 
persons,11 The conduct of the study was approved by the Medical Ethics Committee 
of Erasmus University, The baseline survey started in 1990 and was completed in 
June 1993, All inhabitants of Ommoord, a suburb of Rotterdam, the Netherlands, who 
were 55 years of age or older, were invited to participate in the study, Both 
independently living and institutionalized subjects were included, Of the 10,275 
eligible subjects, 7,983 (78%) agreed to participate and signed informed consent 
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statements. In the cross-sectional survey, all participants were interviewed at home 
and 6,969 underwent the complete baseline neurologic screening examination for 
parkinsonism. Follow-up examinations took place from September 1993 till the end 
of 1994. Persons who had a neurologic screening examination at base-line and were 
free of parkinsonism and dementia at that time, and thus at risk for incident PO, were 
followed up for incident PO (n = 6,566). Subjects of whom baseline smoking history 
data were incomplete (n = 124) were excluded from the present study, resulting in a 
study population of 6,442 subjects. 
Case-finding and diagnostic procedures 
80th at baseline and at follow-up, we used a two-phase design to identify subjects 
with PD." In the first phase of the screening for parkinsonism, participants were 
briefly examined neurologically by one of the study physicians. Those who screened 
positive or those with incident parkinsonism who were reported by their general 
practitioner or neurologist during the follow-up interval, were invited for further 
evaluation in a second phase by a neurologist or a neurologist in training. A 
structured clinical work-up was used to establish the diagnosis parkinsonism and to 
classify this parkinsonism. PO was diagnosed if at least two of four cardinal signs 
(i.e., resting tremor, rigidity, bradykinesia, or impaired postural reflexes) were present 
in a subject not taking anti parkinsonian drugs or when in a subject treated with 
antiparkinsonian medication one or more signs, documented by medical history, had 
improved by treatment. For the diagnosis of incident PO, all causes of secondary 
parkinsonism, and dementia before the onset of incident parkinsonism, had to be 
absent as well. 
For all 1,282 subjects who could not be reexamined at follow-up (320 had died, 51 
could not be reached, 480 refused, and 431 random subjects did not undergo the 
complete neurologic screening examination due to logistic reasons) we obtained 
information through a surveillance system by computer linkage with the general 
practitioners' automated medical record systems. Through this surveillance system 
we were notified of incident patients with parkinsonism and had access to their 
medical records. We took the midpoint between age at baseline and age at diagnosis 
as the age at onset of PD. As PO has an insidious onset, an objective indication of 
when the first symptom of the disease had actually started is hard to achieve for all 
patients in an equally adequate way. Given the relatively short follow-up period, the 
age at midpoint of follow-up was considered a good approximation of the age at 
onset. 
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Data collection on smoking 
At baseline, smoking status was assessed in all subjects. Subjects were categorized 
into a group who at baseline had never smoked (non-smokers), a group who had 
smoked but had quit smoking before baseline examinations (ex-smokers), and a 
group of persons who were still smokers at baseline (baseline-smokers). The 
combination of the latter two groups, ex-smokers and baseline-smokers, formed the 
group ever-smokers. In smokers, we also asked the average number of cigarettes 
smoked, the age at which a subject had started smoking, and the number of years 
that a subject had smoked. In ex-smokers, the age at which subjects quit smoking 
was assessed. 
Data analysis 
We calculated the cumulative incidences of PD for non-smokers, ever-smokers, and 
for ex-smokers and baseline-smokers separately. Using Cox proportional hazard 
analyses, we estimated the age- and sex-adjusted relative risk (RR) with 
corresponding 95% confidence interval (95% CI) of PD among non-smokers as 
compared with smokers, both ex- and baseline-smokers combined and separately. 
In a separate analysis, we stratified by sex to assess whether the effect of smoking 
was modified by sex. A dose-effect relation was analyzed by defining smoking 
exposure according to pack years, calculated as the average number of cigarettes 
smoked per day divided by 20 and multiplied by the number of years smoked. 
In all analyses, we adjusted for age at entry in the study and sex, and took each 
participant's contributed follow-up time into account. To assess whether selective 
mortality had biased the associations, 13·" we also stratified by age by categorizing the 
cohort into two groups; one consisting of subjects younger than 75 years of age, and 
of 75 years of age and over. To determine whether the inverse effect of smoking 
resulted from persons quitting smoking in a very early phase of the disease as a 
result of the disease,' we additionally excluded incident PD patients who had an 
estimated onset of PD within one year after baseline screening, and we compared the 
time that had elapsed since quitting smoking between ex-smokers who did and who 
did not develop PD. To investigate whether the proportion of ex-smokers in PD 
patients differed significantly from the proportion of ex-smokers in non-parkinsonian 
subjects, we used a logistic regression model in which we adjusted for sex and age 
at baseline. To assess whether smoking delays the age at onset of PD,' we also 
compared the age at onset of non-smoking incident PD patients with that of smoking 
PD patients, controlling for sex and follow-up time by analysis of covariance. 
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Results 
Table 5,3,1 shows the baseline characteristics of the study population at risk to 
develop incident PD, The cohort was followed for a median period of 2,12 years (SD 
± 0,84), The proportion of baseline-smokers and ex-smokers among those who could 
not be reexamined in person at follow-up was similar to those who had been 
reexamined, 
Table 5.3.1 Baseline characteristics of the study population at risk for incident 
Parkinson's disease' 
Median age in years (± SO) 
Numbers of men (%) I women (%) 
Number of non-smokers (%) 
Number of ever-smokers (%) 
Baseline-smokers (%) 
Ex-smokers (%) 
Mean number of pack yearst among smokers (±SO) 
Mean number of pack years among baseline-
smokers 
Mean number of pack years among ex-smokers 
SD '" standard deviation. 
68,7 (8,6) 
2,657 (41,2%) /3,785 (58,8%) 
2,240 (34,8%) 
4,202 (65,2%) 
1,487 (23,1%) 
2,715 (42,1%) 
27.4 (23,1) 
31,2 (20,0) 
25,3 (24,1) 
* Persons with either parkinsonism or dementia at baseline (n = 401) have been exduded. 
t Average number of Cigarettes smoked per day divided by 20 and multiplied by the number of years smoked. 
Among the 6,442 participants who were at risk for PD, we identified 34 subjects who 
developed PD during a total of 13,673 person years, Of ever-smokers 0,3% 
developed PD whereas 0,9% of the non-smokers became affected by PD (Table 
5,3,2), Ever-smokers had a statistically significant almost three-fold decreased risk 
of PD (Table 5,3,3), Also, when we stratified by actual baseline smoking status 
(smokers; ex-smokers), or by sex, the risk was decreased though for baseline-
smokers, and for women, this was statistically non-significant. Crude and adjusted 
RRs of PD for the various subgroups are presented in Table 5,3,3, When smoking 
exposure was analyzed as pack years, we found a statistically significant decrease 
in the risk of PD (RR per pack year smoked: 0,98 (95%CI: 0,95-1,00», Ever-smokers 
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Table 5.3.2 The incidence of Parkinson's disease (PO) in non-smokers and smokers, 
overall and for various subgroups, in the Rotterdam Study 
Baseline exposure Persons at incident Cumulative Incidence rate 
risk for PD PD cases incidence (per 1,000 pyrs'j 
Non-smokers (reference) 
Tolal 2,240 21 0.94% 4.39 
Men 220 3 1.36% 6.98 
Women 2,020 18 0.89% 4.13 
Smokers 
Ever-smokers 4,202 13 0.31% 1.46 
Baseline-smokers 1,487 7 0.47% 2.18 
Ex-smokers 2,715 6 0.22% 1.06 
Men (ever-smokers) 2,437 8 0.33% 1.61 
Women (ever-smokers) 1,765 5 0.28% 1.27 
* persons years. 
who developed incident PD, had smoked on average less pack years than smokers 
who stayed free of the disease: in incident PD patients the mean number of pack 
years was 27.4 for baseline-smokers, 14.7 for ex-smokers, and 21.5 for both groups 
combined (ever-smokers); the corresponding figures for smokers without the disease 
were, 31.2, 25.4, and 27.4, respectively. However, none of these differences were 
statistically significant.Stratification by age led to similar results in both age-groups; 
for ever-smokers younger than 75 years of age the RR of PD was 0.36 (95%CI: 0.10-
1.22), and for ever-smokers aged 75 years and over the RR was 0.35 (95%CI: 0.11-
1.09). Exclusion of incident PD patients with an estimated onset of PD within one 
year after baseline screening (n = 16) did not alter the results, the RR was 0.38 
(95%CI: 0.11-1.27). The proportion ex-smokers was lower among ever-smokers who 
developed PD (46%) than among ever-smokers without incident PD (65%), but this 
difference was statistically non-significant. Moreover, ex-smokers with incident PD 
had not quit more recently than ex-smokers without PD (mean time since quitting was 
25.5 (± 14.7) versus 19.6 (± 12.6)). 
The median age at onset among PD patients who smoked was higher than the age 
at onset among incident PD patients who had never smoked: 80.7 versus 76.5 years 
of age, but this was statistically non-significant (p = 0.6). 
128 Chapter 5.3 
Table 5.3.3 The relalive risk (RR) of Parkinson's disease (crude and age- and sex 
adjusted) with 95% confidence interval (95% el) for smokers compared with non-
smokers 
Baseline exposure Crude 95% CI Adjusted 95% CI 
RR RR 
Non-smokers 1.00 Reference 1.00 Reference 
Ever-smokers 0.33 0.17-0.66 0.37 0.15-0.89 
(baseline- and ex-smokers 
combined) 
Baseline-smokers 0.50 0.21-1.17 0.50 0.18-1.43 
(Ex-smokers excluded) 
Ex-smokers 0.24 0.10-0.59 0.26 0.09-0.78 
(Baseline-smokers excluded) 
Men (ever-smokers) 0.24 0.06-0.89 0.26 0.07-0.99 
Women (ever-smokers) 0.31 0.12-0.84 0.39 0.14-1.08 
Ever-smokers (tl1ose with an onset of 0.31 0.15-0.64 0.41 0.17-1.03 
PO 1 year after baseline screening 
excluded) 
Discussion 
We found that smokers had a significantly decreased risk of PD. which was not 
modified by age. The findings could not be explained by artefactual associations due 
to quitting smoking in the early phase of disease, as was suggested previously.5 
The strengths and limitations of our study are several. At the time of the baseline 
collection of information on smoking history, all participants were free of PD. As a 
result neither the participants nor the interviewers were aware of the participants' 
future disease status. Both at baseline and follow-up, participants were screened in 
person for PO by the use of a similar examination and similar diagnostic work-up. For 
those who were screened at baseline but could not be examined at follow-up, we 
achieved complete follow-up through a computer surveillance system, by which 
interval cases were reported at time of diagnosis. Among the individuals who could 
not be reexamined at follow-up, however, we may have missed some very early PO 
patients with mild signs and those who had not sought medical attention yet. Our 
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follow-up period was relatively short. This may have reduced the proportion of 
subjects who could not be rescreened in person, and ensured a more complete case-
ascertainment, but led to smaller numbers of incident PO patients. Though these 
numbers were small, the statistical power was large enough to detect strong 
differences in risk. 
The methodological limitations of cross-sectional and retrospective studies on 
smoking and PO have been extensively discussed previously by Morens et al .. ' The 
few prospective studies that were based on follow-up of mortality of smokers had 
limitations as well. In these studies, smoking related diseases may predominate the 
diagnosis of PO as the listed primary cause of death, especially in smokers. This may 
lead to an underestimation of the PO frequency among smokers and to a seemingly 
protective effect of smoking on PD. Even in countries with excellent death certificate 
registration, in only 70% of diagnosed PO patients the PO diagnosis is listed on death 
certificates. 16 The only published prospective community-based study on smoking and 
PO to date showed a reduced risk of PO for smokers similar to what we found.' This 
study is not completely comparable with ours, however, because no in-person 
screening for PO was conducted at baseline and it was restricted to men of Japanese 
and Okinawan ancestry.' 
Despite the robust finding of an inverse association between smoking and PO in most 
studies, it is still speculative which biologic mechanism is involved in the protective 
effect.,,1o Recently, Fowler et ai" using Positron Emission Tomography scanning 
technique, found that in the substantia nigra of smokers monoamine oxidase B (MAO 
B) levels are reduced by 40%.10 As a result, MAO B-mediated dopamine oxidation will 
be less, yielding a neuroprotective effect through reduced free radical production, In 
contrast to studies in which neuroprotective treatment in symptomatic PO patients did 
not reveal convincing results,17 neuroprotection over decades and in the preclinical 
phase of the disease may be more effective.18 In smokers, who may have been 
smoking for years and presumably long before the accelerated deterioration of 
dopaminergic cells in the substantia nigra, the continuous inhibition of MAO B could 
have exerted an effective neuroprotection. Another beneficial effect of MAO B 
reduction regards the increased synaptic dopamine availability, thereby reducing the 
symptom severity or delaying the onset of clinical PD.' Our finding that incident PO 
patients who are smokers may have a later age at onset compared with non-smokers, 
endorses this latter possibility. Reduced MAO B levels may also implicate less MAO 
B mediated oxidation of protoxins to neurotoxins."'" The compounds of cigarette 
smoke that inhibit MAO B are not known. 10,22,23 
Besides the MAO B related processes, smoking may induce other enzymatic 
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processes that are involved in the metabolism of xenobiotics, thereby augmenting 
protection against oxidative stress or toxins." Other possible mechanisms pertain to 
direct stimulation of dopamine release20,,. or nicotine receptors'6,,, by nicotine, or to 
protection through smoking-associated carbon monoxide against peroxidation of the 
membrane.28 
A different point of view contains the key role in reward mechanisms and addiction 
that has been ascribed to dopamine."'" Higher dopamine levels may be linked to 
novelty-seeking behavior," and could facilitate addiction to cigarettes. Reduced 
dopamine levels in the brains of preclinical PD patients" may keep these subjects 
from smoking long before the signs become clinically overt. Also, regardless whether 
or not dopamine related, a less novelty-seeking behavior in persons who later 
develop PD has been suggested" and this may, with other pre morbid personality 
features, predelict these persons to restrain from smoking,"" resulting in a 
comparatively high frequency of PD among non-smokers. To date, good evidence to 
support this pre morbid personality hypothesis is lacking as it was only investigated 
in case-control studies based on prevalent cases, and thus cause and effect bias and 
recall bias may have occurred. 
In conclusion, smokers have an almost three-fold decreased risk of PD. This inverse 
association is dose-dependent and this supports a causal explanation. The 
association cannot be explained by PD patients who quit smoking in the preClinical 
phase of the disease, and is independent of age. Although the benefits of smoking 
regarding protection against PD will not outweigh the disadvantages of smoking, 
better insight into the smoking-related neuroprotection may help to understand the 
etiology of PD and eventually to prevent PD. 
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5.4 Family history and the risk of Parkinson's 
disease 
Although numerous potential risk factors for Parkinson's disease (PO) have been 
studied, the cause of this neurodegenerative disease still remains unknown. Since the 
end of the nineteenth century, when Gowers reported 15% familial occurrence of PO, 1 
a genetic component in the etiology of PO has been suspected. In twin studies 
performed in the seventies and eighties, however, low concordance rates of PO were 
found and it was concluded that hereditary factors had no major role in PO.,·, 
Recent reports on PO candidate genes,'·' and familial aggregation of PO,·" as well 
as hypotheses regarding enhanced susceptibility to PO through genetically 
determined deficient enzymes that are involved in detoxicification of neurotoxins in 
the brain 17·19 illustrate the renewed interest in a genetic contribution to the 
pathogenesis of PO. However, the studies on familial aggregation that have been 
published thusfar have various methodologic limitations as most were case-control 
studies in which the information had been collected retrospectively, were hospital- or 
register-based, and pertained to a relatively young study population. 
Prospective community-based familial aggregation studies in elderly could overcome 
these limitations, but to date no such studies exist. Therefore, we prospectively 
assessed the risk of PO among persons with a family history of either PO or dementia 
as compared with those without in a general elderly population. In our community-
based cohort study, subjects were neurologically screened at baseline and at follow-
up. 
Methods 
Study population 
This study was part of the Rotterdam Study, a prospective community-based cohort 
study that focuses on prevalence, incidence, and determinants of cardiovascular, 
locomotor, ophthalmologic, and neurodegenerative diseases." For this cohort study, 
all inhabitants aged 55 years or older from the suburb of Ommoord in Rotterdam, the 
Netherlands, were invited to participate. Both independently living and institutionalized 
residents were included in the cohort. The baseline survey started in 1990 and was 
completed in June 1993. Of the 10,275 eligible subjects, 7,983 (78%) agreed to 
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participate and signed informed consent statements. At baseline, all participants were 
interviewed at home and 6,969 subsequently underwent the complete in-person 
baseline screening for parkinsonism at a research center. Follow-up examinations 
took place from September 1993 till the end of 1994. Persons who had a neurologic 
screening examination at base-line, were free of parkinsonism and dementia at the 
time, and of whom the baseline data on family history of Parkinson's disease and 
dementia were complete, were followed up for incident PO (n = 6,341). 
Case-finding and diagnostic procedures 
Both at baseline and follow-up, we used a two-phase design to identify subjects with 
PO." In the first phase of the screening for parkinsonism, every participant was briefly 
neurologically examined by one of the study physicians, and those who screened 
positive were invited for further evaluation in a second phase by a neurologist or a 
neurologist in training. A structured clinical work-up was used to establish the 
diagnosis parkinsonism and to classify this parkinsonism. PO was diagnosed if at 
least two of four cardinal signs (Le., resting tremor, rigidity, bradykinesia, or impaired 
postural reflexes) were present in a subject not taking antiparkinsonian drugs or when 
in a subject treated with anti parkinsonian medication one or more signs, documented 
by medical history, had improved by treatment. In addition, all other causes of 
parkinsonism had to be excluded." 
For the 1,238 subjects who were not reexamined at follow-up (295 had died, 44 could 
not be reached, 468 refused, and 431 random subjects did not undergo the complete 
neurologic screening examination due to logistic reasons), we obtained information 
through a surveillance system by computer linkage with the Ommoord general 
practitioners' and pharmacies' automated medical record systems. Through this 
surveillance system we were notified of incident patients with parkinsonism and were 
allowed access to their medical records. 
Data collection on family history 
As part of the baseline data collection in the Rotlerdam Study, information was 
obtained on family history for various diseases among first degree relatives. Formal 
pedigrees were constructed by asking the participants the year of birth of their 
parents, sibs, and children and, if applicable, the age of death of these relatives. 
Next, using a comprehensive list of diseases including PO and dementia, each 
participant was asked to indicate for each family member separately whether that 
family member was affected by a specific disease. 
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Data analysis 
We calculated the cumulative incidences of PO among subjects with a family history 
of PO, dementia, and either PO or dementia, and among subjects without such family 
history. We used Cox proportional hazard analyses to estimate the crude and the 
age- and sex-adjusted relative risk (RR) of PO, with corresponding 95% confidence 
interval (95% CI), for the various groups with a positive family histories compared with 
those without such a family history. For PO and dementia separately, we calculated 
the RRs for persons with at least one affected relative, persons with one affected 
relative, and persons with at least two affected relatives. Also the RR of PO among 
persons with an affected relative with either PO or dementia was estimated. In all 
analyses, each participant's contributed follow-up time was taken into account, and 
for the adjusted RRs, we controlled for age at entry in study and sex. 
Results 
Table 5.4.1 presents the age- and sex-distribution of the study population at risk to 
develop PO and the distribution of those with a family history of PO or dementia, or 
both. 
Table 5.4.1 Baseline characteristics of the study population at risk for incident 
Parkinson's disease' 
Baseline characteristics 
Number of persons at risk for PO 
Median age in years (± SO) 
Number of women (%) 
Persons without a relative with either PO or dementia (%) 
Persons with relatives with PO (%) 
Persons with at least two relatives with PO (%) 
Persons with relatives with dementia (%) 
Persons with at leastlwo relatives with dementia (%) 
Persons with at least one relative with either PO or dementia (%) 
SD :: standard deviation. 
r Persons \'lilh either parkinsonism or dementia at baseline (0:: 401) have been excluded. 
6,341 
68.7 (8.6) 
3,730 (58.8%) 
4,655 (73.4%) 
313 (4.9%) 
24 (0.4%) 
1,498 (23.6%) 
158 (2.5%) 
1,686 (26.6%) 
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From the cohort at risk to develop PD, 32 incident PD patients emerged after a total 
follow-up time of 13,201 person years. The 2.1 year cumulative incidence of PD for 
those with a family history of PD was higher than for those without; 0.96% versus 
0.43% (Table 5.4.2). 
Table 5.4.2 The incidence of Parkinson's disease (PO) in persons with a family 
history of PO, dementia, or both, and in those without 
a positive family history 
Baseline information 
No family history of PO or dementia 
Persons with at least one relative with 
PD 
Persons at incident Cumulative Incidence 
risk for PD' PO cases' incidence ralet 
4.655 
313 
20 
3 
0.43% 
0.96% 
2.1 
4.8 
Persons with at least two relatives 24 4.17% 24.0 
with PD 
Persons with at least one relative with 
dementia 
Persons with at [east two relatives 
with dementia 
Persons with a family history of PD or 
dementia 
* Numbers 
t Incidence rate in cases per 1,000 persons years. 
1.498 
158 
1,686 
11 0.73% 3.5 
2 1.27% 6.1 
12 0.71% 3.4 
Of the 24 persons who had at least two relatives affected by PD, one developed 
incident PD. For persons with a positive family history of PD the adjusted RR risk of 
PD was 2.5, but this did not reach statistical significance (95% CI 0.8-8.4)(Table 3). 
Having at least two affected relatives with PD increased the risk of PD more than 9-
fold (Figure 5.4.1), and this was significant (RR 9.3 (1.3-68.2». Subjects with a family 
history of dementia had a borderline significantly increased risk, RR 1.7 (0.9-3.7), 
which seems a little bit higher for those with at least two demented relatives, RR of 
2.4 (0.6-10.2). In Figure 5.4.1 the adjusted RRs for those with one, respectively at 
least two affected family members is graphically displayed. For the various 
subgroups, the cumulative incidences, and the crude and the age- and sex-adjusted 
RRs of PD are presented in Tables 5.4.2 and 5.4.3. 
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Table 5.4.3 The relative risk (RR) of Parkinson's disease (crude, and the age- and 
sex adjusted) for persons with a family history of Parkinson's disease (PO), 
dementia, or both. Persons without a positive family history have a relative risk of 1.0 
(reference) 
Baseline information 
Persons with at least 1 relative with PO 
Persons with at least 1 relative with dementia 
Persons with at least 1 relative with either 
PD or dementia 
'" 95% confidence inlelVa1. 
100 
f 
g> 10 
"" o 
n. 
'l5 
~ 
~ 1 
.Jg 
C2 
--
Crude RR 
2.6 (0.8-8.4)' 
1.8 (0.9-3.7) 
1.7 (0.8-3.4) 
-, 
-'--
Adjusted RR 
2.5 (0.8-8.4) 
1.8 (0.9-3.7) 
1.7 (0.8-3.4) 
<. Family history of PO Family history of dementia 
0,1-"--> '------'----'-----'------'----~-~ 
o 1 ",2 0 1 ",2 
Number of affected 1 at degree relatives 
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Discussion 
This is the first prospective community-based study in which the risk of incident PD 
was investigated among non-parkinsonian subjects with a family history in first degree 
relatives of either PD or dementia compared with those without. Our preliminary 
results showed that both persons with family members with PD and persons with 
demented relatives run a higher risk to develop PD as compared with persons without 
such history, although this increased risk reached statistical significance only for 
those with at least two relatives affected by PD. 
To interpret our findings, we first have to consider the limitations and strengths of our 
study. Although the present prospective cohort study is the largest in its kind and 
included more than 6,000 participants who were screened and interviewed at 
baseline, only a small number of persons have a family history of PD among first 
degree relatives, and the number of incident PD patients was small due the low 
incidence of PD. 
Concerning the reliability of the collected information on family history, some remarks 
have to be made. Due to the size of the cohort and the age distribution of the 
members of this cohort (the oldest participant was 106 years of age), it was not 
feasible to verify the family history in each reported affected relative. Therefore, we 
chose to rely on self-reported family history. Though this may have introduced some 
misclassification of diagnosis of PD or dementia in relatives, this will probably have 
been similar in those who developed PD and in those who stayed free of the disease 
as the data were collected in non-parkinsonian persons at baseline. The 
approximately five times higher percentage of persons with a family history of 
dementia than the percentage of persons with a family history of PD in our study is 
in agreement with the overall prevalences of dementia and PD in the Rotterdam 
Study; 6.3% and 1.4%.,,·22 Erroneously classifying essential tremor in relatives as PD 
may, to some extent, have occurred, but this unlikely explains our findings: a much 
higher proportion of persons with a positive family history of PD would have been 
expected because essential tremor is highly prevalent in an elderly population. 
Unique features of our study are that the study is prospective, community-based and 
not register-based or hospital-based, and that participants were examined in person 
at baseline and at follow-up. Regarding the first, through the prospective design many 
potential sources of biases, that might have flawed all previous studies on family 
history of PD, will have been reduced. All participants were at the time of the baseline 
interview free of both PD and dementia, and were, like the interviewers, not aware 
of their future disease status. Consequently, information bias with regard to collected 
data on family history (observer and recall bias) is a very unlikely explanation for our 
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findings. As the study is community-based, the incident PD patients will reflect a 
general PO population, thereby minimizing selection bias. Also, compared with 
retrospective or cross-sectional studies the role of selective mortality will be less in 
prospective studies. Prospective studies, however, that solely rely on incident PO 
patients retrieved through medical records may still potentially bear some form of 
selection bias such as detection bias, e.g., it is easy to conceive that new PO patients 
arising from families with familial PO are to be recognized and referred earlier for their 
signs than sporadic cases. In an earlier report, we have shown that in a general 
population a substantial proportion of PO patients go undetected ". In our study, this 
type of bias was circumvented by the use of similar in-person screening examinations 
for PO at both baseline and follow-up. 
Among the many efforts to disclose a genetic contribution to the etiology of PO are 
studies on familial aggregation or association of PO that have been recently 
reported, 10·12.14·1. all showing familial aggregation, sometimes up to 22% in first degree 
relatives.",1. However, these studies have to be interpreted with some caution, All 
were hospital- or register-based, through which selection bias of the cases may have 
been occurred. Especially in the studies that were conducted in specialized 
movement disorder clinics, PO patients referred to these clinics may be different with 
respect to family history than PO patients who have been recruted in a general 
population, The latter is, in part, refiected by the relatively young age in those cases, 
Also, the studies that compared the frequency of family history of PO between PO 
patiens and controls, selection of controls may have been biased as well as they 
were spouses of friends and not population-based controls, 12, 14, ,. In all, the 
information on family history was collected retrospectively which also may have 
introduced bias, such as information bias, as mentioned earlier. Still, these findings 
suggest that PD is very prevalent in many families. This is confirmed by the 
accumulating number of reports on multicase families,9,11,,,.,, In most reports on 
multicase families, the sole atypical feature of the PO is the young age of onset." 
The segregation ratios in most of these families suggest autosomal dominant 
inheritance with reduced penetrance. The genetic association studies, however, that 
have been conducted in an effort to identify polymorph isms of genes that may play 
a role in the pathogenesis of PO have led to conflicting results,5.7,29.35 
Evidence is growing that PD is a multifactorial disease in which environmental factors 
and genetic factors interplay, e,g., neurotoxins may only exert their potentially toxic 
effect if the exposure occurs in a genetically susceptible subject." Hence, a more 
fruitful approach may be to inclUde putative risk factors in the analyses of association 
or linkage of candidate genes, 
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An alternative explanation for familial aggregation of PO alone, or of both PO and 
dementia,13,36,37 may be that family members share the environment, and thus the 
environmental risk factors," The finding in our study that persons with more affected 
family members faced a higher risk of PO does not preclude this alternative 
explanation, 
In conclusion, our prospective study suggests that hereditary factors do contribute to 
the pathogenesis of PD. Longer follow-up of the cohort will be needed to confirm 
these preliminary findings. The findings may warrant a further search for candidate 
genes involved in the pathogenesis of PO, 
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Chapter 6 
General discussion 

6 General discussion 
In this thesis, studies on various epidemiologic aspects of Parkinson's disease (PO), 
such as diagnosis, frequency, and determinants of the disease, have been described. 
In order to interpret and appreciate the findings from these studies, some remarks 
related to the general study design and methodology, diagnosis, and implications of 
the findings have to be made. As for each study the more specific methodologic items 
have been dicussed in the corresponding chapter, this final chapter will mainly deal 
with advantages and limitations of community-based studies as the Rotterdam Study. t 
Also, the contribution of the findings to current knowledge of PO will be discussed. 
Finally, some research topics on PO will be sketched that may be explored as an 
extension to the studies in this thesis. 
Methodologic considerations 
The setting of the studies 
The core of this thesis consists of studies that were conducted as part of the 
Rotterdam Study, except for Chapters 3.2 and 4.2 in which comparisons were made 
with other community-based studies. The unique feature of these community-based 
studies regarding PO is that all individuals were screened in person. In a defined 
population, such approach should allow us, if the screening instrument is adequate, 
to identify virtually all subjects with one or more symptoms of the parkinsonian 
syndrome. This is in particular relevant for PO as many persons with this disease go 
undetected in the population.'·3 As a conseq uence, PO patients who have not been 
diagnosed before due to various reasons will be included in the study, yielding better 
prevalence and incidence estimates of the disease. Yet, in large community-based 
studies, it is impractical to administer a full neurologic examination by neurologists 
to each participant. Therefore, often a stepped approach is followed through which 
subjects most likely to be affected by parkinsonism will be further evaluated in a 
diagnostic phase. We decided to rely on an in-person screening examination rather 
than on a screening questionnaire. As shown in Chapter 3.1, the sensitivity of a 
questionnaire based on important clinical features of parkinsonism is low and may not 
enable researchers to detect all parkinsonian subjects in a population. Interestingly, 
a French community survey that based its screening mainly on a symptom 
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questionnaire yielded lower prevalence estimates than other European prevalence 
surveys with an otherwise similar methodology.' We feel that the application of a 
more objective tool such as a screening examination conducted by a physician may 
improve the detection rate of the disease. 
Etiologic and prognostic studies that are embedded in community-based studies with 
an in-person screening for PD have an advantage as well, conditional on several 
assumptions such as random participation non-response. Such studies will yield an 
aselective PD patient popUlation, in contrast to patient populations derived from 
specialized movement disorder clinics. Also, persons from the same study population 
who have not been identified with parkinsonism are suitable subjects to serve as 
controls because they have emerged from the same population and have been 
subjected to the same screening. Therefore, such a design enhances both internal 
and external validity. 
Non-response 
In all studies, non-response bears some potential for selection bias. A common 
assumption is that the higher the non-response is, the higher the risk of bias will be 
that might influence the validity of the study. This is, however, only true if the non-
response is selective: if non-response is related to the determinant or outcome of 
interest, the findings will be flawed. The overall response rate in the Rotterdam Study 
was good (78%), considering the average age of the study population, and the 
extensiveness of the investigations. As for the PD survey it was decided not to rely 
on the screening questionnaire but on a complete screening examination (Chapter 
4.1), the response was somewhat lower, 68%. 
Direct assessment of selective non-response is difficult to achieve, but an indirect 
approach can be used if some characteristics of the total target population are known 
like age and sex' Regarding the PD survey that was part of the Rotterdam Study, the 
prevalence figures were strikingly similar to those derived from various European 
prevalence surveys with a variation of response rates (Chapters 4.1 and 4.2), both 
in rural and urban settings, using similar diagnostic criteria. Screening procedures, 
however, differed slightly across studies. Although we cannot exclude that actually 
existing differences have been obscured by differences in participation rates or 
sensitivities of the screening instruments, the very similar estimates for all studies 
using similar methodology and diagnostic criteria suggest that the higher non-
response in the Rotterdam Study compared with some other community-based 
studies has not led to serious selection bias. 
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Diagnosis 
In epidemiologic studies, the sole approach for diagnosing parkinsonism is the use 
of an ante-mortem diagnosis of PO, and thus a clinical diagnosis. It was shown 
previously that a substantial proportion of the cases, who during life had been 
diagnosed as PO, had a neuropalhologic diagnosis (gold standard) other than PO' 
Preliminary data now show that refinement of clinical diagnostic criteria for PO had 
improved diagnostic accuracy.7 However, although application of very strict clinical 
criteria may improve the clinico-neuropathologic correlation,'" it will lead to exclusion 
of more than 30% of pathologically genuine PO patients.' Moreover, it can be debated 
whether the neuropathologic diagnosis should indeed be regarded the gold standard 
because the neuropathologic diagnosis of PO is not unequivocal and diagnostic errors 
in the neuropathologic examination may occur as well. In addition, one has to bear 
in mind that many of the clinico-neuropathologic correlation studies have been 
conducted in specialized movement disorder clinics that may attract the more atypical 
PO cases. Also, especially the more atypical cases will come to autopsy, thereby 
possibly underestimating the accuracy of a clinical diagnosis. 
The different clinical diagnostic criteria for PO have been extensively discussed in 
Chapter 3.2. In some of the sets of the criteria, levodopa response is a prerequisite 
for the diagnosis PO in a parkinsonian subjec\.'·' In an epidemiologic study with an 
in-person screening for parkinsonism, by the virtue of its design, many thusfar 
unrecognized patients wilh PO may emerge' in whom administration of levodopa for 
diagnostic purposes is unethical and impracticle. Taken these considerations into 
account, a diagnosis of PO based on neurological symptoms wilhout additional 
requirements is adequate and feasible for epidemiologic studies. For studies on 
effectiveness of new antiparkinsonian drugs or genetic linkage stUdies of PO, more 
stringent diagnostic criteria may be preferred. 
Cross-sectional studies 
Two stUdies on etiology of PO described in this thesis (Chapters 5.1 and 5.2) are 
cross-sectional. In general, cross-sectional studies have a larger potential of bias than 
longitudinal stUdies. In particular, selection bias due to selective mortality, information 
bias, and cause-effect bias have to be considered when interpreting the associations. 
In Chapter 5.2, in which the relation between dietary antioxidant intake and PO is 
described, extensive attention has been paid to information bias and cause-effect bias 
(the observed relationship may be a consequence rather than a cause of the 
disease). Selection bias due to selective mortality unlikely explains the inverse 
association between dietary vitamin E intake and PO: either PO patients with a high 
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dietary vitamin E intake should have been selectively removed from the population 
or relatively more persons, except those who have PO, with low intake of vitamin E 
should have died. Both possibililies are not easy to conceive. 
In cross-sectional association studies on disease and polymorph isms of a gene, 
information bias and cause-effect bias are unlikely to playa major role. Information 
bias could only occur if the genotyping depends on the diagnosis of the disease, or 
vice-versa. In our study on the association between apolipoprotein E genotype 
(APOE) and dementia in PO (Chapter 5.1), both diagnosis and genotyping were done 
independently. As PO does not affect the APOE genotype, cause-effect bias is not 
a matter of concern. However, selection bias could have occurred and the 
associations wilhin the PO patient group may, to some extent, also be the result of 
an increased or decreased survival related to the APOE genotypes 2 and 4 if 
compared with those who are homozygous for APOE 3 genotype. For example, an 
increased risk of dementia in PO associated with the APOE 2 allele (APOE*2) may 
be found if demented PO patients who carry this allele live longer than non-demented 
PO patients carrying APOE*2. To rule out a possible effect of selective mortality, the 
findings of our study, presented in Chapter 5.1, will have to be confirmed in follow-up 
studies. 
Longitudinal studies 
The etiologic studies described in Chapters 5.3 and 5.4 are longitudinal which should 
limit sources of biases that may exist in cross-sectional studies. A possible bias that 
still remains is selection bias. Selection bias due to selective mortality has been in 
part addressed in the previous section. In Chapter 5.3 we described the decreased 
risk of PO among smokers. Smoking is a risk factor that typically influences mortalily. 
However, our findings of a protective effect of smoking for PO would only be the 
result of selective mortality if smokers who were to develop PO later during follow-up 
had selectively died before the diagnosis of PO could be established. This unlikely 
explains our findings because the short follow-up period will not have allowed such 
a strong effect by selective mortalily. 
The various pros and cons regarding the findings on family history of PO or dementia 
and the risk of PO presented in Chapter 5.4 have been extensively discussed before. 
These are preliminary findings which were based on small numbers. Of the 313 
persons with a positive family history of PO in first degree relatives, 4 developed PO 
and of 1,498 persons who reported a family history of dementia, 11 became affected 
by PO. As a consequence, the 95% confidence intervals were wide. Nevertheless, the 
findings were in agreement with the hypothesis, and it may be expected that after a 
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longer follow-up with more statistical power, due to more incident cases, the 
associations will be confirmed. 
Implications of the findings 
In the following section, the impact of some the findings from this thesis, and what 
perspective they put on current knowledge, will be addressed. 
Screening 
Not until now did studies exist that provide data on prevalence of subjective 
complaints suggestive for parkinsonian signs in a general population. We showed that 
this prevalence is high, and that this lowers positive predictive values of these 
complaints for the true presence of related parkinsonian signs. Also, our study makes 
clear that, in a general elderly population, a questionnaire based on two questions 
related to subjective complaints is probably not an adequate tool for screening for 
parkinsonism because of the low sensitivity, especially in the highest age-groups. 
Furthermore, we made clear that age strongly modifies the screening properties of 
a screening instrument. Besides age, other factors may be modifiers as well. This 
knowledge can be used in future studies that pursue complete case-ascertainment 
of parkinsonism and PD in a general population. 
Diagnosis 
It has been suggested that environmental factors playa role in the etiology of PD, 
solely based on comparisons of existing prevalence studies that yielded wide 
variations in prevalence estimates. We have shown that, besides case-finding 
strategies, differences in diagnostic criteria can change prevalence figures 
dramatically. For studies on frequency of the disease, we therefore argue to use 
similar diagnostic criteria, or, if prevalence estimates are being compared, to 
recalculate the prevalences applying similar diagnostic criteria. To allow such an 
approach, the sensitivity of the screening instruments used in the studies under 
comparison has to be similar. 
Frequency 
Prevalence 
The first community-based studies wilh an in-person screening on the prevalence of 
PD that were published, showed a high prevalence of the disease that continued to 
rise with age. Later, studies with a similar design, like ours, confirmed these findings 
and the current opinion is that in the Western world prevalence of PD is virtually 
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similar across countries and regions. The latter is nicely illustrated in the 
EUROPARKINSON prevalence study on PO, a study with a large methodological 
homogeneity. 
Incidence 
The study on the incidence of parkinsonism and PO (Chapter 4.3) indicates that the 
incidence rates are higher than has previously been reported by others based on 
registers or medical records. However, based on the prevalence estimates by 
community-based surveys with an in-person screening and on the age-specific life 
expectancy of PO patients, incidence rates of PO should be that high. 
Apart from the incidence rates of PO itself, the pattern that the incidence follows 
across the various age-groups, may reveal important information on the etiology of 
PD. The hypothetical pattern that age-specific incidence rates will follow depends on 
the underlying process or event that causes PD. In Figure 6.1 some of the patterns 
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Figure 6.1 Several patterns Ihal Ihe dopaminergic cell loss in Ihe subslantia nigra 
of Parkinson's disease (PO) patients may follow, based on age-specific incidence 
estimales of Ihe disease. If PO is caused by an event in persons susceptible at a 
cerlain momenl (B), Ihen a peak in Ihe incidence rale would be found. If PO is 
caused by an acceleraled aging process (A) or by a vulnerability 10 degeneration 
increasing with age (C), incidence rales would increase with age without a leveling 
off (C). 
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pertaining to the rate of excessive degeneration of dopaminergic cells in PO that have 
been proposed, to. 11 are visualized. If PO is caused by an accelerated normal aging 
process (A) or if the vulnerability of the dopaminergic cells to degeneration increases 
with age (C), an increase in the incidence of PO with age would be expected, even 
in the highest age-groups. If, on the contrary, the degenerative process in PO is 
induced by an event in persons around a specific age (B), possibly on the basis of 
some genetic susceptibility, then a decrease in incidence rates in the highest age-
groups could be expected as well. In our study, longer follow-up is needed to disclose 
the pattern of incidence rates in the oldest old. 
Determinants 
Apolipoprotein genotype 
The associations we found between APOE'2, APOE'4, and PO need confirmation in 
longitudinal stUdies. Some lines of evidence, including neuropathologic, suggest that 
APOE'4, and maybe also APOE'2, may be involved in dementia in PO. It still has to 
be elucidated through which mechanism APOE genotypes may exert their effect in 
the pathogenesis of dementia in PO. 
Vitamin E 
In 1989 the large OATATOP trial started to investigate the putative protective effective 
of treatment with the antioxidant tocopherol (a component of vitamin E) in PO patients 
in an early phase of the disease,12 although the biological availability of dietary 
vitamin E in the human brain, and the relation between dietary intake and PO had not 
been assessed before. This study showed no effect of vitamin E supplementation in 
PO patients." The relation between vitamin E intake and its availability in the human 
brain has to be explored further. A recent study, that was published after we had 
submitted our study for publication, did not show a correlation between supplemental 
vitamin E and ventricular cerebrospinal fluid concentrations of vitamin E." However, 
this study was based on only 5 relatively young PO patients with a median disease 
duration of almost 20 years, and the vitamin E uptake mechanisms in the brains of 
these PO patients may have been altered compared with healthy persons. The 
findings from that study need to be confirmed in a larger series of healthy subjects. 
Our finding that high dietary vitamin E intake, presumably during a considerable long 
period, is inversely associated with PO also needs confirmation in the follow-up phase 
of the Rotterdam Study, but it supports the hypothesis of involvement of oxidative 
stress in the etiology of PO. 
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Smoking 
The convincing result that smoking is strongly related to a decreased risk of PO, 
when potential biases have been avoided as much as possible, confirms most earlier 
reports on smoking and PD. It still may not be compounds of cigarette smoke that 
protect against PO, but low endogenous dopamine levels in the brain that keep 
persons who are to get PO from starting to smoke. Another, yet unidentified, factor 
(confounder) may also be related to smoking. This needs further investigation. 
Family history 
Our prospective study on family history of PO and of dementia suggests that also in 
a general population of elderly persons hereditary factors do contribute to the 
pathogenesis of PD. Before our study, none of the studies that investigated these 
associations were prospective nor community-based and the results from those 
studies could be critized on methodologic grounds as discussed in Chapter 5.4. Our 
findings may warrant a further search for candidate genes involved in the 
pathogenesis of PD. 
Recommendations for future research 
In this final section, suggestions for research on issues related to the etiology and 
prognosis of PO, and that are within the scope of this thesis, will be dicussed. In 
general, to overcome biased study results, prospective cohort studies on 
determinants of PO patients are needed, preferably in community settings in which 
each individual is regularly screened for PD. This approach will allow inferences on 
etiology that held for general PO patient populations. Similarly, prognostic research 
in PO populations derived from community-based studies will have an advantage over 
studies on prognosis of PO that are hospital-based as in the latter studies selection 
bias may have occurred. 
Etiologic research 
Genetic factors 
Despite many efforts to elucidate a major role of genetic factors in the pathogenesis 
of PO, it is still unknown which genes are involved, and to which extent. Evidence 
exists that polymorphisms of genes encoding for enzymes involved in the production 
or elimination of free radicals, in specific subunits of the mitochondrial respiratory 
chain (such as cytochrome P450 (CYP2D6)), or in xenobiotics, and genes involved 
in dopamine synthesis or metabolism (such as monoaomino oxidase B (MAO B» are 
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linked to PD. It has been hypothesized that persons with an altered function of such 
enzymes are more susceptible to PD. Thusfar, results from association studies on 
allelic associations with PO and candidate gene polymorph isms were inconclusive 15·24 
possibly due to heterogeneous patient groups. The limited knowledge on the 
pathogenesis of PO, and, as a consequence, the lack of promising candidate genes, 
further reduce the chance of a positive association. Better insight into the biochemical 
or pathophysiological mechanisms linked to the onset of PO may result in new 
candidate genes that can be tested in association studies using homogeneous patient 
groups. Also, larger, collaborative, linkage studies in multiple case families are 
needed to identify genes that are linked to the expression of PD. At the moment, a 
large European multi-center study is conducted to map and identify genes that confer 
genetic susceptibility to PO by using affected sib-pairs. Once such genes are 
identified, understanding of their function may yield new clues to prevention and 
treatment of PD. A different approach is genomic search in PO patients derived from 
a genetic isolate in order to enhance the probability of finding a gene associated with 
PD. If in one common ancestor a mutation causing PO has occurred, then the PO 
patients descending from this ancestor will not only share the mutation but also larger 
parts of the chromsome around the gene. Such larger parts are easier to search for. 
In a genetic isolate, the chance of having a common ancestor is considerably high. 
In the Netherlands, such study among PO patients from a genetic isolate is currently 
underway (Dr Van Ouijn, Dr Oostra, Prof. van Ommen). 
Gene-environment interaction 
It seems likely that it is not only genetic factors, but the interplay between genetically 
determined susceptibility and specific environmental factors that lead to PD. 
Therefore, if the interaction between genes and environmental factors were studied, 
the results might be more promising. Several mechanisms of gene-environment 
interaction have been proposed." In one of the hypothetical models, both the risk 
factor and the gene are required to increase the risk of the disease. If such a model 
would apply in the pathogenesis of PO, associations with genes and PO have to be 
investigated in relation to exposure of related factors. With regard to smoking and 
neurotoxins in relation to PO, the extent to which the effect of exposure is modified 
or potentiated by putative susceptibility genes could be investigated in populations, 
but this requires large numbers of patients. CYP206 polymorphisms have been 
suggested to interact with smoking," and this could also be the case with other 
enzymes. However, studies exploring this hypothesis have not been performed yet, 
except for the MAO B polymorphism,27 and are hampered by the lack of suitable 
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candidate genes. 
In an attempt to probe the hypothesis of gene-environment interaction in the etiology 
of PD, family history of PD can be used as a proxy for genetic susceptibility. 
Preliminary results from the Rotterdam Study suggest that interaction between a 
positive family history and smoking may modify the risk of PD." 
Toxins 
Toxins, like pesticides, have been implicated in the etiology of PD. Still, the extent to 
which toxins are responsible for the widely and uniformally distributed PD is debated. 
Differences in frequency estimates of PD, derived from prevalence and incidence 
studies with an in-person screening and similar methodology and diagnostic criteria, 
in urban and rural populations may hint at an environmetal factor to playa role in PD. 
The best approach, however, is direct measurement of the exposure in individuals 
and to follow these persons up till the disease becomes overt. In a setting as the 
Rotterdam Study, such an approach is not feasible because PD and the exposures 
are relatively rare. An alternative for research on the role of toxins in the 
pathogenesis of PD is either prospectively or retrospectively follow-up of cohorts with 
a higher than usual exposure to specific substances that have been implicated in the 
etiology of PD, e.g., farmers or industrial workers, using job exposure matrices to 
indicate objectively the compounds that carry the risk. 
Antioxidants 
Our finding that vitamin E is inversely associated with PD needs to be confirmed, and 
will prospectively be investigated in the Rotterdam study if more incident PD patients 
have been collected. Other prospective community-based studies which have 
originally not been designed to study PD but in which dietary vitamin intake in the 
participants was assessed, may also be suitable to investigate the risk of PD in 
relation to antioxidant intake. In some of these studies, large numbers of incident PD 
cases are to be expected as the follow-up period is long and a large number of 
participants have been incorporated at baseline. In the follow-up phases of these 
studies, however, a screening instrument for PD has to be implemented. Also, studies 
on the correlation between intake of (supplemental) vitamin E and cerebrospinal fluid 
concentrations of vitamin E should be extended to larger number of healthy subjects. 
Prognostic research 
When does Parkinson's disease start? 
Clarification of the pattern of the preclinical period in PD might help to gain insight 
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into the pathogenesis of PD. It is still a question whether PO develops insidiously and 
gradually over time (and if so, over what time), or results from an acute event. A 
sudden start of the degeneration of the dopaminergic cells could point towards an 
environmental insult or to a sudden failure of the dopaminergic system to 
counterbalance oxidative stress because of an accumulation of toxic compounds 
above a certain threshold (in genetically susceptible individuals). On the other hand, 
a slow process could indicate, for example, a failure of the defence system against 
repeated oxidative stress thereby, after years, exceeding the threshold at which the 
parkinsonian signs become clinically overt (depletion of endogenous dopamine 
content by approximately 80%). 
Several models and time frames regarding the pattern of start and progression of the 
deterioration of the dopaminergic system in PO have been proposed, as is illustrated 
in Figure 6.1. Recent reports, based on positron emission tomography (PET)-
scanning studies correlating in vivo the proportion of functional dopaminergic neurons 
with the disease duration, suggested a short 5 year period of progressive decline of 
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Figure 6.2 Two hypothetical patterns of dopaminergic cell loss in the SUbstantia 
nigra of Parkinson's disease (PO) patients based on possible findings from positron 
emission tomography (PET)-scanning in ullra-early Parkinson's disease patienls. X 
denoles Ihe slrialal F-dopa uplake. If Ihe uplake is low (eg 25%), then PO may be 
caused by a process, with a long preclinical period. If, in contrast, the uptake is 
higher (40%), PO may be caused by an acute event, wilh a short preclinical period. 
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the dopaminergic system before clinical symptoms become overt.29. 30 This time frame 
was assessed through exponential extrapolation of PET-scanning data in function of 
disease duration. It is however unclear whether this kind of extrapolation is warranted. 
Thusfar no PET-scanning studies in subjects with ultra-early PO have been carried 
out, except in twins and in sib pairs discordant for PD. In collaboration with the Paul 
Scherrer Institut, Villigen, Switzerland (Head: Prof. K.L. Leenders), we are currently 
conducting a 18F-dopa PET-scanning in possibly ultra-early PO patients, detected 
through the active screening in the Rotterdam Study. The amount of F-dopa uptake 
in the striatum of these persons may enable us to estimate the curve of degeneration 
in preclinical PO (see Figure 6.2). Whilst PET-scanning has a great potential for 
scientific research, its use in a general clinical setting will be limited. The PET-
scanning technique is elaborative, expensive, and requires, besides a cyclotron unit, 
a very skillful team. Single Photon Emission Computed Tomography (SPECT)31.32 may 
be an useful alternative tool to visualize in vivo dopaminergic dysfunction in the PO 
patient's brain. This technique is more widely avaible, easier to use, and new 
radioligands will make the SPECT-scanning technique even more accessible for 
persons at high risk for PD. 
Progression 
Identification of factors that contribute to a rapid progression of the clinical picture in 
PO patients is necessary. Only few factors such as age at onset, cognitive function 
at onset of the disease, depression, and severity of symptoms at onset have been 
investigated and have been associated with a more rapid progression of PD. 
However, these factors cannot be influenced, in contrast to lifestyle factors, co-
medication, and blood pressure that, among others, are factors that may be also 
related to a different prognosis of the disease. Future prognostic research should 
focus on such preventable and modifiable factors. 
Comorbidity and mor/alily 
A clinical important issue is comorbidity. Comorbidity, such as osteoporosis and 
fracture risk, cardiovascular disease, cerebrovascular disease, and cognitive 
dysfunction, will impose an even larger burden to the PO patient. Remarkably, for 
many of these diseases little is known about the occurrence in PO patients. The 
Rotterdam Study provides an unique opportunity to study comorbidity in a general PO 
population. ' 
General discussion 157 
Ultimately, insight into the etiology of PD, and into the preclinical phase of the 
disease, could give clues to neuroprotective treatment. If PD were indeed preceded 
by a short preclinical period, this could have important implications for prevention and 
treatment of the disease. Also, more knowledge on concurrent diseases in PD and 
on preventable factors associated with a poor prognosis of PD may reduce the 
disease burden in a PD patient. Identification of groups at a high risk of developing 
clinically overt PD by either risk profile assessment or SPEeT may result in measures 
to prevent this devastating disease in the elderly. 
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Chapter 7 
Summary 
3.1 Summary 
3.2 Summary in Dutch (samenvatting) 

7.1 Summary 
As in Western societies the proportion of elderly persons is growing, more and more 
persons will be affected by neurodegenerative diseases. Among the most frequent 
is Parkinson's disease (PO), a disease that is neuropathologically characterized by 
selective loss of dopaminergic neurons in the substantia nigra and other brainstem 
ganglia, leading to depletion of endogenous dopamine. The cause of this 
degeneration is still unknown. In this thesis, studies on various epidemiologic aspects 
of PO, such as diagnosis, frequency, and etiology, are described. All studies in this 
thesis are community-based with an active screening for PO in each individual, and 
most are part of the Rotterdam Study, a prospective community-based cohort study 
on prevalence, incidence and determinants of diseases among elderly persons. All 
inhabitants of Ommoord, a suburb of Rotterdam, the Netherlands, who were 55 years 
of age or older, either living independently or institutionalized, were invited to the 
study of whom 7,983 (78%) agreed to participate. For the studies decribed in this 
thesis, we included the 6,969 participants who underwent the complete neurologic 
screening examination at baseline. The Rotterdam Study started in 1990 and the 
baseline survey was completed in June 1993. The first follow-up phase run from 
September 1993 till the end of 1994. 
In Chapter 2 an overview is given of recent developments in epidemiologic research, 
most from the past decade, with the emphasis on large cross-sectional population-
based studies and prospective studies. 
Various aspects of screening for parkinsonism and PO, and diagnostic criteria of PO 
are discussed in Chapter 3. 
Little is known about the prevalence and predictive value of subjective complaints 
suggestive for the presence of parkinsonism. For screening purposes and in clinical 
practice there is need for such information. In Chapter 3.1 w~ investigated the 
prevalence of subjective complaints and related parkinsonian signs, and the 
sensitivity, specificity, positive predictive values (PPV), and likelihood ratios of 
subjective complaints for parkinsonian signs in a general elderly population. The 
proportion of persons that reported to have a tremor or slowness andlor stiffness 
increased with age, and was higher than estimated by the study physicians. For self-
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reported tremor, the sensitivity, specificity, PPV, and likelihood ratio were 39.3%, 
89.7%,29.9%, and 3.8, respectively. For self-reported slowness and/or stiffness these 
figures were 44.7% for sensitivity, 77.4% for specificity, 13.0% for PPV, and 2.0 for 
the likelihood ratio. These results suggest that subjective complaints are very 
prevalent in a general elderly population and attribute little to the detection of true 
parkinsonian signs. 
In Chapter 3.2 examples are given how the choice of diagnostic criteria affects 
research results. Using data on PO from three community studies (from Argentina, 
the Netherlands, Italy), we compared the impact on prevalence of several sets of 
diagnostic criteria. Each set was based on cardinal signs-resting tremor, 
bradykinesia, rigidity, impaired postural reflexes-and required that other 
parkinsonism be excluded. Some sets had additional requirements related to duration 
of symptoms, asymmetry of signs, or response to medication. In terms of prevalence, 
much lower estimates were associated with the requirements of asymmetry of signs 
and response to medication. The assessment of these clinical features may not be 
practical in community studies. Impaired postural reflexes, as a cardinal sign, seemed 
superfluous. For community studies of PO, we recommend the following diagnostic 
criteria: at least two of resting tremor, bradykinesia, or rigidity, in the absence of other 
apparent causes of parkinsonism. 
The frequency (prevalence and incidence of parkinsonism and PO) is handled in 
Chapter 4. The first part of this chapter (Chapter 4.1) deals with the prevalence of 
PO in the Rotterdam Study. All participants were examined, and those who either had 
at least one possible cardinal sign of parkinsonism at the neurologic screening, 
reported that they had PO, or were taking antiparkinsonian drugs were invited for 
further evaluation. The prevalence of PO in this population was 1.4% ( 1.2% for men, 
1.5% for women). Prevalence increased with age, and prevalence figures were 0.3% 
for those aged 55 to 64 years, 1.0% for those 65 to 74, 3.1% for those 75 to 84, and 
4.3% for those 85 to 94 years. The corresponding age-specific figures for men were 
0.4%,1.2%,2.7% and 3.0%, and for women 0.2%,0.8%,3.4% and 4.8%. Among 95-
to 99-year old women the prevalence was 5.0%. Twelve percent of the subjects with 
PO were detected through the screening and had not been diagnosed previously. 
These findings are in line with the few other studies that followed a similar 
methodology. 
In Chapter 4.2 a comparison is made of the prevalence of parkinsonism and PO in 
five European populations that were surveyed with similar methodology and 
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diagnostic criteria. The five community surveys are Gironde (France), 8 centres in 
Italy, Rotterdam (the Netherlands), Girona (Spain), and Pamplona (Spain). The 
individuals were screened in person for parkinsonism. Overall, these surveys included 
14,636 participants aged 65 years or older. The overall prevalence (per 100 
population), age-adjusted to the 1991 European standard population, was 2.3 for 
parkinsonism and 1.6 for PO. The overall prevalence of parkinsonism increased from 
0.9 for the age groups 65 to 69 years, to 5.1 for the age group 85 to 89 years. The 
corresponding age-specific figures for PO were 0.6 and 3.5. When adjusting for age 
and sex, the prevalence figures did not differ significantly across studies, except for 
the French study in which prevalence was lower. Prevalence was similar in men and 
women. Overall, 24% of the subjects with PO were newly detected through the 
surveys, and this percentage increased with age. The findings from this study suggest 
that the drop in the prevalence of PO as reported in many studies is probably 
artefactual due underdiagnosis of PO in the oldest old and stress the importance to 
screening actively for PO in a population. 
In Chapter 4.3 data on incidence of parkinsonism and PO in the Rotterdam Study are 
presented. Incidence data on parkinsonism and PO are sparse. Most incidence 
studies on parkinsonism and PO have been register-based and this presents serious 
methodologic limitations. The cohort, in which all participants were screened to detect 
PO, included 6,566 non-parkinsonian non-demented people. Between 1993-1994, 
5,236 participants were reexamined, and the remainder was followed up through a 
surveillance system. The mean follow-up time was 2.14 years. The incidence rate per 
1,000 person years (pyrs) of any parkinsonism was 4.3 (3.4 for men; 4.8 for women), 
and of PO 2.5 (2.2 for men; 2.7 for women). Incidence rates of parkinsonism 
increased from 0.5/1,000 pyrs for those aged 55 to 64 years to 14.3/1,000 pyrs for 
those aged 85 to 94 years. The corresponding rates of PO were 0.2/1,000 pyrs and 
4.2/1,000 pyrs. The differences between men and women were statistically non-
significant. Our findings suggest that incidence of parkinsonism and PO strongly 
increases with age and are higher than previously reported. However, the results 
were not conclusive on the pattern that the incidence figures would follow in the 
highest ages. For this, a longer follow-up will be needed. 
Chapter 5 is about studies, all from the Rotterdam Study, that focus on the etiology 
of PO. 
In Chapter 5.1 the cross-sectional relation of apolipoprotein E genotype (APOE) with 
PO and PO dementia is decribed. APOE was genotyped in 80 PD patients (19 with 
dementia) and in 1,008 randomly selected non-demented, non-parkinsonian control 
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subjects. Overall, we found no association of APOE'4 or APOE'2 alleles with PO. 
Within the PO patients group however, carriers of APOE'4 (odds ratio 4.8, 95%CI1.3-
17.9) or APOE'2 (odds ratio 3.3, 95%CI 0.8-14.5) were more often demented as 
compared with PO patients with APOE3E3, suggesting that APOE contributes to the 
dementia pathogenesis in PO. 
Oxidative stress has been implicated in the etiology of PO. From this may be inferred 
that high antioxidant intake might protect against degeneration of dopaminergic cells. 
A cross-sectional study that investigated whether high dietary intake of antioxidants 
might decrease the risk of PO is presented in Chapter 5.2. Besides the individual 
screening for parkinsonism, the participants were administered a semi-quantitative 
food frequency questionnaire. The study population comprised 5,342 non-demented 
independently living persons, including 31 patients with PO (Hoehn & Yahr stages 1 
to 3). We calculated odds ratios as an estimate of the relative risk of PO. The odds 
ratio of PO was 0.5 (95% confidence interval: 0.2-0.9) per 10 mg daily dietary vitamin 
E intake; 0.6 (0.3-1.3) per 1 mg B-carotene intake; 0.9 (0.4-1.9) per 100 mg vitamin 
C intake, and 0.9 (0.7-1.2) per 10 mg flavonoids intake, all adjusted for age, sex, 
current smoking, and energy intake. The association wilh vilamin E intake was dose-
dependenl (p-Irend 0.03). To assess whelher the association was differenl in palients 
wilh more advanced disease, we excluded PO palienls wilh Hoehn & Yahr slage 2.5 
or 3. This did nol fundamentally aller Ihe resulls. Several olher issues are addressed 
Ihal preclude low anlioxidant inlake as a resull of the disease. These data suggesl 
thai a high inlake of dielary vilamin E may prolecl against the occurrence of PO. 
In Chapter 5.3 results are presented from the study in which we prospectively 
assessed the risk of PO in smokers compared wilh non-smokers. Most studies on 
smoking and PO were either retrospective or cross-sectional and therefore 
susceptible to bias. To date no community-based prospective studies on smoking and 
the risk of PO in a general elderly population have been published. The cohort 
comprised all subjects who were screened in person for parkinsonism at the baseline 
survey (1990-1993) and were free of parkinsonism and dementia at the time, and of 
whom information on smoking history was collected at baseline (n= 6,442). After a 
mean follow-up period of 2.12 years, participants were reexamined for incident PO. 
We calculated the age- and sex-adjusted relative risk of PO, including 95% 
confidence intervals (95%CI), in smokers compared with non-smokers. We identified 
34 incident patients with PO. Ever-smokers at baseline (ex-smokers included) had a 
strongly decreased risk of PO; the adjusted relavlive risk was 0.37 (0.15-0.89). For 
baseline-smokers the relative risk of PO was 0.50 (0.18-1.43), and for ex-smokers 
0.26 (0.09-0.78). The inverse associalion of smoking and PO was dose-dependent. 
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This study strongly confirms the inverse association of smoking with PD. Smokers 
have an almost three-fold decreased risk of PD. The inverse association with smoking 
may give clues to the etiology of PO, and several mechanisms through which 
smoking-related protection may act are discussed. 
In Chapter 5.4 we address the genetics in PD. Since long, it has been suspected that 
genetic factors may contribute to the pathogenesis of PD. All studies that investigated 
the association between a positive family history of PD and the occurrence of PD 
were either retrospective or cross-sectional. We prospectively assessed the risk of 
PO among persons with a positive family history of PD or dementia as compared to 
persons without (first degree relatives). Persons with a positive family history of PD 
had a more than two-fold increased risk of PD although this was non-significant (RR 
2.5, 95%CI 0.8-8.4). Persons with at least two relatives with PD had a 9-fold 
significantly increased risk of PO (9.3, 95%CI 1.3-68.2). For those with a positive 
family history of dementia the RR of PO was 1.8 (0.9-3.7), and for those with at least 
two demented relatives RR 2.4 (0.6-10.2). This finding supports genetic involvement 
in the etiology of PO and may warrant a further search for genes that are linked to 
PD. 
Chapter 6 deals with various aspects of this thesis, such as study design and 
methodology, diagnosis of PO, and implications of the findings. An important feature 
of the studies decribed in this thesis is that they all are community-based and rely 
on an in-person screening for PD. Through this approach, persons with PO who had 
not been diagnosed before will be included. As a result, an unselected PD patient 
population will be obtained. The Rotterdam Study provides an excelent opportunity 
to follow up this group of patients for several types of prognostic factors and 
outcomes. Finally, recommendations are made for reseach topics that are an extent 
to the studies in this thesis. 

7.2 Summary in Dutch (samenvatting) 
Met de vergrijzing van de bevolking in Westerse landen zullen steeds grotere 
aantallen mensen getroffen worden door neurodegeneratieve aandoeningen. Een van 
de neurodegeneratieve aandoeningen die het meest frequent v66rkomt is de ziekte 
van Parkinson. De ziekte van Parkinson wordt neuropathologisch gekenmerkt door 
selectief verlies van dopaminerge cellen in de substantia nigra met typische 
inclusielichaampjes in de overlevende neuronen ("Lewy bodies") waardoor een te kort 
ontstaat aan endogeen 
In dit proefschrift Worden onderzoeken naar verschillende epidemiologische aspecten 
van de ziekte van Parkinson, zoals diagnose, etiologie en frequentie van de ziekte, 
beschreven. Aile onderzoeken die in dit proefschrift beschreven worden, zijn 
bevolkingsonderzoeken waarin elke deelnemer werd gescreend op de aanwezigheid 
van de ziekte van Parkinson. Het leeuwedeel van de onderzoeken in dit proefschrift 
vormt een onderdeel van het ERGO-onderzoek, in het Engels "the Rotterdam Study" 
genoemd. Het ERGO-(Erasmus Rotterdam, Gezondheid en Ouderen) onderzoek is 
een prospectief bevolkingsonderzoek onder aile zelfstandig wonende of in een 
verzorgingshuis verblijvende inwoners van 55 jaar en ouder van de wijk Ommoord in 
Rotterdam. Van de 10275 potentiele deelnemers namen er 7983 (78%) dee I aan het 
onderzoek. Aile deelnemers werden thuis uitgebreid geinterviewd en het merendeel 
van hen (7129) bezocht het onderzoekscentrum voor aanvullend onderzoek en 
metingen. In de onderzoeken welke beschreven zijn deze dissertatie werden de 6969 
deelnemers ingesloten die allen een compleet neurologisch screeningsonderzoek 
hadden ondergaan tijdens het dwarsdoorsnede-onderzoek. Het ERGO-onderzoek 
nam een aanvang in 1990 en het dwarsdoorsnede-onderzoek werd medio 1993 
afgerond. Het eerste vervolgonderzoek begon in de tweede helf! van 1993 en 
eindigde eind 1994. 
In hoofdstuk 2 wordt een overzicht gegeven van recente epidemiologische 
ontwikkelingen op het gebied van de ziekte van Parkinson, waarbij de nadruk wordt 
gelegd op grote bevolkingsonderzoeken of prospectieve onderzoeken. 
Verschillende aspecten wat betreft screening naar en diagnose van de ziekte van 
Parkinson worden besproken in hoofdstuk 3. Zo werd in hoofdstuk 3.1 de 
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prevalentie van subjectieve klachten en overeenkomstige symptomen onderzocht die 
zouden kunnen wijzen op een parkinsonisme. Bovendien werden de sensitiviteit, 
specificiteit, positief voorspellende waarde en likelihood ratio van de subjectieve 
klachten onderzocht in relatie tot de aanwezigheid van symptomen passende bij 
parkinsonisme. De proportie mensen dat last had van een tremor of van traagheid 
en/of stijfheid nam toe met de leeftijd en was hoger dan dat de arten vaststelden. De 
sensitiviteit, specificiteit, positief voorspellende waarde en likelihood ratio van tremor 
als subjectieve klacht waren respectievelijk 39%, 90%, 30% en 3.8; voor klachten van 
traagheid c.q. stijfheid waren deze waarden 45%, 77%, 13% en 2.0. Het lijkt dat 
subjectieve klachten van beven en traagheid/stijlheid veel voorkomen bij ouderen en 
dat deze klachten van weinig waarde zijn bij het screenen naar symptom en van 
parkinsonisme. 
In hoofdstuk 3.2 laten we zien hoe het gebruik van verschillende diagnostische 
criteria voor de ziekte van Parkinson onderzoeksresultaten kunnen be'invloeden. 
Hiertoe werden data vergeleken van 3 bevolkingsonderzoeken (uit Argentinie, !talie 
en Nederland). Gekeken werd hoe verschillende diagnostische criteria, allen 
gebaseerd op combinaties van hoodfsymptomen van parkinsonisme - rusttremor, 
bradykinesie, rigiditeit en gestoorde houdingsreflexen- en met uitsluiting van aile 
secundaire oorzaken van parkinsonisme, de prevalentieschattingen van de ziekte van 
Parkinson kunnen veranderen. Bij sommige criteria moest aan aanvullende 
voorwaarden worden voldaan zoals een asymmetrisch begin van de symptomen en 
goede reactie op levodopamedicatie. De prevalentie bleek het laagst te zijn indien 
een asymmetrisch begin of een goede medicatiereactie vereist werden maar aan 
deze voorwaarden is in een bevolkingsonderzoek vaak moeilijk te voldoen. Gestoorde 
houdingsreflexen als een van de vier hoofdsymptomen lijken niet bij te dragen tot de 
diagnose parkinsonsime. Voor het gebruik in bevolkingsonderzoeken bevelen we dan 
ook de volgende diagnostische criteria voor de ziekte van Parkinson aan: van 
rusttremor, rigiditeit en bradykinesie dienen ten minste twee aanwezig te zijn en aile 
andere mogelijke oorzaken van parkinsonisme moeten zijn uitgesloten. 
De frequentie (prevalentie en incidentie) van parkinsonisme en de ziekte van 
Parkinson wordt behandeld in hoofdstuk 4. Het eerste deel van dit hoofstuk 
(hoofdstuk 4.1) gaat over de prevalentie van de ziekte van Parkinson in het ERGO-
onderzoek. Aile deelnemers werden onderzocht en diegenenen die verdacht werden 
van een mogelijk parkinson is me nij de screening, zeiden dat ze de ziekte van 
Parkinson hadden 01 antiparkinsonmedicatie gebruikten, werden verder geevalueerd 
in een tweede, diagnostische lase. De prevalentie van de ziekte van Parkinson was 
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in deze populatie 1.4% ( 1.2% voor mannen, 1.5% voor vrouwen). De prevalentie 
steeg met de leeftijd van 0.3% voor de leeftijdsgroep 55-65 jaar tot 4.3% voor de 
graep van 85 tot 95 jaar. De overeenkomstige cijfers voor mannen waren 0.4% en 
3.0%, en voor vrouwen 0.2% tot 4.8%. De prevalentie onder vrouwen tussen de 
leeftijd van 95 en 100 jaar was 5.0%. Twaalf procent van de personen met de ziekte 
van Parkinson werd ontdekt dankzij de screening en was voordien niet bekend 
wegens de ziekte van Parkinson. Deze bevindingen stemm en overeen met de 
weinige onderzoeken die de zelfde methoden toepasten. 
In hoofdstuk 4.2 worden de prevalentieschattingen van parkinsonisme en de ziekte 
van Parkinson in vijf Europese populaties vergeleken. Deze schattingen waren 
verkregen uit wat methodologie betreft vergelijkbare onderzoeken. Deze 5 
bevolkingsonderzoeken zijn: Gironde (Frankrijk), Rotterdam, Girona (Spanje), 
Pamplona (Spanje) en 8 centra in italie. In al deze onderzoeken werd een individuele 
screening naar parkinsonisme verricht. In het totaal werden 14,636 deelnemers van 
65 jaar en ouder gescreend. De prevalentie van parkinsonsime in deze groep was 
2.3% (Ieeftijdsgecorrigeerd naar de Europese standaard populatie 1991) en 1.6% 
voor de ziekte van Parkinson. De prevalentie van parkinsonisme nam toe van 0.9% 
voor de personen tussen de 65 en 70 jaar tot 5.1% voor de leeftijdsgroep 85-90 jaar. 
V~~r de ziekte van Parkinson waren deze getallen 0.6% en 3.5%. Deze schattingen 
waren tussen de verschillende landen statistisch niet significant verschillend wanneer 
werd gecorrigeerd voor leeftijd en geslacht, be halve het Franse onderzoek dat wat 
afweek met lagere schattingen. De prevalentie was tussen mannen en vrouwen niet 
verschillend. Van aile Parkinsonpatienten was 24% nooit eerder gediagnostiseerd met 
de ziekte en werd dankzij de actieve screennig ontdekt. Oil percentage steeg met de 
leeftijd en suggereert dat de afname van de prevalentie in de hoogste 
leeftijdscategorieen, welke in vele eerdere onderzoeken gevonden werd, waarschijnlijk 
een artefakt was ten gevolge van een onderdiagnose van de ziekte in de hoogste 
leeftijdscategorieen. Oil maakt duidelijk dat een screening voor de ziekte van 
Parkinson belangrijk is, wit men tot een zo correct mogelijke prevalentieschatting 
komen. 
In hoofdstuk 4.3 worden gegevens uit het ERGO-onderzoek over de incidentie van 
parkinson is me en de ziekte van Parkinson getoond. Incidentiecijfers van de ziekte 
van Parkinson zijn nauwelijks voorhanden, en de cijfers die voorhanden zijn, zijn 
gebaseerd op bestaande medische gegevens. Dit heeft beperkingen zoals 
onderschatting van de frequentie. We onderzochten het aantal incidente 
Parkinsonpatienten onder de ERGO-deelnemers die tijdens het dwarsdoorsnede-
onderzoek vrij bleken te zijn Van parkinsonisme en/of dementie (n = 6566). Tijdens 
170 Chapter 7.2 
het vervolgonderzoek van 1993 en 1994 konden 5236 deelnemers wederom 
gescreend worden op parkinsonisme. Van het overige dee I konden we informatie via 
een geautomatiseerd hUisartseninformatiesysteem verkrijgen. Het incidentiecijfer per 
1000 persoonsjaren (pi) van parkinsonisme was 4.3 (3.4 voor mannen; 4.8 voor 
vrouwen) en voor de ziekte van Parkinson 2.5 (2.2 voor mannen; 2.7 voor vrouwen). 
De incidentiecijfers van parkinsonisme namen toe met de leeftijd, 0.5/1000 pj voor 
55 tot 65 jarigen tot 14.3/1000 pj voor personen uit de leeftijdgroep 85 tot 95 jaar. 
Voor de ziekte van Parkinson waren deze cijfers 0.2/1000 pj en 4.211000 pj. Er waren 
geen statistisch significante verschillen tussen mannen en vrouwen. Uit ons 
onderzoek blijkt dat de incidentie van parkinsonisme en de ziekte van Parkinson sterk 
toeneemt met de leeftijd. Het patroon van de incidentie in de allerhoogste 
leeftijdsgroepen staat echter nog niet vas!. Hiervoor zal een langere vervolg in de tijd 
nodig zijn. 
Hoofdstuk 5 gaat over onderzoeken die aile deel uitmaakten van het ERGO-
onderzoek en zich richtten op de etiologie van de ziekte van Parkinson. 
In hoofdstuk 5.1 wordt de associatie beschreven tussen het apolipoprote'ine E 
genotype (APOE) en de ziekte van Parkinson met en zonder dementie. APOE 
genotypen werden bepaald in 80 parkinsonpatienten (19 met dementie) en in 1008 
willekeurig geselecteerde controlepersonen die vrij waren van dementie en 
parkinsonisme. Over de hele groep genomen vonden we geen associatie van 
APOE*4 of APOE*2 allelen met de ziekte van Parkinson. Onder de 
parkinsonpatienten bleek echter dat dragers van APOE*4 (odds ratio 4.8, 95%BI1.3-
17.9) of APOE*2 (odds ratio 3.3, 95%BI 0.8-14.5) vaker dement waren dan patienten 
met APOE3E3. Hieruit kan worden afgeleid dat APOE een rol speelt in de 
pathogenese van de dementie bij de ziekte van Parkinson. 
Er is geopperd dat oxidatieve stress verband houdt met het onstaan van de ziekte 
van Parkinson. Hieruit kan worden afgeleid dat een hoge inname van antioxidanten 
de dopaminerge cellen zou kunnen beschermen tegen degeneratie. We onderzochten 
of personen met een hoge inname van antioxidanten via de gewone voeding minder 
vaak de ziekte van Parkinson hadden (hoofdstuk 5.2). Bij een grote groep niet-
demente, zelfstandig wonende personen, inclusief 31 parkinsonpatienten (1 tot 3 op 
de Hoehn & Yahr-schaal) werd een semi-quantitatieve voedingsvragenlijst 
afgenomen. We berekenden de odds ratios als een schatting van het relatieve risico 
op de ziekte van Parkinson. De odds ratio op de ziekte van Parkinson was 0.5 
(95%BI 0.2-0.9) per 10 mg dagelijkse vitamine E inname; 0.6 (95%BI: 0.3-1.3) per 1 
mg IS-caroteen inname; 0.9 «95%BI: 0.4-1.9) per 100 mg vitamine C inname, en 0.9 
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(95%BI: 0.7-1.2) per 10 mg flavonoiden inname, aile gecorrigeerd voor leeftijd, 
geslacht, roken en energieinname. De associatie van vita mine E inname met de 
ziekte van Parkinson was dosis gerelateerd (p-trend 0.03). Nagegaan werd of deze 
associatie anders zou zijn bij parkinsonpatienten met een verder gevorderd stadium 
van de ziekte (2.5 en 3 op Hoehn & Yahr-schaal). Na uitsluiting van deze personen 
waren deze associaties ongewijzigd. Deze resultaten sluiten goed aan bij de 
hypothese dat een hoge vita mine E inname via de voeding zou kunnen beschermen 
tegen het ontstaan van de ziekte van Parkinson. 
In hoofdstuk 5.3 worden de resultaten getoond van een prospectief onderzoek naar 
het risico op de ziekte van Parkinson onder niet-rokers in vergelijking met rokers. De 
meeste onderzoeken die deze associatie onderzochten waren retrospectieve of 
dwarsdoorsnede-onderzoeken en daardoor gevoelig voor meedere vormen van bias. 
Tot nu toe bestaan er geen prospectieve onderzoeken naar roken en het risico op de 
ziekte van Parkinson welke in een algemene oudere bevolking werden uitgevoerd. 
Het cohort bestond uit aile ERGO-deelnemers die tijdens het dwarssnede-onderzoek 
geen dementie en parkinson is me hadden en van wie informatie over de 
rookgewoonten aanwezig was (n= 6442). Na een periode van gemiddeld 2.12 jaar 
werden de deelnemers nogmaals gescreend op de ziekte van Parkinson. De leeftijd-
en geslacht-gecorrigeerde relative risico's (RR) op de ziekte van Parkinson werden 
berekend voor rokers in vergelijking met niet-rokers. Vierendertig person en bleken 
incident de ziekte van Parkinson te hebben. Het risico op de ziekte was onder rokers 
sterk verminderd, een RR van 0.37 (95%BI: 0.15-0.89). De inverse associatie van 
roken met de ziekte van Parkinson was dosis-afhankelijk. Dit onderzoek bevestigt de 
inverse associatie van roken met de ziekte van Parkinson en zou tot nieuwe inzichten 
kunnen leiden wat betreft de etiologie van de ziekte van Parkinson. Vervolgens wordt 
in dit hoofdstuk geschetst via welke mogelijke mechanismen de protectieve werking 
van roken zou kunnen verlopen. 
In hoofdstuk 5.4 richtten we ons op de genetica en de ziekte van Parkinson. Sinds 
lange tijd bestaat het vermoeden dat genetische factoren een belangrijke rol spelen 
in het ontstaan van de ziekte van Parkinson. Aile onderzoeken die de associatie 
onderzochten tussen de ziekte van Parkinson en een posilieve familiegeschiedenis 
hiervoor waren retrospectief en gebaseerd op ziekenhuispopulaties. Wij vergeleken 
het RR op de ziekte van Parkinson onder personen met en zonder een positieve 
familiegeschiedenis voor de ziekte van Parkinson en/of dementie (1ste graads 
familieleden). Personen met een tenminste een familielid met de ziekte van Parkinson 
badden een meer dan tweevoudig toegenomen risico op de ziekte maar dit was 
statistisch niet significant (RR 2.5, 95%BI: 0.8-8.4). Personen met tenminste twee 
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familieleden aangedaan door de ziekte van Parkinson hadden een 9-keer verhoogde 
kans op de ziekte (9.3, 95%BI: 1.3-68.2). Het risico op de ziekte was ietwat hoger 
voor hen met tenminste een familielid met dementie (RR 1.8, 95%BI: 0.9-3.7), en het 
RR voor hen met tenminste twee demente familieleden was 2.4 (95%BI: 0.6-10.2) . 
. Deze resultaten suggereren dat genetische factoren inderdaad betrokken kunnen zijn 
bij het ontstaan van de ziekte van Parkinson en dat een verdere zoektocht naar 
kandidatgenen haar vruchten zou kunnen afwerpen. 
In Hoofdstuk 6 worden de verschillende aspecten van dit proefschrift besproken, 
zoals onderzoeksopzet en methodologie, diagnosis, en de implicaties van de 
resultaten die in dit proefschrift gepresenteerd worden. Een belangrijk kenmerk van 
aile onderzoeken in dit proefschrift is dat ze aile bevokingsonderzoeken zijn die 
gebruik maakten van een individuele screening voor de ziekte van Parkinson. 
Hierdoor konden nieuwe patienten, die nog niet waren gediagnostiseerd, worden 
gei"dentificeerd en kon een ongeselecteerde patientenpopulatie worden verkregen. 
Het Rotlerdamse ERGO-onderzoek bied een uniek kans om zo'n patientengroep 
gedurende meerdere jaren te volgen voor prognostische factoren en eindpunten. 
Tenslotte worden aanbevelingen gedaan voor onderzoeken die een uitbreiding 
zouden kunnen zijn op het werk dat in dit proefschrift is beschreven. 
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Epilogue 
Na ontelbare uren knoppenbonken, na honderden brieven verstuurd te hebben, na 
enkele bomen door de printer te hebben gedraaid (gewoon superwit papier), na in 
afstand meer dan 4 maal de aarde zijn rond getreind, na heel wat liters 
cafe'fnehoudende dranken te hebben genuttigd is het zover: het "baekje" is afl En 
dat het gebeurd is, is een verdienste van velen die ik niet allemaal persoanlijk zal 
noemen. 
Professor Hofman echter, mijn eerste promotor, mag natuurlijk niet onvermeld 
blijven. Zonder Bert geen ERGO, en zonder ERGO niet dit boekje. Beste Bert, zo 
simpel ligt het gelukkig niet en dat weet je. Ik heb het erg op prijs gesteld dat je 
me de ruimte liet af en toe een eigen richting aan het onderzoek te geven maar 
me oak op tijd bijstuurde. 
Mijn tweede promotor Professor van der Meche, ik ben u nag steeds erkentelijk 
voar het feit dat u mij "getipt" heel! voar he! onderzaek dat tot dit proefschril! heel! 
geleid en het aandurfde om een tienjarig cont(r)act aan te gaan. Uw heldere 
gezichtspunten en commentaar hebben dit proefschril! zeker tot een beter 
proefschril! gemaakt. 
Beste Monique, het doet me een genoegen jou als co-promotor in de 
promotiecommissie te hebben. Je concrete en goede methodologische aanpak en 
je vindingrijkheid op o.a. tekstueeI gebied hebben voor een aanzienlijk deel de 
vorm van de artikelen bepaald die we gezamelijk hebben geschreven. Oat we niet 
altijd op dezelfde lijn zaten, heel! het er aileen maar op verbeterd en ik hoop dan 
ook da! de samenwerking zal worden voartgezet. 
De velen in het eerste uur (o.a. Rene Vermeeren, Michael Koenders, Ada 
Haoghart, Coby van den Heuvel, Anneke Karving), het complete ERGO-team, het 
Lab (Ton de Bruijn c.s.), Secretariaat (Paula, Nicky, Margaret, Andrea), Yolanda, 
Peter (waar is toch die goede oude "boerlageer"tijd?), de Jongens van de 
Automatisering en de Ommoordse huisartsen ben ik veel dank verschuldigd. 
Gerda Graveland heel! mij met veel enthausiasme de klinische beginselen van de 
ziekte van Parkinson bijgebracht en was altijd bereid af te reizen naar Ommoad 
voor een second opinion. 
I also want to express my gratitude to my colleagues from abroad. Dear 
EUROPARKINSON-collaborators, dear Annick and Christophe, I will remember the 
colloboration and the joint meetings as very usefull and pleasant. For this I am 
very grateful. I highly appreciate the collaboration with Walter Rocca. Dear Walter, 
thank you very much for the hospitality of you and your family during my stay at 
Mayo Clinic. I am very glad that you accepted to be a member of my PhD-
committee. Through Walter I was so fortunate to got to know Dallas Anderson and 
Jim Maraganore. Dallas, thank you for your great help in writing our joint paper, 
together with Jim and Walter, and for being a walking encyclopedia. Dear Juan 
Pablo Alonso, finally the joint paper is finished, time to discuss other things. 
Ik zal mijn collega-ERGO-onderzoekers, het theeklessebesse met Dorothee en 
Sandra, de verhandelingen over het steenketsen met Carl en Paul en de rust en 
hulp van Alewijn missen. Bedankt voor aile dingen die jullie voor mij gedaan 
hebben. 
De paranimfen Paul van Daele en Marianne Geleijnse hebben niet aileen nu maar 
ook in het verleden een menig dankbaar steentje bijgedragen aan de promotie op 
onderzoeks-technisch en persoonlijk vlak waar ik hen erg dankbaar voor ben. 
Een speciale vermelding verdienen mijn kamergenoten op de Epi want mede door 
hen bewaar ik zo'n goede herinningen aan mijn promotietijd. Marianne, meer dan 
4 jaar kamergenoot, jouw relativeringsvermogen zou iedere onderzoeker moeten 
bezitten, in jouw humor ben je uniek. Paul Steegmans, Danielle Majoor-Krakauer 
(ik ben nog steeds benieuwd naast wie gezet zal worden op haar promotiefeest) 
en later ook Anske, Bruno Stricker, Caroline van Rossum, Bettina Samren, en 
eventjes Irene vormden de meest idea Ie kamergenoten die ik me kon wensen en 
die voor een vrolijke sfeer op de Ee2132 zorgden. Bedankt hiervoor. 
Mijn ouders dank ik, naast aile andere dingen die ze voor mij gedaan hebben, in 
het bijzonder voor aile kansen die ze mij geboden hebben. En een speciaal woord 
voor Miek. Liefste Miek, ik heb het telkenmale enorm gewaardeerd dat je altijd op 
een volkomen onbaatzuchtige manier mij steunde in mijn toekomstplannen en 
beslissingen die mij meestal niet dichter tot Belgie brachten. Bedankt ook voor de 
tijd die jij de laatste maanden ongemerkt opofferde, ondanks jouw eigen 
promotieperikelen, om mij dit proefschrift te kunnen laten afronden. Dankzij jou 
heeft de kleine Arthur er niet ondergeleden. 
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